WO2004000299A1 - Body fat degradation promoters and foods and drinks - Google Patents

Body fat degradation promoters and foods and drinks Download PDF

Info

Publication number
WO2004000299A1
WO2004000299A1 PCT/JP2003/007736 JP0307736W WO2004000299A1 WO 2004000299 A1 WO2004000299 A1 WO 2004000299A1 JP 0307736 W JP0307736 W JP 0307736W WO 2004000299 A1 WO2004000299 A1 WO 2004000299A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
medium
chain fatty
fat
glycerin
Prior art date
Application number
PCT/JP2003/007736
Other languages
French (fr)
Japanese (ja)
Inventor
Hisami Shinohara
Osamu Noguchi
Fumie Asami
Hatsumi Shimada
Toshiyuki Inui
Original Assignee
The Nisshin Oillio Group, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Nisshin Oillio Group, Ltd. filed Critical The Nisshin Oillio Group, Ltd.
Priority to AU2003242466A priority Critical patent/AU2003242466A1/en
Publication of WO2004000299A1 publication Critical patent/WO2004000299A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, in particular, a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient, / 33-adrenergic receptor expression
  • the present invention relates to enhancers, body fat degradation promoters, body fat blood release promoters, and their foods, drinks, raw materials, and fats and oils compositions, and to their use in the pharmaceutical and food fields. Background art
  • the main focus of diet is energy consumption, and food ingredients that are more energy-prone and do not easily add fat to the body are attracting attention.
  • Medium-chain fatty acids mainly contained in coconut oil are Compared to the long-chain fatty acids, which are the main component, they are rapidly absorbed when ingested into the body and burned immediately by the liver, making them more energy-efficient. It has already been reported (see, for example, J. Liid Res. 37, 708-726 (1996)).
  • the fat and oil composition containing 31% by mass or more of triglycerides containing two medium-chain fatty acid residues in the molecule among the fat and oil composition components composed of diglyceride and triglyceride also has low body fat accumulation.
  • diacyl glycerol-conjugated linoleic acid has an effect of specifically enhancing the expression of uncoupling protein (for example, JP 2001-64171 A, — See Japanese Patent Application Publication No. 81020.
  • the medium-chain triglyceride specifically enhances the hormone-sensitive lipase 3-adrenoceptor receptor and has a positive anti-obesity effect as a result.
  • the accumulated body fat is decomposed or the decomposed body fat is transferred into the blood. Disclosure of the invention
  • the present invention provides a formulation, food and drink having a function of decomposing fat accumulated in the body. As a result, it provides a body fat reducing effect and a slimming effect. In addition, in the aspect of the body fat reduction, a smooth body fat reduction is provided by preferentially burning from subcutaneous fat in accordance with internal energy consumption.
  • the present inventors have conducted intensive studies in order to achieve the above object, and found that glycerin fatty acid esters containing medium-chain fatty acids and z or medium-chain fatty acids, The present inventors have found that high-chain fatty acid triglycerin fatty acid ester (hereinafter sometimes referred to as “medium-chain fatty acid triglyceride” (MCT)) degrades fat accumulated in the body, and completed the present invention. In addition, they have found that the mode of decomposing fat is preferentially decomposed from subcutaneous fat with the consumption of internal energy, and completed the present invention.
  • MCT medium-chain fatty acid triglyceride
  • the present invention includes the following contents.
  • a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a subcutaneous adipocyte hormone-sensitive lipase expression enhancer comprising, as an active ingredient, a medium-chain fatty acid or a glycerin fatty acid ester containing a medium-chain fatty acid.
  • a ⁇ 3-adrenergic receptor expression promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a body fat degradation promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a subcutaneous lipolysis promoter comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
  • a body fat blood release promoter comprising a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a subcutaneous fat blood release promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a constitution modifying agent for a constitution in which subcutaneous fat is easily decomposed comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
  • a fat / oil composition for enhancing expression of hormone-sensitive lipase comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • An oil / fat composition for enhancing ⁇ 3-adrenergic receptor expression comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • An oil / fat composition for promoting body fat decomposition comprising a medium-chain fatty acid and a glycerol fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • An oil / fat composition for promoting body fat blood release comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
  • a food or drink for enhancing expression of hormone-sensitive lipase comprising a medium-chain fatty acid salt or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a food or drink for enhancing the expression of subcutaneous adipocyte hormone-sensitive lipase comprising a medium-chain fatty acid and ⁇ ⁇ or a glycerol fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a food and drink for enhancing the expression of 3-adrenergic receptors comprising a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a food or beverage for promoting body fat decomposition comprising a medium chain fatty acid and Z or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
  • a food and drink for promoting subcutaneous lipolysis comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • a food and drink for promoting release into body fat blood comprising a medium chain fatty acid and Z or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
  • a food or drink for modifying the body fat into a degradable body comprising a medium-chain fatty acid and Z or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
  • FIG. 1 is a diagram showing fatty acid metabolism in adipose tissue.
  • FIG. 2 is a diagram illustrating the process of burning free fatty acids in the body.
  • a of FIG. 3 shows oxidative phosphorylation at the inner mitochondrial membrane and uncoupling by uncoupling protein (UCP).
  • UCP uncoupling protein
  • FIG. 3 (B) is a diagram showing the actions of adrenergic receptors, hormone-sensitive lipase, and uncoupling protein (UCP) in fat cells during the fat burning process.
  • UCP uncoupling protein
  • a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid preferably a medium-chain fatty acid triglycerin fatty acid ester has a hormone-sensitive lipase ⁇ j33 -adrenergic receptor expression enhancing function
  • a function of promoting body fat degradation preferably from this, they have found that they have a function of promoting the release of body fat into blood, so that glycerin fatty acid esters containing medium-chain fatty acids or medium-chain fatty acids
  • functional agents, foods, and the like containing a medium-chain fatty acid triglycerin fatty acid ester are completed.
  • body fat is reduced as a result of the expression of the body fat decomposition promoting function and the body fat blood release promoting function, and it is preferable that the medium chain fatty acid and / or a glycerin fatty acid ester containing the medium chain fatty acid be used.
  • a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester is used as a raw material for the functional agent or the like.
  • a body fat decomposing agent, a food or a drink, and a raw material containing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester are used for the above-mentioned lipolysis function subcutaneously.
  • the inventors have found that fat is preferentially decomposed from fat, and have completed the present invention.
  • VLDL very low density lipoprotein
  • Free fatty acid taken up by such a pathway is converted to acyl-CoA by the action of acyl-CoA synthetase (ACS) and synthesized into triglycerides (neutral fat: accumulated). Is oxidized to acetyl-CoA, which produces energy through the TCA cycle (taenoic acid cycle).
  • ACS acyl-CoA synthetase
  • gnorecose in the blood is taken in via gnorecose transporters (GLUT1, GLUT4) to produce glycerol-3-phosphate (G3P) and acetyl-CoA.
  • Acetyl-CoA is synthesized into acetyl-CoA by the action of acetyl-CoA carboxylase (ACC).
  • Triglyceride neutral fat: accumulation
  • acyl-CoA and glycerol monophosphate by esterification.
  • HSL hormone-sensitive lipase
  • Free fatty acids are released extracellularly and used as an energy source for muscle and heart, or converted to acyl-CoA and synthesized again into triglycerides.
  • the acyl-CoA temporarily binds to the hydroxyl group of car-tin (car II itine), and the fatty acid isyl-carnitine is transported across the inner mitochondrial membrane by a specific transporter.
  • Mitochondrial oxidation of fatty acids occurs in three stages.
  • the first step is oxidation, which removes two consecutive units from the carboxyl terminus of the fatty acid acyl group in the form of acetyl ⁇ ⁇ . Palmitic acid with 16 carbons goes through the three oxidation pathways seven times and is converted to eight 2-carbon acetyl OA.
  • Asechiru residues ⁇ Se chill C o A in the second stage is oxidized to 00 2 through the Kuen acid cycle.
  • fatty acid oxidation steps result in reduced electron carriers, NADH and FADH2, which donate electrons to the mitochondrial respiratory chain, which is passed on to oxygen through the respiratory chain.
  • ATP adenosine triphosphate
  • Physiological fluctuations of free fatty acids are large. On fasting plasma free fatty acids increase and decrease after meals. Hormone-sensitive lipase is activated by exchange nerve activators such as epinephrine. It is a factor that increases free fatty acids such as cold and stress.
  • FIG. 3 shows the relationship between oxidative phosphorylation at the inner mitochondrial membrane and uncoupling by uncoupling protein (UCP).
  • UCP uncouples mitochondrial oxidative phosphorylation Is a protein that That is, in normal mitochondria, the electron transport system and ATP synthesis cooperate closely via the electrochemical gradient of protons through the inner membrane.
  • UCP is a special channel that short-circuits this concentration gradient, and when activated, the chemical energy of the oxidized substrate is converted to heat instead of being used for ATP synthesis. In other words, the expression of UCP promotes the burning of free fatty acids.
  • UCP has been confirmed from UC P_1 to UC P-3.
  • UCP-1 is present in brown adipose tissue. However, it decreases with growth in many mammals, including humans, and is difficult to identify visually in adults.
  • UCP-2 is widely present in the human body, and UCP-3 is strongly expressed in skeletal muscle.
  • FIG. 3 (B) This illustrates the above function in a brown fat tissue.
  • Mature production by UCP-1 in brown adipose tissue is directly regulated by abundantly distributed sympathetic nerves in this tissue.
  • norepinephrine (NE) secreted from the end of menstruation by hyperactivity of the sympathetic nerve adenylate cyclase (AC) is activated via an adrenergic receptor (AR) present in the cell membrane, and intracellular Fatty acids are released through a series of reactions, such as increasing cAMP levels, activating protein kinases (PKA), and decomposing stored triglycerides. Therefore, an increase in the expression level of the / 3 adrenergic receptor, hormone-sensitive lipase, and UCP promotes the burning of body fat.
  • NE norepinephrine
  • AC adenylate cyclase
  • AR adrenergic receptor
  • Fatty acids are released through a series of reactions, such as increasing cAMP
  • the outline of the functions of the various functional agents of the present invention is as follows. Ingestion of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, particularly medium-chain fatty acid triglycerides Hormone sensitivity in body adipose tissue Activated lipase degrades glycerin fatty acid esters (such as LCT) accumulated in body fat tissue to break down into free fatty acids, and releases the free fatty acids into the blood. This will reduce the accumulated body fat.
  • glycerin fatty acid esters such as LCT
  • the term "glycerin fatty acid ester containing a medium-chain fatty acid” refers to any one or more of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I) containing the above-mentioned medium-chain fatty acid.
  • triglycerin fatty acid ester having all of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I), and diglycerin in which one of the constituent fatty acids R1, 2, and R3 is hydrogen
  • Fatty acid esters are composed of monoglycerin fatty acid esters, only one of which is a constituent fatty acid.
  • the constituent fatty acids R1, R2, and R3 all have the above-mentioned medium-chain fatty acid form, they are called medium-chain fatty acid triglycerides, which will be described in detail later.
  • the number of the medium-chain fatty acid residues at the 1,3-positions is 40% by mass / 0 or more, preferably 50% by mass or more, more preferably 6% by mass or more.
  • the content is preferably 0% by mass or more, particularly preferably 70% by mass or more, and most preferably 80% by mass or more, for example, because of good decomposition and absorption in the intestinal tract and the like when taken orally.
  • the glycerin fatty acid ester containing a medium-chain fatty acid preferably contains a medium-chain fatty acid triglyceride, and if the amount of the medium-chain fatty acid is the same, it is preferable that the MLCT is used. It is preferably a structure.
  • the content can be defined according to the required strength of the function, etc., with reference to the content of the medium-chain fatty acid.
  • the medium-chain fatty acid triglyceride contains 3 to 30% by mass, preferably 3 to 23% by mass, preferably 4 to 20% by mass, more preferably 5 to 17% by mass, and particularly preferably 6 to 1% by mass. 5% by weight, most preferably 7 to 14% by weight. / 0 , most particularly preferably from 8 to 13% by weight.
  • Sa in the case of MLCT, it is 1 to 80% by mass, preferably 2 to 70% by mass, more preferably 3 to 60% by mass, particularly preferably 5 to 50% by mass, and most preferably 7 to 70% by mass.
  • the structure is 1 to 80% by mass, preferably 2 to 70% by mass, more preferably 3 to 60% by mass, and particularly preferably 5 to 50% by mass. 50% by weight, most preferably 7% to 20% by weight, most preferably 8% to 14% by weight. .
  • MLCT is a glycerin fatty acid ester containing a medium-chain fatty acid, in which the number of medium-chain fatty acids is 1 or 2, and the others are long-chain fatty acids.
  • the absorbability, the function in the body, and the like differ depending on the number and the binding position of the medium-chain fatty acids, and it is preferable to appropriately adjust them according to the purpose.
  • MLCT in which a medium-chain fatty acid is bonded to at least one of the 1,3-positions, particularly both, is preferable.
  • Structural fats and oils can be designed with respect to the types of fatty acids other than medium-chain fatty acids that bind to glycerin, the positions where these bind, and the like.
  • Preferred structural fats and oils include, for example, those in which a medium-chain fatty acid is bonded to one or both of the 1- and 3-positions, and a specific fatty acid is bonded to the 2-position.
  • a linear fatty acid is preferable, particularly from the viewpoint of natural abundance, etc., and a linear unsaturated fatty acid is more preferable.
  • Examples of these structural fats and oils include M-oleic acid-M, M-a linolenic acid-M, M- ⁇ linolenic acid-M, M-eicosapentaenoic acid-M, M-docosapentaenoic acid-M, M_docosahexaenoic acid-M, M-conjugated linoleic acid-M and the like can be exemplified.
  • MLCTs and structural fats and oils can be produced by a transesterification reaction, and are preferably produced using an enzyme having regiospecificity.
  • the medium-chain fatty acid triglycerides that can be used in the present invention are generally referred to as MCT (Medium Cin Triglycerides), and therefore have 6 to 12 carbon atoms, preferably 8 to 10 carbon atoms, such as coconut oil-decomposed fatty acids. It is a mono- or mixed-acid triglyceride composed of a saturated fatty acid.
  • MCT Medium Cin Triglycerides
  • triglycerides having a strength of prillic acid (C8) / force of phosphoric acid (C10) 60 to 75/25 to 40 (weight ratio) can be used.
  • the triglyceride can be produced by subjecting the medium-chain fatty acid and glycerin to an esterification reaction by a conventional method, but the use of a commercially available product is convenient.
  • Examples of the fat and oil composition containing the medium-chain fatty acid triglyceride include ordinary edible fats and oils such as soybean oil, rapeseed oil, oleic rapeseed oil, corn oil, sesame oil, sesame salad oil, perilla oil, linseed oil, peanut oil, Safflower oil, high-oleic acid safflower oil, sunflower oil, high-oleic sunflower oil, cottonseed oil, pudow seed oil, macadamia nut oil, hazelnut oil, capocia seed oil, walnut oil, camellia oil, teaseed oil, egoma oil, borage Oil, olive oil, rice bran oil, wheat germ oil, palm oil, palm kernel oil, coconut oil, cocoa butter, tallow, lard, chicken fat, milk fat, fish oil, seal oil, algae oil, low saturation due to quality improvement
  • the medium-chain fatty acid of the present invention is preferably a fatty acid having 6 to 12 carbon atoms, and examples thereof include caproic acid, caprylic acid, capric acid, and lauric acid. Further, saturated fatty acids having 8 to 10 carbon atoms, particularly caprylic acid and capric acid, are preferred.
  • Glycerin fatty acid esters containing medium-chain fatty acids can be obtained naturally or synthetically.
  • fats and oils such as palm oil, palm kernel oil and coconut oil having medium chain fatty acids having 6 to 12 carbon atoms as constituent fatty acids are used as raw materials. It can be produced by transesterification, but is not limited thereto.
  • the conditions for the ester bond reaction are not particularly limited. For example, it can be obtained by reacting under pressure without using a catalyst and a solvent.
  • glycerin fatty acid esters containing medium-chain fatty acids can be obtained from the oil seeds of genetically modified plants, or medium-chain fatty acids can be obtained from medium-chain fatty acids obtained from oil-seed plants of genetically modified plants. It is also possible to produce glycerin fatty acid esters. It can also be obtained by an enzymatic reaction using an enzyme. Flavor of oils and fats. Color / Ant Considering the whole surface or oral ingestion, it is preferable to manufacture by enzymatic transesterification, but it is not limited to this.
  • composition of the fatty acids at the 1- and 3-positions of the obtained transesterified fat may or may not be biased, but the more fatty acids at the 1- and 3-positions, the more suitable the decomposition etc. It is preferable because of the tendency. '
  • a fat and oil such as palm kernel oil or coconut oil having a medium chain fatty acid having 6 to 12 carbon atoms as a constituent fatty acid is used as a raw material, and a transesterification treatment is performed using a lipolytic enzyme (lipase).
  • lipolytic enzyme include Al Carigenes, Candida, Rhizopus, Muconore or Shoe Lipases derived from Domonas sp., Phospholipase A derived from liver and the like are preferred, and lipases derived from Candida or Rhizopus are particularly preferred.
  • the method of performing the transesterification reaction using a c- lipidase capable of appropriately selecting the type of the enzyme depending on the conditions is not particularly limited, and specific examples of the method are given below.
  • the temperature is adjusted within the range of 40 to 100 ° C, which is the reaction temperature at which the activity of the lipolytic enzyme is sufficiently exhibited.
  • the lipolytic enzyme is added to the mixture at a ratio of 0.05 to 10% by mass, and the transesterification is performed for a period of 2 to 48 hours. This reaction is desirably carried out in a nitrogen stream at normal pressure. Completion of the reaction is confirmed by measuring the triglyceride composition of the reaction product by gas chromatography.
  • the reaction product is washed with water, dried, and then decolorized and deodorized by an ordinary method.
  • a medium-chain fatty acid it is preferable to remove free fatty acids by a thin-film evaporator after the reaction is stopped.
  • the present invention can be produced by mixing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, or by mixing and mixing oils and fats containing these.
  • the hormone-sensitive lipase expression enhancer, the ⁇ 3-adrenoceptor expression enhancer, the body fat degradation promoter, and the body fat blood release promoter of the present invention are medium-chain fatty acids and glycerin containing ⁇ or medium-chain fatty acids as described above. It is characterized by containing fatty acid esters, and its use is optional.
  • hormone-sensitive lipase expression enhancer, / 33-adrenoceptor It can be used as a body expression enhancer, a body fat degradation promoter, and a body fat blood release promoter.
  • an agent for enhancing expression of hormone-sensitive lipase of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids [33-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter
  • the amount to be mixed in depends on the application, dosage form, although it varies depending on the conditions such as the type, age, sex, weight, degree of symptoms, and health condition of the administration target, it is not specified, but it is contained to the extent that it exerts its functions on adipose tissue.
  • the content of the medium-chain fatty acid and the glycerin fatty acid ester containing Z or the medium-chain fatty acid in the entire hormone-sensitive lipase expression enhancer of the present invention is not particularly limited as long as it has a hormone-sensitive lipase expression-enhancing effect.
  • the term “containing as an active ingredient” means that the lipase is contained to such an extent as to enhance the expression of mRNA of the hormone-sensitive lipase.
  • the content is not particularly limited, and the frequency of ingestion, the amount of ingestion, and the use of It may be appropriately adjusted depending on the purpose of use.
  • the amount required to obtain the effect depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited.
  • 0.5 g / day or more, preferably lgZ days or more It is preferably 2 g Z days or more, more preferably 5 g days or more, particularly preferably 8 g Z days or more, and most preferably 10 g Z days or more.
  • the content of the product of the present invention for obtaining the effect over a long period of time depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited.
  • 0.5 mass% or more. Preferably 1% by mass or more, more preferably 5% by mass. / 0 or more, more preferably 5-9 9.9 mass%, the properly especially preferred 1 0-9 9.9 mass 0/0, most particularly preferably 1 3-9 9.9 mass%.
  • the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid is not particularly limited as described above. 0-9 9. 9% by weight, preferably 7 0-9 9. 9 wt%, rather more preferably may be exemplified 9 0-9 9. 9 mass 0/0.
  • Medium chain fatty acids and glycerin fatty acid esters containing no or medium chain fatty acids are generated by the presence of medium-chain fatty acids.
  • the characteristics of the effect differ depending on the content ⁇ the structure of the glycerin fatty acid ester.
  • the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
  • fatty acid esters in which at least one or more medium-chain fatty acids are bonded to glycerin (hereinafter referred to as “MLCT”), or glycerin specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids
  • MLCT medium-chain fatty acids
  • structure specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids
  • Fatty acid esters hereinafter referred to as "structure” and “structured fat”
  • the content of the medium-chain fatty acid and the content of the MLCT and the structured fat / oil in the preparation or the like containing the MLCT or the structure (oil / fat) can be referred to the above.
  • the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
  • the ratio of medium-chain fatty acids to total fatty acids is 3 to 23% by mass, preferably 4 to 20% by mass, and more preferably.
  • the 5-1 7 wt%, in particular rather preferably from 6 1 to 5 wt ° / 0, most preferably 7-1 4 wt%, rather most particularly preferred is 8-1 3 mass 0/0.
  • the amount required as a medium-chain fatty acid for obtaining the hormone-sensitive lipase expression-enhancing effect is not particularly limited as described above, but is, for example, 0.4 g / day or more, preferably 1 g day or more, more preferably Is 2 gZ days or more, more preferably 5 g / day or more, particularly preferably 8 gZ days or more, and most preferably 10 g / day or more. .
  • a preferred embodiment of the present invention relates to a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient.
  • the medium-chain triglycerin fatty acid ester is as described above.
  • the content in this case is not particularly limited as described above, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, and further preferably 5 to 99.9% by mass. %, Particularly preferably from 10 to 99.9% by weight, most preferably from 13 to 99.9% by weight.
  • the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid in the whole 3-adrenergic receptor expression enhancer of the present invention is such that the agent has a 3-adrenergic receptor expression enhancing action. It is not particularly limited.
  • containing as an active ingredient means that it is contained to such an extent that it enhances mRNA expression of the 3-adrenergic receptor, but its content is not particularly limited, and the frequency and frequency of ingestion It may be adjusted as appropriate depending on the amount and purpose of use.
  • the amount required to obtain the effect depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited.For example, 0.5 g Z days or more, preferably 1 g / day or more, More preferably, the amount is 2 g / day or more, further preferably 5 g / day or more, particularly preferably 8 g / day or more, and most preferably 10 g / day or more.
  • the content is not particularly limited, for example, 0.5 quality % By mass, preferably 1% by mass or more, more preferably 5% by mass or more, still more preferably 5 to 99.9% by mass, particularly preferably 10 to 99.9% by mass, most particularly preferably 13 to 99.9% by mass.
  • the content of the medium-chain fatty acid or the glycerin fatty acid ester containing the medium-chain fatty acid is not particularly limited as described above. , 50 to 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass.
  • the medium chain fatty acid and / or glycerin fatty acid ester containing the medium chain fatty acid, that is, each function is generated by the presence of the medium chain fatty acid.
  • the characteristics of the effect vary depending on the content and the structure of the glycerin fatty acid ester. +
  • the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
  • the strength of the effect, temporal characteristics (immediate effect, sustainability), occurrence of other factors, etc. differ depending on the structure of the absorption pathway depending on the structure.
  • it is possible to design the strength of functions, temporal characteristics, etc., and to design safety.
  • MLCT fatty acid ester
  • Glycerin fatty acid esters hereinafter, referred to as “structures” and “structured fats and oils”) can be exemplified.
  • the content of the medium-chain fatty acid, the MLCT, and the content of the structural fat in the preparation containing the MLCT or the structure (oil or fat) can be referred to the above.
  • the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
  • the ratio of medium-chain fatty acids to total fatty acids is 3 to 23% by mass, preferably 4 to 20% by mass, and more preferably. Is from 5 to 17% by weight, particularly preferably from 6 to 15% by weight, most preferably from 7 to 14% by weight, most preferably from 8 to 13% by weight.
  • the amount required as a medium-chain fatty acid for obtaining the effect of enhancing the expression of 3-adrenergic receptor is not particularly limited as described above, but is, for example, 0.4 g or more days, preferably 1 g Z days or more. More preferably, 2 gZ days or more, further preferably 5 gZ days or more, particularly preferably 8 gZ days or more, and most preferably 10 gZ5 or more.
  • a preferred embodiment of the present invention relates to a 3-adrenergic receptor expression enhancer containing a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient.
  • the medium-chain triglycerin fatty acid ester is as described above.
  • the content in this case is not particularly limited as described above, but is, for example, 0.5 mass% or more, preferably 1 mass% or more, more preferably 5 mass% or more, and further preferably 5 to 99.9 mass%. %, Particularly preferably from 10 to 99.9% by weight, most preferably from 13 to 99.9% by weight.
  • the content of the medium-chain fatty acid and the glycerin fatty acid ester containing the medium Z or the medium-chain fatty acid in the whole body fat degradation promoter of the present invention is not particularly limited as long as the content thereof has the body fat degradation promoter action.
  • To be contained as an active ingredient means to be contained to such an extent that the body fat degradation promoter is exhibited, but the content is not particularly limited, and may be appropriately adjusted according to the frequency of ingestion, the amount of ingestion, and the purpose of use. . The amount required to obtain the effect depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited.
  • 0.5 g or more Z days preferably 1 g / day or more More preferably, it is 2 g Z days or more, more preferably 5 g / day or more, particularly preferably 8 g / 7 days or more, and most preferably 10 g / day or more.
  • the content is not particularly limited, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, further preferably 5 to 99.9% by mass, and particularly preferably 10% by mass. From 9 to 99.9% by weight, most preferably from 13 to 99.9% by weight.
  • the content of a medium-chain fatty acid and a glycerin fatty acid ester containing a medium- or medium-chain fatty acid is not particularly limited as described above. To 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass.
  • Medium chain fatty acids and glycerin fatty acid esters containing Z or medium chain fatty acids, ie, their functions are generated by the presence of medium chain fatty acids.
  • the characteristics of the effect vary depending on the content and the structure of the glycerin fatty acid ester.
  • the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
  • fatty acid esters in which at least one or more medium-chain fatty acids are bonded to glycerin hereinafter referred to as “MLCT”
  • MLCT medium-chain fatty acids
  • structures specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids
  • Fatty acid esters hereinafter, referred to as “structures” and “structured fats and oils”.
  • the content of the medium-chain fatty acid, the MLCT, and the content of the structural fats and oils in the preparations containing the MLCT and the structure (oils and fats) can be referred to the above.
  • the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
  • the ratio of medium-chain fatty acids to total fatty acids is 3 to 23 mass%, preferably 4 to 20 mass ° / 0 , It is more preferably from 5 to 17% by weight, particularly preferably from 6 to 15% by weight, most preferably from 7 to 14% by weight, most preferably from 8 to 13% by weight.
  • the amount required as a medium-chain fatty acid for obtaining the body fat degradation promoting effect is not particularly limited as described above, but is, for example, 0.4 g Z days or more, preferably 1 g days or more, more preferably Is more than 2 g Z days, more preferably more than 5 g Z days, particularly preferably more than 8 g / day, most particularly preferably
  • More than 10 g Z days can be exemplified.
  • a preferred embodiment of the present invention relates to a body fat degradation promoter containing a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient.
  • the medium-chain triglycerin fatty acid ester is as described above.
  • the content in this case is not particularly limited as described above, but is, for example, 0.5% by mass or more, preferably Is 1% by mass or more, more preferably 5% by mass or more, further preferably 5 to 99.9% by mass, particularly preferably 10 to 99.9% by mass, and most preferably 13 to 99.9% by mass. 9 mass is 0/0.
  • a medium-chain fatty acid triglycerin fatty acid ester as a main component, and the content can be exemplified as described above.
  • the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid relative to the whole body fat blood release-promoting agent of the present invention is particularly limited as long as it contains the body fat blood release-promoting agent.
  • containing as an active ingredient means containing the substance to the extent that it exerts its body fat blood release promoter, but the content is not particularly limited, and the frequency of ingestion, the amount of ingestion, and the use of What is necessary is just to adjust suitably according to the objective. Requirements for obtaining the effect, ingestion of forms, subject's sex, weight, varies based on the physical condition and the like are not particularly limited, for example, 0.
  • 5 ⁇ Bruno day or more preferably lg day or more, more It is preferably 2 g / 3 or more, more preferably 5 gZ days or more, particularly preferably 8 gZ days or more, and most preferably 10 g / day or more.
  • the content is not particularly limited, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, further preferably 5 to 99.9% by mass, and particularly preferably 10% by mass. To 99.9% by weight, most preferably 13 to 99.9% by weight.
  • the content of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids is not particularly limited as described above. 50 to 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass.
  • the effect differs depending on the content of glycerin and the structure of the glycerin fatty acid ester.
  • the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
  • fatty acid esters in which at least one or more medium-chain fatty acids are bonded to glycerin (hereinafter referred to as “MLCT”), or glycerin specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids
  • MLCT medium-chain fatty acids
  • structures and structured fats and oils
  • the content of the medium-chain fatty acid and the content of the MLCT and the structured fat / oil in the preparation or the like containing the MLCT or the structure (oil / fat) can be referred to the above.
  • the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
  • the proportion is 3 to 2 3% by weight of medium chain fatty acids to the total fatty acids, the preferred properly 4-2 0 weight 0/0, more preferably 5-1 7 mass%, particularly preferably rather from 6 1 to 5 wt%, and most preferably 7 to 4% by weight, most particularly rather preferably is 8-1 3 mass 0/0.
  • a medium-chain fatty acid for obtaining the body fat blood release promoting effect.
  • the required amount is not particularly limited as described above, for example, 0.4 g / or more, preferably 1 g / day or more, more preferably 2 g / day or more, and still more preferably 5 g / day Above, particularly preferably 8 g / day or more, most preferably 10 g Z day or more.
  • a preferred embodiment of the present invention relates to a body fat blood release promoter containing a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient.
  • the medium-chain triglycerin fatty acid ester is as described above.
  • the content in this case is not particularly limited as described above, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, and still more preferably 5 to 99.9% by mass. Particularly preferably, it is 10 to 99.9% by mass, most preferably 13 to 99.9% by mass.
  • a medium-chain fatty acid triglycerin fatty acid ester as a main component, and the content can be exemplified as described above.
  • the hormone-sensitizing lipase expression enhancer, J33-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, etc. of the present invention are used in humans and animals, as pharmaceuticals, It can be safely administered orally or parenterally as a quasi drug.
  • Parenteral administration includes, for example, intravenous injection, arterial injection, intramuscular injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intraspinal injection, epidural injection, transdermal administration, pulmonary administration, nasal administration, Enteral administration, buccal administration, transmucosal administration and the like are mentioned, and examples of the dosage form include injections, suppositories (such as rectal suppositories, urethral suppositories, and vaginal suppositories).
  • suppositories such as rectal suppositories, urethral suppositories, and vaginal suppositories.
  • Oral preparations include, for example, tablets for internal use (uncoated tablets, sugar-coated tablets, coated tablets, enteric-coated tablets, chewable tablets, etc.) and oral tablets (pacal tablets, sublingual tablets, troche tablets, adhesive tablets, etc.) ), Powders, capsules (hard capsules, soft capsules, etc.), granules (coated, pills, troches, liquids, or pharmaceutically acceptable sustained-release preparations thereof) No. Oral throw ,
  • liquid preparations include water solutions for internal use, shaking mixtures, suspensions, emulsions, syrups, dry syrups, elixirs, dips, decoctions, limonades, and the like. There is no particular limitation.
  • the embodiment of the oil and fat composition is also one of the preferred embodiments.
  • compositions are formulated together with pharmacologically acceptable bases, carriers, excipients, binders, disintegrants, lubricants, coloring agents, etc. according to known pharmaceutical manufacturing methods. Is administered.
  • Carriers and excipients used in these preparations include, for example, saccharides (lactose, sucrose, pudose, etc.), starch (corn, potato, wheat), mannitol, calcium carbonate, calcium phosphate, calcium sulfate, crystalline cellulose, Examples include microcrystalline cellulose, powdered Canzo powder and gentian powder.
  • Binders used in these preparations include, for example, starch, tragacanth gum, gelatin, syrup, polyvinyl alcohol, polyvinyl butyral, polyvinylpyrrolidone, hydroxypropinoresenorelose, methinoreserulose, ethinorescellulose, carboxymethylcellulose. And so on.
  • Disintegrants used in these preparations include, for example, starch, agar, gelatin powder, sodium carboxymethylcellulose, calcium carboxymethylcellulose, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, sodium alginate and the like.
  • Lubricants used in these preparations include, for example, magnesium stearate, talc, hydrogenated vegetable oil, macrogol and the like.
  • coloring agents used in these preparations those permitted to be added to pharmaceuticals can be used.
  • each functional agent of the present invention is an oily component, nutritional and physiological functions that have good solubility in these are included.
  • Q phospholipids, triterpenes, oryzanol, etc. can be added.
  • hormone-sensitized lipase expression enhancer of the present invention is characterized by containing a medium-chain fatty acid and a glycerin fatty acid ester containing z or a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester.
  • hormone-sensitive lipase is a lipase (an enzyme that hydrolyzes the ester bond of acylglycerol) present in adipose tissue, and converts triglycerin fatty acid esters accumulated in adipose tissue into glycerol and free fatty acids.
  • hormone-sensitive lipase expression enhancer refers to an agent that enhances the mRNA expression level of the enzyme.
  • an increase in the mRNA expression level of an enzyme indicates an increase in the enzyme activity, and thus serves as a criterion for determining the strength of the enzyme activity.
  • the mRNA expression level of the enzyme is measured by real-time quantitative PCR using specific primers. Thus, the expression amount of the enzyme niRNA was quantitatively calculated and the increase or decrease was confirmed.
  • a standard curve was prepared using as a standard a sample of total RNA derived from adipose tissue of the same age in rats fed normal chow and converted to DNA using reverse transcriptase.
  • the relative value of the mRNA expression level of the enzyme relative to the mRNA level of the housekeeping gene / 3 / 3-actin was calculated in% and evaluated by comparing it with that of rats fed the long-chain fatty acid triglycerin fatty acid ester. ing. By taking the product of the present invention for a long time, this value is 125 to 170%. Therefore, a suitable hormone-sensitive lipase expression enhancer can be provided by the present invention.
  • the above hormone-sensitive lipase is stimulated by sympathetic nerves or the like by ingesting medium-chain fatty acid Z or glycerin fatty acid ester containing medium-chain fatty acid, preferably medium-chain fatty acid triglycerin fatty acid ester. It is thought that it is transmitted into cells via receptors on adipocytes and activated as a result of increased expression of the enzyme mRNA gene. In fact, the ingestion of the product of the present invention has been found to increase the mRNA expression level of / 33-adrenoceptor, one of the receptors for adrenergic, a sympathetic nerve active substance, on adipocytes.
  • the invention provides a J33-adrenergic receptor expression enhancer comprising a medium chain fatty acid and a glycerin fatty acid ester containing a medium chain fatty acid, preferably a medium chain fatty acid triglycerin fatty acid ester.
  • a medium chain fatty acid preferably a medium chain fatty acid triglycerin fatty acid ester.
  • the increase in mRNA expression of the 3-adrenergic receptor can be used as an index of the increase in mRNA expression of the hormone-sensitive lipase.
  • the expression of the 3-adrenergic receptor is enhanced, it is considered that the expression of the hormone-sensitive lipase is enhanced.
  • the body lipolysis-promoting action is based on the hormone-sensitive lipase mRNA described above. It is easily recognized by the increase in the present amount and the amount of free fatty acids in blood described in detail below. In other words, body fat accumulated in fat cells is broken down by hormone-sensitive lipase and released into the blood as free fatty acids, or oxidized again in fat cells to become an energy source, resulting in the breakdown of body fat You can see that Investigations based on these indices revealed that the ingestion of medium-chain fatty acids Z or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain fatty acid triglycerin fatty acid esters, resulted in hormone-sensitive lipase! ! ! The expression level was increased about 1.3 to 2 times as compared to the intake of soybean oil. C Furthermore, the blood free fatty acid concentration was also significantly increased, indicating that the body fat degradation is progressing according to the present invention.
  • Triglycerin fatty acid esters accumulated in fat cells as body fat are converted into free fatty acids by ingesting medium chain fatty acids and / or glycerin fatty acid esters containing medium chain fatty acids, preferably medium chain fatty acid triglycerin fatty acid esters.
  • the free fatty acids are released into the blood. It can be seen that the long-term intake of the present invention significantly increased the free fatty acid concentration in blood as compared to the target soybean oil intake group.
  • Ingestion of the product of the present invention causes some signals to be generated from the sympathetic nerves, etc., that the presence of MCT itself acts as a stimulant, and that ketone bodies formed by burning MCT in the liver cause irritation. It is considered that they are caused by the combination of these.
  • MCTs are completely burned and the energy sources derived from ingestion have died, so peripheral energy storage organs It is considered that free fatty acids are released from the adipose tissue by the same mechanism of action as described above, and lipoprotein is supplied to each tissue as an energy source.
  • the amount may be a certain amount for the signal and the like to be emitted and for the function to be exhibited. In other words, it is as if you only need to take a certain amount necessary to press the switch.
  • the purpose can be achieved by ingesting a high-concentration product or a large amount, but the purpose can also be achieved by ingesting a relatively low-concentration product or a small amount. Based on this point, it can be adjusted according to the usage mode and the intake period as described above. In particular, since glycerin fatty acid esters containing medium-chain fatty acids and glycerol or medium-chain fatty acids are energy sources, products designed to suppress excessive intake are preferred. Is preferred.
  • the effect of reducing body fat can be measured by the amount of body fat in the total body weight of an animal. That is, after a test animal ingests the product of the present invention or the long-chain fatty acid triglyceride for a long time, the visceral fat and percutaneous fat such as perirenal adipose tissue, epididymal adipose tissue, and mesenteric adipose tissue are combined. It is determined by comparing the amount of body fat in the body per body weight.
  • the visceral fat weight is reduced by approximately 8 to 15%, the subcutaneous fat weight is reduced by 10 to 20%, and the combined body fat weight is reduced by 10 to A decrease of about 18% was observed, and a significant decrease was observed.
  • the results of the long-term feeding test using the animal show that UCP is expressed in subcutaneous fat higher than visceral fat with the consumption of energy in the test animal.
  • This and the above test results show that the decomposition of body fat according to the present invention is preferentially performed from subcutaneous fat. That is, the present invention provides a smooth body fat decomposition that does not burden the body.
  • the body fat reducing effect of the present invention differs from the conventionally known low body fat accumulating property in the content of the effect.
  • Low body fat accumulation simply means that the ingested medium-chain fatty acid triglyceride, etc. is not easily accumulated in the body, but is easily burned without energy, so that it is easy to generate fat because it easily becomes energy.
  • the body fat reduction effect found in the present invention means that the body fat is reduced by ingestion and continuous intake, in addition to low accumulation, by decomposing body fat accumulated so far. Is shown.
  • the present invention when the present invention is taken continuously for a long period of time, the body weight is reduced, and the body protein and water content are different even though the food intake is almost the same as when LCT was taken. This indicates that the body fat weight is clearly reduced. That is, the change in body weight is reduced by 7 to 15% and the weight of body fat is reduced by about 10 to 18% as compared with the intake of LCT. Therefore, an excellent slimming effect is recognized.
  • the present invention relates to an increase in the expression of hormone-sensitive lipase containing medium-chain fatty acid and glycerin fatty acid ester containing Z or medium-chain fatty acid as an active ingredient, an increase in expression of ⁇ 3-adrenoceptor, promotion of body lipolysis, and release of body fat into blood.
  • the present invention relates to a fat and oil composition for promotion.
  • the expression of hormone-sensitive lipase containing medium-chain fatty acid triglycerin fatty acid ester as an active ingredient is enhanced,
  • the present invention relates to an oil / fat composition for enhancing expression of adrenergic receptors, promoting body fat degradation, and promoting body fat blood release.
  • the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid can be obtained from fats and oils, and has good solubility in fats and oils.
  • Adrenaline receptor expression enhancer, body fat degradation promoter, body fat blood release promoter One of the preferred forms of food and drink for enhancing the expression of hormone-sensitive lipase, enhancing the expression of / 33-adrenergic receptor, promoting body fat degradation, and promoting the release of body fat into blood, as shown below, is a medium chain.
  • An oil / fat composition containing a glycerin fatty acid ester containing a fatty acid and / or a medium-chain fatty acid is exemplified.
  • the oil / fat composition is preferably produced in the process.
  • the form of the oil / fat composition may be any of a liquid, a solid, and a semi-solid, and is not particularly limited.
  • the oil / fat composition of the present invention is also a form of the above-mentioned hormone-sensitive lipase expression enhancer, 3-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, and It is a form of food and drink for enhancing the expression of lipase, enhancing the expression of 33-adrenoceptor, promoting the decomposition of body fat, and promoting the release of fat into the body, and also as a raw material to be added to these. It can also be used for cooking, and as a result of its use in foods and drinks, indirectly affects foods and drinks.
  • the content of medium-chain fatty acid and glycerin fatty acid ester containing z or medium-chain fatty acid and medium-chain fatty acid triglycerin fatty acid ester in the oil / fat composition is the content of the agent when it is used as an agent, and is used as a food or drink. If it is used, it is the content of food and drink.
  • the content is different by the use of the food, For example 5-9 0% by weight, preferably 7-9 0 weight 0/0, more preferably 1 0 to 90% by mass, more preferably 15 to 70% by mass or more, and particularly preferably 20 to 25% by mass or more.
  • the oil / fat composition of the present invention can be obtained by subjecting an oil / fat containing a medium-chain fatty acid triglycerin fatty acid ester to a transesterification treatment as described above, and using a gene recombination technique as described above.
  • oil and fat composition of the present invention for example, soybeans, rapeseed, corn, palm, palm, olive, linseed, sunflower, safflower, tsubaki, cottonseed, khair, etc. It is.
  • the fat and oil composition of the present invention obtained as described above can be used as it is or as a cooking fat and oil composition by blending additives usually used in cooking fat and oil compositions.
  • additives examples include polyglycerin fatty acid esters, sucrose fatty acid esters, and sorbitan fatty acid esters for the purpose of improving storage stability, improving oxidative stability, improving thermal stability, suppressing crystallization at low temperatures, and the like. .
  • additives that can be added in the above-mentioned hormone-sensitive lipase expression enhancer, 33-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, etc. are also blended. can do.
  • the oil / fat composition of the present invention has a flavor equal to or higher than ordinary edible oils such as rapeseed oil, corn oil, safflower oil, and soybean oil, and is used for cooking stir-fry, fried food, marinade, etc. Not only can it be used, but it can also be used for foods containing fats and oils such as dressings, mayonnaise, margarine, confectioneries, cakes and beverages.
  • the flavor characteristics differ depending on the type of food, but it is possible to make a refreshing dish that takes advantage of the taste of the ingredients.
  • the degree of splash of oil during frying is equal to or lower than that of ordinary cooking oil.
  • the present invention relates to a hormone-sensitive lipase-containing expression-enhancing agent containing medium-chain fatty acids and glycerol fatty acid esters containing Z or medium-chain fatty acids, a 3-adrenergic receptor expression-enhancing agent, body fat decomposition promotion, body fat blood release promotion Drinking
  • the present invention relates to foods and the like, preferably foods for enhancing the expression of hormone-sensitive lipase containing a medium-chain fatty acid triglycerin fatty acid ester, enhancing the expression of / 33-adrenoceptor, promoting body fat degradation, and promoting body fat blood release.
  • Foods and drinks containing medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain fatty acid triglycerin fatty acid esters, are preferably orally ingested by eating and drinking to enhance the expression of hormone-sensitive lipase. It is a preferred form because it has an effect of enhancing adrenergic receptor expression, promoting body fat decomposition, and promoting body fat release into blood.
  • the amount of intake is not particularly limited, but the amount of intake for the various agents described above can be referred to. In addition, excessive intake naturally cannot obtain the effects of the present invention.
  • the content of the food or drink can be adjusted according to the number of times of ingestion, the amount, etc., and is not particularly limited.
  • a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid for example, 0.1 to 0.1 50% by mass, preferably 0.2 to 50% by mass, more preferably 0.5 to 40% by mass, further preferably 1 to 20% by mass, particularly preferably 2 to 10% by mass, when medium chain fatty acid triglyceride, for example, 0.0 5-3 0 weight 0/0, preferably from 0.1 to 3 0 wt%, more preferably from 0.2 to 2 0% by weight, more preferably 0.5 To 10% by mass, particularly preferably 1 to 5% by mass.
  • the content of the medium-chain fatty acid needs to be in a range in which the function can be obtained, and is preferably in the above range, and has a bad effect on the human body.
  • the above-mentioned hormone-sensitive lipase expression enhancer, 3-adrenergic receptor expression enhancer, body lipolysis promoter, body fat blood release promoter, hormone-sensitive lipase expression enhancer, 3-adrenergic receptor expression enhancer In foods and drinks for promoting body fat degradation and promoting release of body fat into the blood, the content can be defined by medium-chain fatty acids or the total amount of medium-chain fatty acids and medium-chain fatty acid residues. It can be calculated from the content of the medium-chain fatty acid triglyceride.
  • the form of the food or drink for enhancing the expression of the hormone-sensitive lipase of the present invention, enhancing the expression of / 33-adrenoceptor, promoting body fat degradation, and promoting body fat blood release is not particularly limited.
  • Food and beverages include beverages, nutritional drinks, confectionery, processed foods, fats and oils, dairy products, retort foods, range foods, frozen foods, seasonings, health supplements, etc., and the shape and properties are particularly limited. Instead, they may be solid, semi-solid, gel, liquid, powder, etc., and may be tablets, capsules, liquids, granules, etc.
  • the foods and drinks for enhancing the expression of hormone-sensitive lipase, enhancing the expression of 133-adrenoceptor, promoting body fat degradation, and promoting body fat blood release according to the present invention are listed below, but the present invention is not limited thereto. Not something.
  • the food and drink for enhancing the expression of hormone-sensitive lipase, enhancing the expression of 3-adrenoceptor, promoting body fat degradation, and promoting the release of body fat into blood according to the present invention are not particularly limited with regard to the form and the like.
  • Retort foods such as tsukudani, curry, stew, etc., miso, soy sauce, sauce, ketchup, pyon, grilled meat sauce, curry roux, stew ingredients, soup ingredients, soup ingredients, various seasonings such as rice, oil and fat, margarine Fats and oils processed products such as oils, shortenings, mayonnaises and dressings, and various types of frozen foods containing oils and fats.
  • cooked rice and various seasonings, and oils and fats and processed products such as margarine, shortening, mayonnaise, and dressing are preferable.
  • shape and properties are not particularly limited, and may be any of solid, semi-solid, gel, liquid, powder, etc., tablets and soft capsules for use as a health supplement food and drink, etc. ⁇ Filled into hard capsules ⁇ Any added forceps, liquids, granules, etc. may be used.
  • Particularly preferred forms are foods and drinks in the form of fats and oils compositions, and foods and drinks cooked using the fats and oils composition, and foods and drinks mixed therewith.
  • medium-chain fatty acid triglycerides and the like are fats and oils, Since it can be obtained in the process of producing medium-chain triglycerides, it is excellent in usability, stability, manufacturability and the like.
  • the uncoupling protein expression enhancer and the oil / fat composition can be blended. Moreover, it can also be obtained by cooking using the fat or oil composition. Foods and drinks for enhancing the expression of hormone-sensitive lipase, enhancing the expression of 3-adrenoceptor, promoting body fat degradation, and promoting release of body fat into the blood are used for diabetes, arteriosclerosis, hyperlipidemia, and hypertension. It is preferable because it is expected to have a preventive and / or Z- or ameliorating effect on lifestyle-related diseases such as.
  • medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain triglycerin fatty acid esters can be used as a hormone-sensitive lipase expression enhancer.
  • a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester can be used as a ⁇ 3-adrenergic receptor expression enhancer.
  • a medium-chain fatty acid or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester can be used as a body fat degradation promoter.
  • a medium-chain fatty acid and a glycerin fatty acid ester containing a medium- or medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester can be used as a body fat blood release accelerator.
  • the present invention provides a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and a glycerol fatty acid ester containing a medium-chain fatty acid, a / 33-adrenergic receptor expression-increasing agent, and a body fat degradation promoting agent.
  • a hormone-sensitive lipase expression enhancer characterized by containing medium-chain fatty acid triglyceride, 33-ad The present invention relates to raw materials for a renaline receptor expression enhancer, a body fat degradation promoter, and a body fat blood release promoter.
  • the hormone-sensitized lipase expression enhancer, ⁇ 3-adrenoceptor expression enhancer, body fat degradation accelerator, body fat blood release enhancer, etc. of the present invention are medium-chain fatty acids and / or glycerin fatty acids containing medium-chain fatty acids. It is characterized by containing an ester, especially a medium-chain fatty acid triglyceride, which enhances the expression of hormone-sensitive lipase, increases the expression of 3-adrenergic receptor, promotes body fat degradation, and releases body fat into the blood. It has a promoting effect.
  • medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids are those that enhance the expression of hormone-sensitive lipase, those that increase the expression of ⁇ 3-adrenoceptor, and those that degrade body fat. It is suitable as a raw material for an accelerator and a body fat blood release accelerator, and those containing a high concentration are particularly suitable as raw materials.
  • the content is not particularly limited, but is, for example, 5 to 99.9% by mass, preferably 10 to 99.9% by mass, more preferably 20 to 99.9% by mass, and further preferably 5 to 99.9% by mass. 0-99.9 mass. / 0 , particularly preferably 70 to 99.9% by mass, and most preferably 90 to 99.9% by mass.
  • RNA in the extracted epididymal fat was homogenized with Isogen (manufactured by Nitsubon Gene), and then extracted with black mouth form and isopu pill alcohol to obtain total RNA.
  • Isogen manufactured by Nitsubon Gene
  • reverse transcriptase of M—MLV manufactured by Promega
  • reaction buffer 0.5 mM dNTP (manufactured by Invitrogen)
  • 25 g / m1 oligo (dT) 15 primer Promega
  • cDNA type II from rat epididymal fat fed solid feed (Lab MR—Stock: manufactured by Nippon Agricultural Products) was used as a reference.
  • the expression level of hormone-sensitive lipase melon in cDNA type I derived from the same organ in each group was measured using a quantitative PCR device (Light Cycler: manufactured by Roche Diagnostics). The expression level (%) was compared with the ⁇ -actin mRNA expression level, as shown in Equation 1. The expression of 3-adrenergic receptor mRNA was compared by the same method.
  • MRNA expression level (%) of hormone-sensitive lipase, etc. (mRNA expression level of rat hormone-sensitive lipase, etc.) Z (rat 3-actin mRNA expression level of rat) X100 Hormone-sensitive lipase by the above method)
  • the effect of enhancing the expression of 33-adrenoceptor mRNA was evaluated. The results are shown in Table 1 as mRNA expression levels (%). Table 1>
  • the triglycerin fatty acid ester stored in the adipose tissue is suitably decomposed into glycerol and free fatty acids.
  • the fat composition of the present invention decomposed body fat accumulated in adipose tissue compared to soybean oil and released it into the blood, It can be seen that an excellent effect can be obtained by ingestion.
  • the fat and oil composition containing a medium-chain fatty acid triglyceride as an active ingredient has a power s and a low body fat accumulation effect.
  • the fat composition-added group showed a particularly large decrease in subcutaneous fat weight compared to the rats in the soybean oil-added group. In other words, there is relatively little loss of visceral fat, It can be seen that the body fat is reduced while maintaining the function.
  • comparison with Example 1 shows that an increase in the expression level of hormone-sensitive lipase and J33-adrenoceptor greatly affects fat burning.
  • the manner of burning fat in various parts of the body when the medium-chain fatty acid triglyceride was administered was investigated and examined in comparison with the case where the medium was not administered.
  • the investigation was performed by comparing the time-dependent changes in the expression level of UCP at each site.
  • changes over time in the expression levels of hormone-sensitive lipase and 33-adrenoceptor were also performed.
  • UC P-2 UC P-2 of rats in the oil composition group
  • UCP-2 ' UCP-2 of rats in the soybean oil-supplemented group.
  • Table 5 shows the measured values in the above table. Table 5>
  • LCT soybean administration group MC :: fat composition addition group
  • Table 6 shows the expression levels of hormone-sensitive lipase and ⁇ 3-adrenoceptor at each site.
  • LCT soybean administration group MC :: fat and oil composition added group
  • MC fat and oil composition added group
  • each substance was mixed well, and the mixture was tableted to obtain a 30 Omg tablet composition per tablet.
  • (1) was first mixed well with (2), and then (3) was added in an appropriate amount to make the total amount 1 ml, whereby an injection was obtained.
  • This solution can be administered by diluting it with an appropriate amount of physiological saline.
  • the mixture obtained in the mixing ratio shown in Table 12 was added to water, molded, and heated and dried in an oven to obtain a spherical cereal food.
  • the raw materials shown in Table 14 were mixed by a conventional method, and quenched and kneaded using a combination to obtain margarine.
  • Rapeseed oil 37.0 g Medium-chain fatty acid triglyceride 2.0 g Hardened rapeseed oil 42.0 g Water 1 7.0 g
  • the raw materials excluding soybean salad oil, medium-chain fatty acid triglyceride, and salted egg yolk were heated to 90 ° C with mixing and stirring, and stirred for 25 minutes while maintaining at 90 ° C. .
  • soybean salad oil, medium-chain fatty acid triglyceride, and salted egg yolk were combined and stirred under reduced pressure to obtain mayonnaise.
  • Soybean salad oil 45.0 g Medium-chain fatty acid triglyceride 30.0 g Water 8.4 g Sugar 1.0 g Sodium glutamate 0.3 g Powder mustard 0.3 g Salt 1.0 g Rice vinegar 4.0 g Salted egg yolk 10.0 g
  • the raw materials shown in Table 17 were mixed by a conventional method, and quenched and kneaded using a combination to obtain margarine.
  • Oil composition A 39.0 g Hardened rapeseed oil 42.0 g Water 1 7.0 g
  • the body fat degradation promoter of the present invention By taking the body fat degradation promoter of the present invention and the like, the accumulated body fat is reduced and the like, so that a very excellent slimming effect can be enjoyed. Also, medium-chain fatty acid triglycerin fatty acid esters and the like are safe for the human body, and the effects of the present invention can be obtained by ingesting them naturally at meals and the like. In addition, calorie restriction is usually imposed in order to obtain a slimming effect, etc., but according to the body lipolysis accelerator of the present invention, health is maintained without overdosing such a body. This effect can be suitably obtained while doing so.

Abstract

It is intended to provide preparations and foods and drinks having an effect of promoting the degradation of body fat, etc., i.e., a hormone-sensitive lipase expression promoter, a β3-adrenaline receptor expression promoter, a body fat degradation promoter, an agent promoting the liberation of body fat into the blood, each containing as the active ingredient medium-chain fatty acids and/or glycerol fatty acid esters containing medium-chain fatty acids (in particular, medium-chain fatty acid triglycerol fatty acid esters), foods and drinks containing the same, materials thereof and fat compositions and use thereof in the fields of medicines and foods. Namely, preparations, foods, drinks and fat compositions having an effect of promoting the degradation of body fat, etc. which contain as the active ingredient medium-chain fatty acids and/or glycerol fatty acid esters containing medium-chain fatty acids. Also, body fat degradation promoters and foods and drinks having an orientation wherein the above-described effect of promoting the degradation of body fat, etc. is preferentially exerted on subcutaneous fat in association with the energy consumption in the body.

Description

明 細 書 体脂肪分解促進剤および飲食物 技術分野  Description Body fat degradation promoter and food and beverage technology
本発明は、 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステル、 特に中鎖脂肪酸トリグリセリン脂肪酸エステルを有効成 分とするホルモン感受性リパーゼ発現亢進剤、 /3 3—アドレナリン受容 体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤、 およびそれ らの飲食物、 原料、 油脂組成物に関し、 これらの医薬ならびに食品分野 におけるその使用に関する。 背景技術  The present invention relates to a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, in particular, a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient, / 33-adrenergic receptor expression The present invention relates to enhancers, body fat degradation promoters, body fat blood release promoters, and their foods, drinks, raw materials, and fats and oils compositions, and to their use in the pharmaceutical and food fields. Background art
近年、 日本人の食事は著しく欧米化し、 高カロリー化が進んでいる。 その結果、 他の先進国同様、 我が国においても肥満患者が増大し、 大き な社会問題になりつつある。 肥満とは、 消費エネルギーよりも摂取エネ ルギ一の方が過剰となり、 脂肪組織が通常以上に蓄積した身体状況のこ とを言う。 肥満になると、 体脂肪が多く蓄積することによって糖尿病、 高血圧症、 心血管障害、 高脂血症、 動脈硬化等の種々の疾病を引き起こ し、 血管障害、 神経障害、 抵抗力低下等の合併症を併発することがある これらいわゆる生活習慣病の予防等の観点から、 肥満を解消する手段に ついて多方面から研究が行われており、 食事療法、 運動療法、 薬物療法 などさまざまな治療法が開発され実施されている。  In recent years, Japanese diets have become remarkably westernized and high in calories. As a result, as in other developed countries, the number of obese patients is increasing in Japan, and it is becoming a major social problem. Obesity is a physical condition in which the intake of energy exceeds the energy expenditure and fat tissue accumulates more than normal. When obesity occurs, a large amount of body fat accumulates, causing various diseases such as diabetes, hypertension, cardiovascular disorders, hyperlipidemia, and atherosclerosis, and is complicated by vascular disorders, neuropathy, reduced resistance, etc. From the perspective of preventing these so-called lifestyle-related diseases, which are sometimes associated with sickness, research has been conducted on various means of resolving obesity, and various treatments such as diet, exercise, and pharmacotherapy have been developed. Developed and implemented.
これらのうち、 特に食事療法のポイントはエネルギー消費が主眼であ り、 よりエネルギーになりやすく体に脂肪がつきにくい食品成分が注目 されている。 主にヤシ油に含まれている中鎖脂肪酸は、 通常の食用油の 主成分である長鎖脂肪酸に比べ、 体内に摂取されると速やかに吸収され かつ肝臓ですぐに燃やされてしまいエネルギー化されやすいことから、 長鎖脂肪酸摂取時に比べ体脂肪の蓄積が少ないことが既に報告されてい る （例えば、 J . L i i d R e s . 3 7、 708 - 726 ( 1 9 9 6) 参照）。 また、 ジグリセリ ドおよぴトリグリセリ ドからなる油脂組 成物成分中、 分子内に中鎖脂肪酸残基を 2つ含有するトリグリセリ ドを 3 1質量％以上含む油脂組成物も、 体脂肪蓄積が少ないことが報告され ている （例えば、 特開平 4— 300826号公報、 特開平 8 _ 60 1 8 0号公報、 特開平 1 0 _ 1 76 1 8 1号公報参照）。 さらに、 ジァシル グリセ口ールゃ共役リノール酸が脱共役蛋白質の発現を特異的に亢進さ せる作用があることが報告されている （例えば、 特開 2001— 64 1 7 1号公報、 特開 2001— 8 1 026号公報参照）。 Of these, the main focus of diet is energy consumption, and food ingredients that are more energy-prone and do not easily add fat to the body are attracting attention. Medium-chain fatty acids mainly contained in coconut oil are Compared to the long-chain fatty acids, which are the main component, they are rapidly absorbed when ingested into the body and burned immediately by the liver, making them more energy-efficient. It has already been reported (see, for example, J. Liid Res. 37, 708-726 (1996)). Also, the fat and oil composition containing 31% by mass or more of triglycerides containing two medium-chain fatty acid residues in the molecule among the fat and oil composition components composed of diglyceride and triglyceride also has low body fat accumulation. (See, for example, JP-A-4-300826, JP-A-8-601800, and JP-A-10-176181). Furthermore, it has been reported that diacyl glycerol-conjugated linoleic acid has an effect of specifically enhancing the expression of uncoupling protein (for example, JP 2001-64171 A, — See Japanese Patent Application Publication No. 81020.
し力 し、 中鎖脂肪酸トリグリセリ ドがホルモン感受性リパーゼゃ 3 ーァドレナリン受容体を特異的に亢進させ、 この結果として積極的な抗 肥満作用を有する旨の報告は未だなされていない。 また、 蓄積している 体脂肪を分解することや、 分解した体脂肪が血中に移行することは知ら れていない。 発明の開示  However, it has not yet been reported that the medium-chain triglyceride specifically enhances the hormone-sensitive lipase 3-adrenoceptor receptor and has a positive anti-obesity effect as a result. In addition, it is not known that the accumulated body fat is decomposed or the decomposed body fat is transferred into the blood. Disclosure of the invention
本発明は、 体に蓄積されている脂肪を分解させる機能を有する製剤、 飲食物を提供する。 その結果、 体脂肪低減効果や痩身効果を得ることを 提供する。 また、 前記体脂肪低減の態様について、 体内エネルギー消費 に伴い皮下脂肪から優先的に燃焼させることによりスムースな体脂肪低 減を提供する。  The present invention provides a formulation, food and drink having a function of decomposing fat accumulated in the body. As a result, it provides a body fat reducing effect and a slimming effect. In addition, in the aspect of the body fat reduction, a smooth body fat reduction is provided by preferentially burning from subcutaneous fat in accordance with internal energy consumption.
本発明者らは、 前記課題を達成する為に鋭意検討した結果、 中鎖脂肪 酸および zまたは中鎖脂肪酸を含むグリセリン脂肪酸エステル、 特に中 鎖脂肪酸トリグリセリ ン脂肪酸エステル （以下 「中鎖脂肪酸トリグリセ リ ド」 （M C T ) ということがある。） 、 体に蓄積された脂肪を分解す ることを見出し、 本発明を完成させた。 また、 前記脂肪を分解する態様 が体内エネルギーの消費に伴い、 皮下脂肪から優先的に分解されること を見出し、 本発明を完成させた。 The present inventors have conducted intensive studies in order to achieve the above object, and found that glycerin fatty acid esters containing medium-chain fatty acids and z or medium-chain fatty acids, The present inventors have found that high-chain fatty acid triglycerin fatty acid ester (hereinafter sometimes referred to as “medium-chain fatty acid triglyceride” (MCT)) degrades fat accumulated in the body, and completed the present invention. In addition, they have found that the mode of decomposing fat is preferentially decomposed from subcutaneous fat with the consumption of internal energy, and completed the present invention.
すなわち、 本発明は以下の内容から成る。  That is, the present invention includes the following contents.
( 1 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とするホルモン感受性リパーゼ発現亢進剤。  (1) A hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 2 ) 中鎖脂肪酸おょぴノまたは中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする皮下脂肪細胞ホルモン感受性リパーゼ発現 亢進剤。  (2) A subcutaneous adipocyte hormone-sensitive lipase expression enhancer comprising, as an active ingredient, a medium-chain fatty acid or a glycerin fatty acid ester containing a medium-chain fatty acid.
( 3 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする β 3—ァドレナリン受容体発現宂進剤。  (3) A β3-adrenergic receptor expression promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 4 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸ェステルを有効成分とする体脂肪分解促進剤。  (4) A body fat degradation promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 5 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする皮下脂肪分解促進剤。  (5) A subcutaneous lipolysis promoter comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
( 6 ) 中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする体脂肪血中放出促進剤。  (6) A body fat blood release promoter comprising a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 7 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする皮下脂肪血中放出促進剤。  (7) A subcutaneous fat blood release promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 8 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする体脂肪が分解しやすい体質への体質改質剤 c (8) Constituent modifier c for medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids as active ingredients, which are suitable for decomposing body fat.
( 9 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪 酸エステルを有効成分とする皮下脂肪が分解しやすい体質への体質改質 剤。 (10) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とするホルモン感受性リパーゼ発現亢進用油脂 組成物。 (9) A constitution modifying agent for a constitution in which subcutaneous fat is easily decomposed, comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient. (10) A fat / oil composition for enhancing expression of hormone-sensitive lipase, comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
(1 1 ) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする β 3—ァドレナリン受容体発現亢進用油 脂組成物。  (11) An oil / fat composition for enhancing β3-adrenergic receptor expression, comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
(1 2) 中鎖脂肪酸および Ζまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする体 ί旨肪分解促進用油脂組成物。  (12) An oil / fat composition for promoting body fat decomposition comprising a medium-chain fatty acid and a glycerol fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 1 3) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂' 肪酸エステルを有効成分とする体脂肪血中放出促進用油脂組成物。  (13) An oil / fat composition for promoting body fat blood release, comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
(14) 中鎖脂肪酸おょぴ または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とするホルモン感受性リパーゼ発現亢進用飲食 物。  (14) A food or drink for enhancing expression of hormone-sensitive lipase, comprising a medium-chain fatty acid salt or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 1 5) 中鎖脂肪酸および Ζまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする皮下脂肪細胞ホルモン感受性リパーゼ発 現亢進用飲食物。  (15) A food or drink for enhancing the expression of subcutaneous adipocyte hormone-sensitive lipase, comprising a medium-chain fatty acid and リ ン or a glycerol fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 1 6) 中鎖脂肪酸および Ζまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする 3—ァドレナリン受容体発現亢進用飲 食物。  (16) A food and drink for enhancing the expression of 3-adrenergic receptors, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 1 7) 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする体脂肪分解促進用飲食物。  (17) A food or beverage for promoting body fat decomposition, comprising a medium chain fatty acid and Z or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
( 1 8) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする皮下脂肪分解促進用飲食物。  (18) A food and drink for promoting subcutaneous lipolysis, comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
( 1 9) 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする体脂肪血中放出促進用飲食物。  (19) A food and drink for promoting release into body fat blood, comprising a medium chain fatty acid and Z or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
(20) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする皮下脂肪血中放出促進用飲食物。 (20) Medium chain fatty acids and / or glycerin fats containing medium chain fatty acids Food and drink for promoting release of subcutaneous fat into blood containing a fatty acid ester as an active ingredient.
(2 1) 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする体脂肪が分解しゃすい体質への体質改質 用飲食物。  (21) A food or drink for modifying the body fat into a degradable body, comprising a medium-chain fatty acid and Z or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
(22) 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを有効成分とする皮下脂肪が分解しやすい体質への体質改 質用飲食物。  (22) A food or drink for modifying the body into a constitution in which subcutaneous fat is easily decomposed, comprising a medium-chain fatty acid and Z or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
(23) 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを含有するホルモン感受性リパーゼ発現亢進剤原料。 ' (24) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを含有する 3一アドレナリン受容体発現亢進剤原料。 (23) A hormone-sensitive lipase expression enhancer raw material containing a medium-chain fatty acid and a glycerol fatty acid ester containing Z or a medium-chain fatty acid. (24) A 3- adrenergic receptor expression enhancer raw material containing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid.
(25) 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを含有する体脂肪分解促進剤原料。  (25) A raw material for body fat degradation promoter containing a medium-chain fatty acid and glycerin fatty acid ester containing Z or a medium-chain fatty acid.
(26) 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂 肪酸エステルを含有する体脂肪血中放出促進剤原料。 図面の簡単な説明  (26) Raw material for body fat blood release promoter containing medium-chain fatty acid and / or glycerin fatty acid ester containing medium-chain fatty acid. BRIEF DESCRIPTION OF THE FIGURES
図 1は、 脂肪組織の脂肪酸代謝を表した図である。  FIG. 1 is a diagram showing fatty acid metabolism in adipose tissue.
図 2は、 体内で、 遊離脂肪酸が燃焼する過程を説明した図である。 図 3の （A) は、 ミ トコンドリア内膜での酸化的リン酸化と脱共役蛋 白質 （UCP) による脱共役を示した図である。  Figure 2 is a diagram illustrating the process of burning free fatty acids in the body. (A) of FIG. 3 shows oxidative phosphorylation at the inner mitochondrial membrane and uncoupling by uncoupling protein (UCP).
図 3の （B) は、 脂肪の燃焼過程について、 脂肪細胞における アド レナリン受容体、 ホルモン感受性リパーゼ、 脱共役蛋白質 （UCP) の 働きを示した図である。  FIG. 3 (B) is a diagram showing the actions of adrenergic receptors, hormone-sensitive lipase, and uncoupling protein (UCP) in fat cells during the fat burning process.
発明を実施するための形態 本発明は、 中鎖脂肪酸および または中鎖脂肪酸を含むグリセリン脂 肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステルが ホルモン感受性リパーゼゃ j3 3—ァドレナリン受容体発現亢進機能を有 することを見出し、 これから体脂肪分解促進機能を有することを見出し ており、 また、 これから体脂肪血中放出促進機能を有することを見出し たことにより、 中鎖脂肪酸おょぴノまたは中鎖脂肪酸を含むグリセリン 脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステル を含有する各機能剤、 飲食物等を完成させている。 さらに、 該体脂肪分 解促進機能および体脂肪血中放出促進機能が発現された結果として体脂 肪が低減することを見出し、 中鎖脂肪酸および/または中鎖脂肪酸を含 むグリセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂 肪酸エステルを含有する機能剤、 飲食物等を完成させている。 また、 中 鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステルを前記機能剤等の 原料とすることを見出している。 また、 中鎖脂肪酸および/ /または中鎖 脂肪酸を含むグリセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグ リセリン脂肪酸エステルを含有する体脂肪分解剤、 飲食物、 原料が、 前 記体脂肪分解機能について、 皮下脂肪から優先的に脂肪が分解されるこ とを見出し、 本発明を完成させている。 BEST MODE FOR CARRYING OUT THE INVENTION The present invention has found that a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester has a hormone-sensitive lipase ゃ j33 -adrenergic receptor expression enhancing function, From this, they have found that they have a function of promoting body fat degradation, and from this, they have found that they have a function of promoting the release of body fat into blood, so that glycerin fatty acid esters containing medium-chain fatty acids or medium-chain fatty acids, Preferably, functional agents, foods, and the like containing a medium-chain fatty acid triglycerin fatty acid ester are completed. Further, they have found that body fat is reduced as a result of the expression of the body fat decomposition promoting function and the body fat blood release promoting function, and it is preferable that the medium chain fatty acid and / or a glycerin fatty acid ester containing the medium chain fatty acid be used. Has completed functional agents, foods and beverages containing medium-chain triglycerin fatty acid esters. Further, they have found that a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester is used as a raw material for the functional agent or the like. In addition, a body fat decomposing agent, a food or a drink, and a raw material containing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester are used for the above-mentioned lipolysis function subcutaneously. The inventors have found that fat is preferentially decomposed from fat, and have completed the present invention.
[用語の説明、 機能の説明]  [Explanation of terms and functions]
以下に、 本発明で使用する用語の説明および脂肪の蓄積、 分解等の機 能の説明を前記用語との関連において説明する。  Hereinafter, explanations of terms used in the present invention and functions of fat accumulation, decomposition, etc. will be explained in relation to the above terms.
[脂肪組織の蓄積と代謝]  [Adipose tissue accumulation and metabolism]
以下の説明は、 「食品成分シリーズ 資質の科学 p . 8 0 - 8 1 板倉弘重編 朝倉書店」 によるものである。 脂肪酸の酸化は主としてミ トコンドリアで行われるが、 合成は細胞質で行われる。 .図 1に脂肪組織 の脂肪代謝を示す。 The following explanation is based on “Food Ingredient Series, Science of Qualities, p. 80-81, Hiroshige Itakura, Asakura Shoten”. Fatty acid oxidation occurs primarily in the mitochondria, while synthesis occurs in the cytoplasm. Fig. 1 Adipose tissue Shows fat metabolism.
消化吸収され血液に取り込まれたグルコースは、 肝臓や筋肉において グリコーゲンとして貯蔵されるがそれには限度がある。 その余剰分は脂 肪として脂肪組織に蓄えられる。 肝臓で合成された脂質は超低比重リポ 蛋白 （VLDL) として放出される。 一方、 食事中の中性脂肪は消化吸 収された後、 腸上皮細胞でカイロミクロンとなり血中に運ばれる。 また、 VLDLレセプター （受容体） により、 VLD Lが直接脂肪細胞に取り 込まれる経路も存在する。 このような経路により取り込まれた遊離脂肪 酸はァシルー C o A合成酵素 （AC S) の働きでァシルー C o Aへと転 換されてトリグリセリ ド （中性脂肪：蓄積） に合成され、 一部は 酸化 を受けァセチルー C o Aとなり、 TCA回路 （タエン酸回路） を介して エネルギー生産を行う。  Glucose that is digested and absorbed into the blood is stored as glycogen in the liver and muscle, but to a limited extent. The surplus is stored in the adipose tissue as fat. Lipids synthesized in the liver are released as very low density lipoprotein (VLDL). On the other hand, triglycerides in the diet are digested and absorbed, then converted into chylomicron in intestinal epithelial cells and transported into the blood. There is also a pathway through which VLDL is directly taken into adipocytes by the VLDL receptor (receptor). Free fatty acid taken up by such a pathway is converted to acyl-CoA by the action of acyl-CoA synthetase (ACS) and synthesized into triglycerides (neutral fat: accumulated). Is oxidized to acetyl-CoA, which produces energy through the TCA cycle (taenoic acid cycle).
また血液中のグノレコースは、 グノレコーストランスポータ （GLUT 1, GLUT 4) を介して取り込まれ、 グリセロールー 3リン酸 （G 3 P) やァセチルー C o Aを生成する。 ァセチル一 C o Aはァセチルー C o A カルボキシラーゼ （ACC) の働きでァシルー C o Aに合成される。 このようにして形成されたァシルー C o Aとグリセロール一 3リン酸 から、 エステル化により トリグリセリ ド （中性脂肪：蓄積） が合成され る。 空腹時にはこれらのトリグリセリ ドはホルモン感受性リパーゼ （H S L) の作用により遊離脂肪酸とグリセロールに加水分解される。 遊離 脂肪酸は、 細胞外に放出されて筋肉や心臓などのエネルギー源として利 用されたり、 ァシルー C o Aへと転換され再びトリグリセリ ドに合成さ れる。  In addition, gnorecose in the blood is taken in via gnorecose transporters (GLUT1, GLUT4) to produce glycerol-3-phosphate (G3P) and acetyl-CoA. Acetyl-CoA is synthesized into acetyl-CoA by the action of acetyl-CoA carboxylase (ACC). Triglyceride (neutral fat: accumulation) is synthesized from the thus formed acyl-CoA and glycerol monophosphate by esterification. On an empty stomach, these triglycerides are hydrolyzed to free fatty acids and glycerol by the action of hormone-sensitive lipase (HSL). Free fatty acids are released extracellularly and used as an energy source for muscle and heart, or converted to acyl-CoA and synthesized again into triglycerides.
[遊離脂肪酸の燃焼]  [Free fatty acid burning]
以下の説明は、 「食品成分シリーズ 脂質の科学 p . 6 7 - 6 8 板倉弘重編 朝倉書店」 によるものである。 遊離脂肪酸の燃焼はミ トコ ンドリアで行われる。 図 2に前記燃焼過程を示す。 血液からサイ トゾル に入る遊離脂肪酸は直接ミ トコンドリア膜を通過できない。 まず、 ミ ト 'コンドリア外膜に存在する遊離脂肪酸はァシルー C o Aシンセターゼに よって脂肪酸ァシルー C o A (f a t t y a c y 1 -C o A) を生成 する。 つぎにァシルー C o Aは一時的にカル-チン （ c a r II i t i n e) の水酸基に結合し、 この脂肪酸ァシルーカルニチンが特異的な輸送 体によってミ トコンドリア内膜を横切って運ばれる。 脂肪酸のミ トコン ドリァでの酸化は 3段階で行われる。 第一段階は 酸化で、 脂肪酸ァシ ル基のカルボキシル端末から 2単位ずつ連続して、 ァセチル C ο Αの形 で除去される。 炭素数 1 6のパルミチン酸だと 3酸化の経路を 7回通過 し、 8個の 2—炭素のァセチル C o Aに変換される。 第 2段階ではァセ チル C o Aのァセチル残基がクェン酸回路を経て 002に酸化される。 これらの脂肪酸酸化の段階によつて還元型の電子伝達体である N AD H と FAD H 2が生じ、 これらはミ トコンドリアの呼吸鎖に電子を与え、 この電子は呼吸鎖を経て酸素に渡される。 この流れと共役して ATP (アデノシン三リン酸） が生産される。 The following explanation is based on “Food Ingredient Series, Science of Lipids, p. 67-68, edited by Hiroshige Itakura, Asakura Shoten”. Burning free fatty acids It takes place in Ndria. Figure 2 shows the combustion process. Free fatty acids entering the cytosol from the blood cannot pass directly through the mitochondrial membrane. First, the free fatty acids present in the outer membrane of mito 'chondria generate fatty acid-COA (fattyacy 1-CoA) by the acyl-COA synthetase. Next, the acyl-CoA temporarily binds to the hydroxyl group of car-tin (car II itine), and the fatty acid isyl-carnitine is transported across the inner mitochondrial membrane by a specific transporter. Mitochondrial oxidation of fatty acids occurs in three stages. The first step is oxidation, which removes two consecutive units from the carboxyl terminus of the fatty acid acyl group in the form of acetyl チ ル. Palmitic acid with 16 carbons goes through the three oxidation pathways seven times and is converted to eight 2-carbon acetyl OA. Asechiru residues § Se chill C o A in the second stage is oxidized to 00 2 through the Kuen acid cycle. These fatty acid oxidation steps result in reduced electron carriers, NADH and FADH2, which donate electrons to the mitochondrial respiratory chain, which is passed on to oxygen through the respiratory chain. . ATP (adenosine triphosphate) is produced in conjunction with this flow.
遊離脂肪酸の生理変動は大きい。 空腹時には血漿遊離脂肪酸は増加し、 食後には減少する。 ホルモン感受性リパーゼはェピネフリンなどの交換 神経活性化物質で活性化される。 寒冷、 ス トレスなど遊離脂肪酸を増加 させる要因である。  Physiological fluctuations of free fatty acids are large. On fasting plasma free fatty acids increase and decrease after meals. Hormone-sensitive lipase is activated by exchange nerve activators such as epinephrine. It is a factor that increases free fatty acids such as cold and stress.
[遊離脂肪酸の燃焼と脱共役蛋白質、 ホルモン感受性リパーゼ、 β 3 一アドレナリン受容体等との関係]  [Relationship between burning of free fatty acids and uncoupled proteins, hormone-sensitive lipase, β 3 -adrenergic receptor, etc.]
以下の説明は 「斎藤、 別冊 ·医学のあゆみ， 脂肪細胞一基礎と臨床、 ρ . 75— 78, 1 9 9 9」 によるものである。 図 3の （Α) に、 ミ ト コンドリア内膜での酸化的リン酸化と脱共役蛋白質 （UCP) による脱 共役の関係を示す。 UCPはミ トコンドリアの酸化的リン酸化を脱共役 させる蛋白質である。 すなわち、 通常のミ トコンドリアでは内膜を介し たプロトンの電気化学的勾配を介して電子伝達系と AT P合成は密に共 役している。 UC Pはこの濃度勾配を短絡的に解消する特殊なチャンネ ルであり、 これが活性化されると酸化基質の化学エネルギーは AT P合 成に利用されず熱へと変換されるのである。 すなわち、 UCPの発現に より遊離脂肪酸の燃焼は促進される。 The following explanation is based on "Saito, Separate Volume, History of Medicine, Adipocyte Basics and Clinical Practice, ρ. 75-78, 1999." Figure 3 (酸化) shows the relationship between oxidative phosphorylation at the inner mitochondrial membrane and uncoupling by uncoupling protein (UCP). UCP uncouples mitochondrial oxidative phosphorylation Is a protein that That is, in normal mitochondria, the electron transport system and ATP synthesis cooperate closely via the electrochemical gradient of protons through the inner membrane. UCP is a special channel that short-circuits this concentration gradient, and when activated, the chemical energy of the oxidized substrate is converted to heat instead of being used for ATP synthesis. In other words, the expression of UCP promotes the burning of free fatty acids.
ここで、 UCPには、 UC P_ 1から UC P— 3まで確認されている。 UCP— 1は褐色脂肪組織に存在する。 しかし、 ヒ トを含め多くの哺乳 動物では成長に伴って減少し、 成人では肉眼的に同定することは困難で ある。 一方、 UC P— 2はヒ トの体内に広く存在しており、 UCP— 3 は骨格筋に強く発現している。  Here, UCP has been confirmed from UC P_1 to UC P-3. UCP-1 is present in brown adipose tissue. However, it decreases with growth in many mammals, including humans, and is difficult to identify visually in adults. On the other hand, UCP-2 is widely present in the human body, and UCP-3 is strongly expressed in skeletal muscle.
ここで、 前記中性脂肪の燃焼におけるホルモン感受性リパーゼ （HS L) 等の働きは図 3の （B) に示したようである。 これは、 褐色脂肪組 織における前記働きを例示したものである。 褐色脂肪組織での UC P— 1による熟産生は、 この組織に豊富に分布する交換神経により直接調整 されている。 すなわち、 交換神経の活動亢進によって祌経終末より分泌 されたノルェピネフリン （NE) 、 細胞膜に存在する アドレナリン 受容体 （ AR) を介してアデ-ル酸シクラーゼ （AC) を活性ィ匕し、 細胞内の cAMP濃度の上昇、 プロテインキナーゼ （PKA) の活性化、 貯蔵中性脂肪の分解といった一連の反応により脂肪酸を遊離させる。 従 つて、 前記 /3アドレナリン受容体、 ホルモン感受性リパーゼ、 UCPの 発現量の増加が体内脂肪の燃焼を促進させるのである。  Here, the action of hormone-sensitive lipase (HSL) and the like in the burning of the neutral fat is as shown in FIG. 3 (B). This illustrates the above function in a brown fat tissue. Mature production by UCP-1 in brown adipose tissue is directly regulated by abundantly distributed sympathetic nerves in this tissue. In other words, norepinephrine (NE) secreted from the end of menstruation by hyperactivity of the sympathetic nerve, adenylate cyclase (AC) is activated via an adrenergic receptor (AR) present in the cell membrane, and intracellular Fatty acids are released through a series of reactions, such as increasing cAMP levels, activating protein kinases (PKA), and decomposing stored triglycerides. Therefore, an increase in the expression level of the / 3 adrenergic receptor, hormone-sensitive lipase, and UCP promotes the burning of body fat.
[本発明の使用の態様等] 本発明の各種機能剤等における機能の概要としては、 中鎖脂肪酸およ び/または中鎖脂肪酸を含むグリセリン脂肪酸エステル、 特に中鎖脂肪 酸トリグリセリ ドを摂取することにより、 体脂肪組織中のホルモン感受 性リパーゼが活性化され、 体脂肪組織に蓄積されているグリセリン脂肪 酸エステル （LCT等） を分解し遊離脂肪酸に分解するとともに、 該遊 離脂肪酸を血中へ放出させる。 これにより、 蓄積されている体脂肪が低 '減することになる。 [Embodiments of Use of the Present Invention, etc.] The outline of the functions of the various functional agents of the present invention is as follows. Ingestion of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, particularly medium-chain fatty acid triglycerides Hormone sensitivity in body adipose tissue Activated lipase degrades glycerin fatty acid esters (such as LCT) accumulated in body fat tissue to break down into free fatty acids, and releases the free fatty acids into the blood. This will reduce the accumulated body fat.
本発明において中鎖脂肪酸を含むグリセリン脂肪酸エステルとは、 下 記一般式 （ I ) に示す構成脂肪酸 R l、 R 2、 ： R 3中のいずれか 1っ以 上が上述した中鎖脂肪酸を含む、 炭素数 6〜 24から選ばれる脂肪酸を 構成脂肪酸とするグリセリン脂肪酸エステルを示す。 詳しくは、 下記一 般式 （I ) に示す構成脂肪酸 R l、 R 2、 R 3全てを有するトリグリセ リン脂肪酸エステル、 構成脂肪酸 R 1、 2, R 3中のいずれか 1つが 水素であるジグリセリン脂肪酸エステル、 いずれか 1つのみが構成脂肪 酸であるモノグリセリン脂肪酸エステルからなる。 さらに、 結合する部 位により R 1および R 3に構成脂肪酸を有するジグリセリン脂肪酸エス テル、 R 1および R 2に構成脂肪酸を有するジグリセリン脂肪酸エステ ル、 R 1または R 3のみに構成脂肪酸を有するモノグリセリン脂肪酸ェ ステル、 R 2のみに構成脂肪酸を有するモノグリセリン脂肪酸エステル も含まれる。 一般式 （I )  In the present invention, the term "glycerin fatty acid ester containing a medium-chain fatty acid" refers to any one or more of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I) containing the above-mentioned medium-chain fatty acid. And glycerin fatty acid esters having a fatty acid selected from the group consisting of 6 to 24 carbon atoms as a constituent fatty acid. Specifically, triglycerin fatty acid ester having all of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I), and diglycerin in which one of the constituent fatty acids R1, 2, and R3 is hydrogen Fatty acid esters are composed of monoglycerin fatty acid esters, only one of which is a constituent fatty acid. Furthermore, diglycerin fatty acid ester having a constituent fatty acid at R 1 and R 3, diglycerin fatty acid ester having a constituent fatty acid at R 1 and R 2, and a constituent fatty acid only at R 1 or R 3 depending on the bonding position Monoglycerin fatty acid esters and monoglycerin fatty acid esters having a constituent fatty acid only in R2 are also included. General formula (I)
C H 2 - O R 1 CH 2 -OR 1
OR 2 -CH OR 2 -CH
CH9— OR 3 で、 トリグリセリン脂肪酸エステルにおいて、 中鎖脂肪酸を含む 形態としては、 上記一般式 （I ) に示す構成脂肪酸 R l、 R 2、 R 3全 てが上述した中鎖脂肪酸からなるもの、 R l、 R 2、 R 3のいずれか 1 つのみが炭素数 6〜 2 4から選ばれる脂肪酸からなるもの、 R 2のみが 炭素数 6〜 2 4から選ばれる脂肪酸からなるもの、 R 1および R 2ない し R 3および； 2が炭素数 6〜 2 4から選ばれる脂肪酸からなるもの、 R 1および R 3が炭素数 6〜 2 4から選ばれる脂肪酸からなるものがあ る。 CH 9 — OR 3, including medium-chain fatty acids in triglycerin fatty acid esters Examples of the form include those in which all of the constituent fatty acids Rl, R2, and R3 represented by the general formula (I) are composed of the above-described medium-chain fatty acids, and only one of Rl, R2, and R3 is carbon. A fatty acid selected from the numbers 6 to 24; R 2 alone consisting of a fatty acid selected from the carbons 6 to 24; R 1 and R 2 or R 3; and 2 having 6 to 24 carbons And R 1 and R 3 each consisting of a fatty acid selected from the group consisting of 6 to 24 carbon atoms.
構成脂肪酸 R l、 R 2、 R 3全てが上述した中鎖脂肪酸の形態を有す るものについては中鎖脂肪酸トリグリセリ ドといい、 後に詳述する。 ここで、 前記中鎖脂肪酸を含むグリセリン脂肪酸エステルの総量に対 し、 1 , 3位の中鎖脂肪酸残基が 4 0質量 °/0以上、 好ましくは 5 0質 量％以上、 さらに好ましくは 6 0質量％以上、 特に好ましくは 7 0質 量％以上、 最も好ましくは 8 0質量％以上である場合、 例えば経口摂取 した場合の腸管等での分解 ·吸収が良いため好ましい。 If the constituent fatty acids R1, R2, and R3 all have the above-mentioned medium-chain fatty acid form, they are called medium-chain fatty acid triglycerides, which will be described in detail later. Here, based on the total amount of the glycerol fatty acid ester containing the medium-chain fatty acid, the number of the medium-chain fatty acid residues at the 1,3-positions is 40% by mass / 0 or more, preferably 50% by mass or more, more preferably 6% by mass or more. The content is preferably 0% by mass or more, particularly preferably 70% by mass or more, and most preferably 80% by mass or more, for example, because of good decomposition and absorption in the intestinal tract and the like when taken orally.
これらの場合、 特に中鎖脂肪酸トリグリセリン脂肪酸エステル自体、 もしくは該中鎖脂肪酸トリグリセリン脂肪酸エステルを高含有させた油 脂を原料としたエステル交換処理をすることで得ることができる。  In these cases, it can be obtained particularly by subjecting the medium-chain fatty acid triglycerin fatty acid ester itself or a transesterification treatment using a fat containing a high content of the medium-chain fatty acid triglycerin fatty acid ester to a raw material.
中鎖脂肪酸を含むグリセリン脂肪酸エステルとして、 中鎖脂肪酸トリ グリセリ ドを含むことが好ましく、 また、 中鎖脂肪酸が同量であれば M L C Tであることが好ましく、 さらには脂肪酸の種類や位置を設計した 構造体であることが好ましい。  The glycerin fatty acid ester containing a medium-chain fatty acid preferably contains a medium-chain fatty acid triglyceride, and if the amount of the medium-chain fatty acid is the same, it is preferable that the MLCT is used. It is preferably a structure.
含量は中鎖脂肪酸の含量を参考に、 必要な機能の強さ等に応じて規定 することができる。 例えば、 中鎖脂肪酸トリグリセリ ドが 3〜 3 0質 量％、 好ましくは 3〜 2 3質量％、 好ましくは 4〜 2 0質量％、 さらに 好ましくは 5〜1 7質量％、 特に好ましくは 6〜1 5質量％、 最も好ま しくは 7〜 1 4質量。 /0、 最も特に好ましくは 8〜 1 3質量％である。 さ らには、 M L C Tの場合は 1 ~ 8 0質量％、 好ましくは 2〜7 0質量％、 さらに好ましくは 3〜 6 0質量％、 特に好ましくは 5〜 5 0質量％、 最 も好ましくは 7〜 2 0質量％、 最も特に好ましくは 8〜 1 4質量％であ る。 さらには、 吸収性、 リパーゼに対する易 難分解性、 分散性等の消 化吸.収機能性やその他の生物化学的機能を付すことを予定して脂肪酸の 種類、 グリセリンに結合する位置を設計した構造体 （構造油脂） である 場合が好ましく、 この場合、 構造体としては 1〜8 0質量％、 好ましく は 2〜 7 0質量％、 さらに好ましくは 3〜 6 0質量％、 特に好ましくは 5〜5 0質量％、 最も好ましくは 7〜2 0質量％、 最も特に好ましくは 8〜 1 4質量％である。 . The content can be defined according to the required strength of the function, etc., with reference to the content of the medium-chain fatty acid. For example, the medium-chain fatty acid triglyceride contains 3 to 30% by mass, preferably 3 to 23% by mass, preferably 4 to 20% by mass, more preferably 5 to 17% by mass, and particularly preferably 6 to 1% by mass. 5% by weight, most preferably 7 to 14% by weight. / 0 , most particularly preferably from 8 to 13% by weight. Sa Further, in the case of MLCT, it is 1 to 80% by mass, preferably 2 to 70% by mass, more preferably 3 to 60% by mass, particularly preferably 5 to 50% by mass, and most preferably 7 to 70% by mass. It is 20% by weight, most preferably 8 to 14% by weight. In addition, we designed the types of fatty acids and their positions to bind to glycerin in order to provide absorption and other biochemical functions, such as absorption, lipase, easy decomposition and dispersibility. It is preferably a structure (structural fat). In this case, the structure is 1 to 80% by mass, preferably 2 to 70% by mass, more preferably 3 to 60% by mass, and particularly preferably 5 to 50% by mass. 50% by weight, most preferably 7% to 20% by weight, most preferably 8% to 14% by weight. .
ここで、 M L C Tは、 中鎖脂肪酸を含むグリセリン脂肪酸エステルで あり、 中鎖脂肪酸の数が 1または 2であり、 その他が長鎖脂肪酸である ものをいう。 本発明においては、 中鎖脂肪酸の数や結合している位置に よって、 吸収性や体内での機能等が異なるため、 これを目的に応じて、 適宜調整することが好ましい。 吸収性を向上させる場合、 1， 3位の一 方以上、 特に双方に中鎖脂肪酸が結合した M L C Tが好ましい。  Here, MLCT is a glycerin fatty acid ester containing a medium-chain fatty acid, in which the number of medium-chain fatty acids is 1 or 2, and the others are long-chain fatty acids. In the present invention, the absorbability, the function in the body, and the like differ depending on the number and the binding position of the medium-chain fatty acids, and it is preferable to appropriately adjust them according to the purpose. In order to improve the absorbability, MLCT in which a medium-chain fatty acid is bonded to at least one of the 1,3-positions, particularly both, is preferable.
構造油脂は、 グリセリンに結合する中鎖脂肪酸以外の脂肪酸の種類や、 これらが結合する位置等について設計することができる。 好ましい構造 油脂として、 例えば、 1 , 3位の一方または双方に中鎖脂肪酸が結合し、 2位に特定の脂^ ¾酸が結合したものがあげられる。  Structural fats and oils can be designed with respect to the types of fatty acids other than medium-chain fatty acids that bind to glycerin, the positions where these bind, and the like. Preferred structural fats and oils include, for example, those in which a medium-chain fatty acid is bonded to one or both of the 1- and 3-positions, and a specific fatty acid is bonded to the 2-position.
特定の脂肪酸としては、 特に自然界での存在量等の面からは直鎖脂肪 酸が好ましく、 さらには直鎖不飽和脂肪酸が好ましく、 その中でも特に、 パルミ トォレイン酸、 ォレイン酸、 パクセン酸、 エル力酸等の一価不飽 和脂肪酸、 リノール酸、 γ—リノレン酸、 ビスホモ γ—リノレン酸、 ァ ラキドン酸等の η— 6系不飽和脂肪酸、 a—リノレン酸、 ステアリ ドン 酸、 エイコテトラエン酸、 エイコサペンタエン酸、 ドコサペンタエン酸、 ドコサへキサェン酸等の n— 3系不飽和脂肪酸、 共役リノール酸、 一 ェレオステアリン酸等の共役脂肪酸等が好ましい。 As the specific fatty acid, a linear fatty acid is preferable, particularly from the viewpoint of natural abundance, etc., and a linear unsaturated fatty acid is more preferable. Among them, palmitooleic acid, oleic acid, paxenoic acid, L-force Monounsaturated fatty acids such as acids, linoleic acid, γ-linolenic acid, bishomo γ-linolenic acid, η-6 unsaturated fatty acids such as arachidonic acid, a-linolenic acid, stearidonic acid, eicotetraenoic acid , Eicosapentaenoic acid, docosapentaenoic acid, Preferred are n -3 unsaturated fatty acids such as docosahexaenoic acid and conjugated fatty acids such as conjugated linoleic acid and monoleostearic acid.
これらの構造油脂の例示としては、 M—ォレイン酸一 M、 M— aリノ レン酸一 M、 M— γ リノレン酸一 M、 M—エイコサペンタエン酸ー M、 M—ドコサペンタエン酸ー M、 M_ドコサへキサェン酸ー M、 M—共役 リノ一ル酸一 M等を例示することができる。  Examples of these structural fats and oils include M-oleic acid-M, M-a linolenic acid-M, M-γ linolenic acid-M, M-eicosapentaenoic acid-M, M-docosapentaenoic acid-M, M_docosahexaenoic acid-M, M-conjugated linoleic acid-M and the like can be exemplified.
これらの MLCTや構造油脂はエステル交換反応により製造すること ができ、 好ましくは位置特異性を有する酵素を用いて製造することがで さる。  These MLCTs and structural fats and oils can be produced by a transesterification reaction, and are preferably produced using an enzyme having regiospecificity.
本発明で使用できる中鎖脂肪酸トリグリセリ ドは、 一般に MCT (M e d i um C h a i n T r i g l y c e r i d e s) と称されるも ので、 ヤシ油分解脂肪酸等の炭素数が 6~1 2、 好ましくは 8〜 1 0の 飽和脂肪酸から構成される単酸基または混酸基トリグリセリ ドである。 例えば力プリル酸 （ C 8 ) /力プリン酸 （C 1 0) = 60〜 75ノ 25 〜40 (重量比） のトリグリセリ ドが使用できる。 該トリグリセリ ドは 前記中鎖脂肪酸とグリセリンとを常法によりエステル化反応せしめて製 造できるが、 市販品の利用が至便である。  The medium-chain fatty acid triglycerides that can be used in the present invention are generally referred to as MCT (Medium Cin Triglycerides), and therefore have 6 to 12 carbon atoms, preferably 8 to 10 carbon atoms, such as coconut oil-decomposed fatty acids. It is a mono- or mixed-acid triglyceride composed of a saturated fatty acid. For example, triglycerides having a strength of prillic acid (C8) / force of phosphoric acid (C10) = 60 to 75/25 to 40 (weight ratio) can be used. The triglyceride can be produced by subjecting the medium-chain fatty acid and glycerin to an esterification reaction by a conventional method, but the use of a commercially available product is convenient.
また、 中鎖脂肪酸トリグリセリ ドを含有する油脂組成物としては、 通 常の食用油脂、 例えば大豆油、 菜種油、 高ォレイン酸菜種油、 コーン油、 ゴマ油、 ゴマサラダ油、 シソ油、 亜麻仁油、 落花生油、 紅花油、 高ォレ イン酸紅花油、 ひまわり油、 高ォレイン酸ひまわり油、 綿実油、 プドウ 種油、 マカデミアナッツ油、 ヘーゼルナッツ油、 カポチヤ種子油、 クル ミ油、 椿油、 茶実油、 エゴマ油、 ボラージ油、 オリープ油、 米糠油、 小 麦胚芽油、 パーム油、 パーム核油、 ヤシ油、 カカオ脂、 牛脂、 ラード、 鶏脂、 乳脂、 魚油、 ァザラシ油、 藻類油、 品質改良によって低飽和化さ れたこれらの油脂おょぴこれらの水素添加油脂、 分別油脂等が挙げられ る。 Examples of the fat and oil composition containing the medium-chain fatty acid triglyceride include ordinary edible fats and oils such as soybean oil, rapeseed oil, oleic rapeseed oil, corn oil, sesame oil, sesame salad oil, perilla oil, linseed oil, peanut oil, Safflower oil, high-oleic acid safflower oil, sunflower oil, high-oleic sunflower oil, cottonseed oil, pudow seed oil, macadamia nut oil, hazelnut oil, capocia seed oil, walnut oil, camellia oil, teaseed oil, egoma oil, borage Oil, olive oil, rice bran oil, wheat germ oil, palm oil, palm kernel oil, coconut oil, cocoa butter, tallow, lard, chicken fat, milk fat, fish oil, seal oil, algae oil, low saturation due to quality improvement These fats and oils, these hydrogenated fats and oils and fractionated fats You.
ここで、 本発明の中鎖脂肪酸とは、 炭素数が 6〜 1 2の脂肪酸が好ま しく、 例としては、 カプロン酸、 力プリル酸、 力プリン酸、 ラウリン酸 が挙げられる。 また、 炭素数が 8〜1 0の飽和脂肪酸、 特に力プリル酸 およぴカプリン酸が好ましい。  Here, the medium-chain fatty acid of the present invention is preferably a fatty acid having 6 to 12 carbon atoms, and examples thereof include caproic acid, caprylic acid, capric acid, and lauric acid. Further, saturated fatty acids having 8 to 10 carbon atoms, particularly caprylic acid and capric acid, are preferred.
中鎖脂肪酸を含むグリセリン脂肪酸エステルは天然、 合成でも得られ るが、 例えば、 炭素数 6〜 1 2の中鎖脂肪酸を構成脂肪酸として有する パーム油、 パーム核油やヤシ油等の油脂を原料として、 エステル交換処 理により製造することができるが、 その限りではない。 エステル結合反 応の条件も特に限定しないが、 例えば無触媒かつ無溶剤にて、 加圧下で 反応して得ることができる。 もちろん、 触媒や溶剤を用いた反応によつ ても、 本発明の中鎖脂肪酸を含むグリセリン脂肪酸エステルを得ること が可能である。 また、 遺伝子組み換え植物の油糧種子から中鎖脂肪酸を 含むグリセリ ン脂肪酸エステル自体^得る、 または、 遺伝子組み換え植 物の油糧種子から得られた中鎖脂肪酸を原料にして、 中鎖脂肪酸を含む グリセリン脂肪酸エステルを製造することも可能である。 また、 酵素を 用いた酵素反応によっても得ることが可能である。 油脂の風味 .色 ·安 全面や経口摂取を考えた場合、 酵素によるエステル交換処理により製造 することが好ましいが、 これに限定するものではない。 また、 得られた エステル交換油脂の 1、 3位の脂肪酸と 2位の脂肪酸の組成に偏りがあ つてもなくてもよいが、 特に 1 , 3位の脂肪酸が多いほど分解等が好適 である傾向があるため好ましい。 '  Glycerin fatty acid esters containing medium-chain fatty acids can be obtained naturally or synthetically.For example, fats and oils such as palm oil, palm kernel oil and coconut oil having medium chain fatty acids having 6 to 12 carbon atoms as constituent fatty acids are used as raw materials. It can be produced by transesterification, but is not limited thereto. The conditions for the ester bond reaction are not particularly limited. For example, it can be obtained by reacting under pressure without using a catalyst and a solvent. Of course, it is also possible to obtain the glycerin fatty acid ester containing the medium-chain fatty acid of the present invention by a reaction using a catalyst or a solvent. In addition, glycerin fatty acid esters containing medium-chain fatty acids can be obtained from the oil seeds of genetically modified plants, or medium-chain fatty acids can be obtained from medium-chain fatty acids obtained from oil-seed plants of genetically modified plants. It is also possible to produce glycerin fatty acid esters. It can also be obtained by an enzymatic reaction using an enzyme. Flavor of oils and fats. Color / Ant Considering the whole surface or oral ingestion, it is preferable to manufacture by enzymatic transesterification, but it is not limited to this. In addition, the composition of the fatty acids at the 1- and 3-positions of the obtained transesterified fat may or may not be biased, but the more fatty acids at the 1- and 3-positions, the more suitable the decomposition etc. It is preferable because of the tendency. '
上述の通り、 炭素数 6〜 1 2の中鎖脂肪酸を構成脂肪酸として有する パーム核油やヤシ油等の油脂を原料とし、 脂質分解酵素 （リパーゼ） を 用いたエステル交換処理をする方法が挙げられる。 酵素としては、 アル カリゲネス属、 キャンディダ属、 リゾプス属、 ムコーノレ属またはシュー ドモナス属由来のリパーゼゃ、 肝臓由来のホスホリパーゼ A等が挙げら れるが、 特にキャンディダ属またはリゾプス属由来のリパーゼが好まし い。 さらに、 酵素は条件によって適宜その種類を選択することができる c 脂質分解酵素を用いてエステル交換反応を行う方法は特に限定されな いが、 具体的方法例を次に挙げる。 脂質分解酵素の活性が十分に発揮さ れる反応温度である 4 0〜 1 0 0 °Cの範囲に調温する。 これに脂質分解 酵素を原料混合物に対して 0 . 0 0 5〜 1 0質量％の割合で添加し、 2 〜4 8時間の範囲でエステル交換反応を行う。 この反応は常圧下で窒素 気流中で行うことが望ましい。 反応の完了はガスクロマトグラフィーに より反応生成物のトリグリセリ ド組成を測定することにより確認する。 反応生成物は水洗、 乾燥の後、 常法にて脱色、 脱臭する。 なお、 中鎖脂 肪酸を使用した場合は、 反応の停止後に遊離脂肪酸を薄膜式ェパポレー ターによって除去しておくことが好適である。 As described above, there is a method in which a fat and oil such as palm kernel oil or coconut oil having a medium chain fatty acid having 6 to 12 carbon atoms as a constituent fatty acid is used as a raw material, and a transesterification treatment is performed using a lipolytic enzyme (lipase). . Enzymes include Al Carigenes, Candida, Rhizopus, Muconore or Shoe Lipases derived from Domonas sp., Phospholipase A derived from liver and the like are preferred, and lipases derived from Candida or Rhizopus are particularly preferred. Further, the method of performing the transesterification reaction using a c- lipidase capable of appropriately selecting the type of the enzyme depending on the conditions is not particularly limited, and specific examples of the method are given below. The temperature is adjusted within the range of 40 to 100 ° C, which is the reaction temperature at which the activity of the lipolytic enzyme is sufficiently exhibited. The lipolytic enzyme is added to the mixture at a ratio of 0.05 to 10% by mass, and the transesterification is performed for a period of 2 to 48 hours. This reaction is desirably carried out in a nitrogen stream at normal pressure. Completion of the reaction is confirmed by measuring the triglyceride composition of the reaction product by gas chromatography. The reaction product is washed with water, dried, and then decolorized and deodorized by an ordinary method. When a medium-chain fatty acid is used, it is preferable to remove free fatty acids by a thin-film evaporator after the reaction is stopped.
本発明においては中鎖脂肪酸および /または中鎖脂肪酸を含むグリセ リン脂肪酸エステルを配合することでも、 また、 これらを含有する油脂 等を配合 ·混合することでも製造することができる。  In the present invention, it can be produced by mixing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, or by mixing and mixing oils and fats containing these.
本発明のホルモン感受性リパーゼ発現亢進剤、 β 3—アドレナリン受 容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤は、 上述の 通り中鎖脂肪酸および Ζまたは中鎖脂肪酸を含むグリセリン脂肪酸エス テルを含有することを特徴とし、 その用途は任意であるが、 例えば、 医 薬品、 医薬部外品、 健康食品等の広い分野で、 ホルモン感受性リパーゼ 発現亢進剤、 /3 3—アドレナリン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤として用いることができる。 こめ時、 中鎖脂肪酸 および/または中鎖脂肪酸を含むグリセリン脂肪酸エステルのホルモン 感受性リパーゼ発現亢進剤、 ]3 3—アドレナリ ン受容体発現亢進剤、 体 脂肪分解促進剤、 体脂肪血中放出促進剤への配合量は、 用途、 投与形態、 投与対象の種類、 年齢、 性別、 体重、 症状の程度、 健康状態などの条件 により異なるので、 一概に規定されないが、 脂肪組織等に対して各機能 を発揮する程度に含有する。 As described above, the hormone-sensitive lipase expression enhancer, the β3-adrenoceptor expression enhancer, the body fat degradation promoter, and the body fat blood release promoter of the present invention are medium-chain fatty acids and glycerin containing Ζ or medium-chain fatty acids as described above. It is characterized by containing fatty acid esters, and its use is optional. For example, in a wide range of fields such as pharmaceuticals, quasi-drugs, and health foods, hormone-sensitive lipase expression enhancer, / 33-adrenoceptor It can be used as a body expression enhancer, a body fat degradation promoter, and a body fat blood release promoter. At the time of transplantation, an agent for enhancing expression of hormone-sensitive lipase of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids,] 33-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter The amount to be mixed in depends on the application, dosage form, Although it varies depending on the conditions such as the type, age, sex, weight, degree of symptoms, and health condition of the administration target, it is not specified, but it is contained to the extent that it exerts its functions on adipose tissue.
上述の通り、 本発明のホルモン感受性リパーゼ発現亢進剤全体に対す る中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エステ ルの含量はホルモン感受性リパーゼ発現亢進作用を有する程度含有すれ ば特に制限されない。 ここで、 有効成分として含有するとは、 そのホル モン感受性リパーゼの m R N A発現亢進を発揮する程度に含有するとい うことであるが、 その含量は特に制限されず、 摂取の頻度、 摂取量、 使 用の目的によって適宜調整すれば良い。 該効果を得るための所要量は、 摂取の形態、 対象者の性別、 体重、 体調等により異なり、 特に制限され ないが、 例えば、 0 . 5 g /日以上、 好ましくは l g Z日以上、 より好 ましくは 2 g Zョ以上、 さらに好ましくは 5 gノ日以上、 特に好ましく は 8 g Z日以上、 最も特に好ましくは 1 0 g Z日以上を例示することが できる。 本発明品を長期間かけて該効果を得るための含量としては、 摂 取の形態、 対象者の性別、 体重、 体調等により異なり、 特に限定されな いが、 例えば、 0 . 5質量％以上、 好ましくは 1質量％以上、 より好ま しくは 5質量。 /0以上、 さらに好ましくは 5〜9 9 . 9質量％、 特に好ま しくは 1 0〜 9 9 . 9質量0 /0、 最も特に好ましくは 1 3〜9 9 . 9質 量％である。 As described above, the content of the medium-chain fatty acid and the glycerin fatty acid ester containing Z or the medium-chain fatty acid in the entire hormone-sensitive lipase expression enhancer of the present invention is not particularly limited as long as it has a hormone-sensitive lipase expression-enhancing effect. . Here, the term “containing as an active ingredient” means that the lipase is contained to such an extent as to enhance the expression of mRNA of the hormone-sensitive lipase.However, the content is not particularly limited, and the frequency of ingestion, the amount of ingestion, and the use of It may be appropriately adjusted depending on the purpose of use. The amount required to obtain the effect depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited. For example, 0.5 g / day or more, preferably lgZ days or more, It is preferably 2 g Z days or more, more preferably 5 g days or more, particularly preferably 8 g Z days or more, and most preferably 10 g Z days or more. The content of the product of the present invention for obtaining the effect over a long period of time depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited. For example, 0.5 mass% or more. , Preferably 1% by mass or more, more preferably 5% by mass. / 0 or more, more preferably 5-9 9.9 mass%, the properly especially preferred 1 0-9 9.9 mass 0/0, most particularly preferably 1 3-9 9.9 mass%.
また、 短期間かつ少量で該ホルモン感受性リパーゼ発現亢進剤の効果 を期待する場合の中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリ ン脂肪酸エステル含量は、 上述の通り特に制限されないが、 例えば、 5 0〜9 9 . 9質量％、 好ましくは 7 0〜9 9 . 9質量％、 さらに好まし くは 9 0〜9 9 . 9質量0 /0を例示することができる。 In addition, when the effect of the hormone-sensitive lipase expression enhancer is expected in a short time and in a small amount, the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid is not particularly limited as described above. 0-9 9. 9% by weight, preferably 7 0-9 9. 9 wt%, rather more preferably may be exemplified 9 0-9 9. 9 mass 0/0.
中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグリセリン脂肪酸エステ ルは、 つまり中鎖脂肪酸の存在により、 各機能が発生する。 ここで、 そ の含量ゃグリセリン脂肪酸エステルの構造により、 その効果の特徴も異 なる。 Medium chain fatty acids and glycerin fatty acid esters containing no or medium chain fatty acids In other words, each function is generated by the presence of medium-chain fatty acids. Here, the characteristics of the effect differ depending on the content ゃ the structure of the glycerin fatty acid ester.
含量については、 機能を得られる範囲であることが必要であり、 好ま しくは前記範囲であって、 かつ、 人体への悪影響の可能性が低いほど好 ましく、 さらには商業上または工業上、 できるだけ低含量であることが 好ましい。  It is necessary that the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
さらには、 構造によって吸収経路の違い等により、 その効果の強さ、 時間的な特徴 （即効性、 持続性）、 他の要因の発生等が異なる。 この構 造の違いを利用して、 機能の強さ、 時間的特徴等の設計や、 安全性の設 計を行うことができる。 例えば、 グリセリンに少なくとも 1以上の中鎖 脂肪酸が結合している脂肪酸エステル （以下、 「M L C T」 という） や、 特に中鎖脂肪酸の結合する位置や他の脂肪酸の種類を特定して設計され たグリセリン脂肪酸エステル （以下、 「構造体」 「構造油脂」 とレ、う） を 例示することができる。 M L C Tや構造体 （油脂） を含有する製剤等に おける中鎖脂肪酸、 該 M L C Tや構造油脂の含量は上記を参考とするこ とができる。  Furthermore, the strength of the effect, temporal characteristics (immediate effect, sustainability), occurrence of other factors, etc., differ depending on the structure of the absorption pathway depending on the structure. By utilizing this difference in structure, it is possible to design the strength of functions, temporal characteristics, etc., and to design safety. For example, fatty acid esters in which at least one or more medium-chain fatty acids are bonded to glycerin (hereinafter referred to as “MLCT”), or glycerin specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids Fatty acid esters (hereinafter referred to as "structure" and "structured fat") can be exemplified. The content of the medium-chain fatty acid and the content of the MLCT and the structured fat / oil in the preparation or the like containing the MLCT or the structure (oil / fat) can be referred to the above.
ここで、 上述したが、 中鎖脂肪酸の含量は機能を得られる範囲である ことが必要であり、 好ましくは前記範囲であって、 かつ、 人体への悪影 響の可能性が低いほど好ましく、 さらには商業上または工業上、 できる だけ低含量であることが好ましい。  Here, as described above, the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
上記視点から検討すると、 例えば、 長期摂取や体質改善を目的とする 場合には、 全脂肪酸に占める中鎖脂肪酸の割合が 3〜2 3質量％、 好ま しくは 4〜 2 0質量％、 さらに好ましくは 5〜 1 7質量％、 特に好まし くは 6〜 1 5質量 °/0、 最も好ましくは 7〜 1 4質量％、 最も特に好まし くは 8〜 1 3質量0 /0である。 さらに、 該ホルモン感受性リパーゼ発現亢進効果を得るための、 中鎖 脂肪酸としての所要量は、 上述の通り特に限定されないが、 例えば、 0 . 4 g /日以上、 好ましくは 1 g 日以上、 より好ましくは 2 g Z日以上、 さらに好ましくは 5 g /日以上、 特に好ましくは 8 g Z日以上、 最も特 に好ましくは 1 0 g /日以上を例示することができる。 . From the above viewpoints, for example, in the case of aiming for long-term intake or improvement of constitution, the ratio of medium-chain fatty acids to total fatty acids is 3 to 23% by mass, preferably 4 to 20% by mass, and more preferably. the 5-1 7 wt%, in particular rather preferably from 6 1 to 5 wt ° / 0, most preferably 7-1 4 wt%, rather most particularly preferred is 8-1 3 mass 0/0. Furthermore, the amount required as a medium-chain fatty acid for obtaining the hormone-sensitive lipase expression-enhancing effect is not particularly limited as described above, but is, for example, 0.4 g / day or more, preferably 1 g day or more, more preferably Is 2 gZ days or more, more preferably 5 g / day or more, particularly preferably 8 gZ days or more, and most preferably 10 g / day or more. .
本発明の好ましい形態として、 中鎖脂肪酸トリグリセリン脂肪酸エス テルを有効成分とするホルモン感受性リパーゼ発現亢進剤に関する。 中 鎖脂肪酸トリグリセリン脂肪酸エステルについては上述の通りである。 この場合の含量も上述の通り特に限定されないが、 例えば、 0 . 5質 量％以上、 好ましくは 1質量％以上、 より好ましくは 5質量％以上、 さ らに好ましくは 5〜 9 9 . 9質量％、 特に好ましくは1 0〜9 9 . 9質 量％、 最も特に好ましくは 1 3〜9 9 . 9質量％である。 また、 上記と 同様に、 中鎖脂肪酸トリグリセリン脂肪酸エステルを主要成分とする場 合が好ましく、 含量も上記を例示できる。  A preferred embodiment of the present invention relates to a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient. The medium-chain triglycerin fatty acid ester is as described above. The content in this case is not particularly limited as described above, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, and further preferably 5 to 99.9% by mass. %, Particularly preferably from 10 to 99.9% by weight, most preferably from 13 to 99.9% by weight. Similarly to the above, it is preferable to use a medium-chain fatty acid triglycerin fatty acid ester as a main component, and the content can be exemplified as described above.
上述の通り、 本発明の 3—アドレナリン受容体発現亢進剤全体に対 する中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エス テルの含量は 3—ァドレナリン受容体発現亢進作用を有する程度含有 すれば特に制限されない。 ここで、 有効成分として含有するとは、 その /3 3—ァドレナリン受容体の m R N A発現亢進を発揮する程度に含有す るということであるが、 その含量は特に制限されず、 摂取の頻度、 摂取 量、 使用の目的によって適宜調整すれば良い。 該効果を得るための所要 量は、 摂取の形態、 対象者の性別、 体重、 体調等により異なり、 特に制 限されないが、 例えば、 0 . 5 g Z日以上、 好ましくは 1 g /日以上、 より好ましくは 2 g /日以上、 さらに好ましくは 5 g /日以上、 特に好 ましくは 8 g /日以上、 最も特に好ましくは 1 0 g /日以上を例示する ことができる。 含量としては、 特に限定されないが、 例えば、 0 . 5質 量％以上、 好ましくは 1質量％以上、 より好ましくは 5質量％以上、 さ らに好ましくは 5〜 99. 9質量％、 特に好ましくは1 0〜9 9. 9質 量％、 最も特に好ましくは 1 3〜 9 9. 9質量％である。 また、 短期間 かつ少量で該 3—ァドレナリン受容体発現亢進の効果を期待する場合 の中鎖脂肪酸おょぴ または中鎖脂肪酸を含むグリセリン脂肪酸エステ ル含量は、 上述の通り特に制限されないが、 例えば、 50〜9 9. 9質 量％、 好ましくは 70〜 9 9. 9質量％、 さらに好ましくは 90〜 9 9. 9質量％を例示することができる。 As described above, the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid in the whole 3-adrenergic receptor expression enhancer of the present invention is such that the agent has a 3-adrenergic receptor expression enhancing action. It is not particularly limited. Here, containing as an active ingredient means that it is contained to such an extent that it enhances mRNA expression of the 3-adrenergic receptor, but its content is not particularly limited, and the frequency and frequency of ingestion It may be adjusted as appropriate depending on the amount and purpose of use. The amount required to obtain the effect depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited.For example, 0.5 g Z days or more, preferably 1 g / day or more, More preferably, the amount is 2 g / day or more, further preferably 5 g / day or more, particularly preferably 8 g / day or more, and most preferably 10 g / day or more. Although the content is not particularly limited, for example, 0.5 quality % By mass, preferably 1% by mass or more, more preferably 5% by mass or more, still more preferably 5 to 99.9% by mass, particularly preferably 10 to 99.9% by mass, most particularly preferably 13 to 99.9% by mass. In the case where the effect of enhancing the expression of the 3-adrenergic receptor is expected in a short time and in a small amount, the content of the medium-chain fatty acid or the glycerin fatty acid ester containing the medium-chain fatty acid is not particularly limited as described above. , 50 to 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass.
中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エステ ルは、 つまり中鎖脂肪酸の存在により、 各機能が発生する。 ここで、 そ の含量やグリセリン脂肪酸エステルの構造により、 その効果の特徴も異 なる。 +  The medium chain fatty acid and / or glycerin fatty acid ester containing the medium chain fatty acid, that is, each function is generated by the presence of the medium chain fatty acid. Here, the characteristics of the effect vary depending on the content and the structure of the glycerin fatty acid ester. +
含量については、 機能を得られる範囲であることが必要であり、 好ま しくは前記範囲であって、 かつ、 人体への悪影響の可能性が低いほど好 ましく、 さらには商業上または工業上、 できるだけ低含量であることが 好ましい。  It is necessary that the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
さらには、 構造によって吸収経路の違い等により、 その効果の強さ、 時間的な特徴 （即効性、 持続性）、 他の要因の発生等が異なる。 この構 造の違いを利用して、 機能の強さ、 時間的特徴等の設計や、 安全性の設 計を行うことができる。 例えば、 グリセリンに少なくとも 1以上の中鎖 脂肪酸が結合している脂肪酸エステル' （以下、 「MLCT」 という） や、 特に中鎖脂肪酸の結合する位置や他の脂肪酸の種類を特定して設計され たグリセリン脂肪酸エステル （以下、 「構造体」 「構造油脂」 という） を 例示することができる。 ML CTや構造体 （油脂） を含有する製剤等に おける中鎖脂肪酸、 該 MLCTや構造油脂の含量は上記を参考とするこ とができる。 ' ここで、 上述したが、 中鎖脂肪酸の含量は機能を得られる範囲である ことが必要であり、 好ましくは前記範囲であって、 かつ、 人体への悪影 響の可能性が低いほど好ましく、 さらには商業上または工業上、 できる だけ低含量であることが好ましい。 Furthermore, the strength of the effect, temporal characteristics (immediate effect, sustainability), occurrence of other factors, etc., differ depending on the structure of the absorption pathway depending on the structure. By utilizing this difference in structure, it is possible to design the strength of functions, temporal characteristics, etc., and to design safety. For example, it was designed by specifying the fatty acid ester (hereinafter referred to as “MLCT”) in which at least one or more medium-chain fatty acids are bonded to glycerin, and in particular, the position where the medium-chain fatty acids are bonded and the type of other fatty acids. Glycerin fatty acid esters (hereinafter, referred to as “structures” and “structured fats and oils”) can be exemplified. The content of the medium-chain fatty acid, the MLCT, and the content of the structural fat in the preparation containing the MLCT or the structure (oil or fat) can be referred to the above. ' Here, as described above, the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
上記視点から検討すると、 例えば、 長期摂取や体質改善を目的とする 場合には、 全脂肪酸に占める中鎖脂肪酸の割合が 3〜2 3質量％、 好ま しくは 4〜 2 0質量％、 さらに好ましくは 5〜 1 7質量％、 特に好まし くは 6〜 1 5質量％、 最も好ましくは 7 ~ 1 4質量％、 最も特に好まし くは 8〜 1 3質量％である。  From the above viewpoints, for example, in the case of aiming for long-term intake or improvement of constitution, the ratio of medium-chain fatty acids to total fatty acids is 3 to 23% by mass, preferably 4 to 20% by mass, and more preferably. Is from 5 to 17% by weight, particularly preferably from 6 to 15% by weight, most preferably from 7 to 14% by weight, most preferably from 8 to 13% by weight.
さらに、 該 3—アドレナリン受容体発現亢進効果を得るための、 中 鎖脂肪酸としての所要量は、 上述の通り特に限定されないが、 例えば、 0 . 4 gノ日以上、 好ましくは 1 g Z日以上、 より好ましくは 2 g Z日 以上、 さらに好ましくは 5 g Z日以上、 特に好ましくは 8 g Z日以上、 最も特に好ましくは 1 0 g Z 5以上を例示することができる。  Further, the amount required as a medium-chain fatty acid for obtaining the effect of enhancing the expression of 3-adrenergic receptor is not particularly limited as described above, but is, for example, 0.4 g or more days, preferably 1 g Z days or more. More preferably, 2 gZ days or more, further preferably 5 gZ days or more, particularly preferably 8 gZ days or more, and most preferably 10 gZ5 or more.
本発明の好ましい形態として、 中鎖脂肪酸トリグリセリン脂肪酸エス テルを有効成分とする 3—アドレナリン受容体発現亢進剤に関する。 中鎖脂肪酸トリグリセリン脂肪酸エステルについては上述の通りである。 この場合の含量も上述の通り特に限定されないが、 例えば、 0 . 5質 量％以上、 好ましくは 1質量％以上、 より好ましくは 5質量％以上、 さ らに好ましくは 5〜9 9 . 9質量％、 特に好ましくは 1 0〜9 9 . 9質 量％、 最も特に好ましくは 1 3〜9 9 . 9質量％である。 また、 上記と 同様に、 中鎖脂肪酸トリグリセリン脂肪酸エステルを主要成分とする場 合が好ましく、 含量も上記を例示できる。  A preferred embodiment of the present invention relates to a 3-adrenergic receptor expression enhancer containing a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient. The medium-chain triglycerin fatty acid ester is as described above. The content in this case is not particularly limited as described above, but is, for example, 0.5 mass% or more, preferably 1 mass% or more, more preferably 5 mass% or more, and further preferably 5 to 99.9 mass%. %, Particularly preferably from 10 to 99.9% by weight, most preferably from 13 to 99.9% by weight. Similarly to the above, it is preferable to use a medium-chain fatty acid triglycerin fatty acid ester as a main component, and the content can be exemplified as described above.
上述の通り、 本発明の体脂肪分解促進剤全体に対する中鎖脂肪酸およ ぴ Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エステルの含量は体脂肪 分解促進剤作用を有する程度含有すれば特に制限されない。 ここで、 有 効成分として含有するとは、 その体脂肪分解促進剤を発揮する程度に含 有するということであるが、 その含量は特に制限されず、 摂取の頻度、 摂取量、 使用の目的によって適宜調整すれば良い。 該効果を得るための 所要量は、 摂取の形態、 対象者の性別、 体重、 体調等により異なり、 特 に制限されないが、 例えば、 0 . 5 g Z日以上、 好ましくは 1 g /日以 上、 より好ましくは 2 g Z日以上、 さらに好ましくは 5 g /日以上、 特 に好ましくは 8 g /7日以上、 最も特に好ましくは 1 0 g /日以上を例示 することができる。 含量としては、 特に限定されないが、 例えば、 0 . 5質量％以上、 好ましくは 1質量％以上、 より好ましくは 5質量％以上、 さらに好ましくは 5〜9 9 . 9質量％、 特に好ましくは 1 0〜9 9 . 9 質量％、 最も特に好ましくは 1 3〜9 9 . 9質量％である。 また、 短期 間かつ少量で該体脂肪分解促進剤の効果を期待する場合の中鎖脂肪酸お よびノまたは中鎖脂肪酸を含むグリセリン脂肪酸エステル含量は、 上述 の通り特に制限されないが、 例えば、 5 0〜9 9 . 9質量％、 好ましく は 7 0〜 9 9 . 9質量％、 さらに好ましくは 9 0〜 9 9 . 9質量％を例 示することができる。 As described above, the content of the medium-chain fatty acid and the glycerin fatty acid ester containing the medium Z or the medium-chain fatty acid in the whole body fat degradation promoter of the present invention is not particularly limited as long as the content thereof has the body fat degradation promoter action. Where To be contained as an active ingredient means to be contained to such an extent that the body fat degradation promoter is exhibited, but the content is not particularly limited, and may be appropriately adjusted according to the frequency of ingestion, the amount of ingestion, and the purpose of use. . The amount required to obtain the effect depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited. For example, 0.5 g or more Z days, preferably 1 g / day or more More preferably, it is 2 g Z days or more, more preferably 5 g / day or more, particularly preferably 8 g / 7 days or more, and most preferably 10 g / day or more. The content is not particularly limited, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, further preferably 5 to 99.9% by mass, and particularly preferably 10% by mass. From 9 to 99.9% by weight, most preferably from 13 to 99.9% by weight. When the effect of the body lipolysis accelerator is expected in a short time and in a small amount, the content of a medium-chain fatty acid and a glycerin fatty acid ester containing a medium- or medium-chain fatty acid is not particularly limited as described above. To 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass.
中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェステ ルは、 つまり中鎖脂肪酸の存在により、 各機能が発生する。 ここで、 そ の含量やグリセリン脂肪酸エステルの構造により、 その効果の特徴も異 なる。  Medium chain fatty acids and glycerin fatty acid esters containing Z or medium chain fatty acids, ie, their functions are generated by the presence of medium chain fatty acids. Here, the characteristics of the effect vary depending on the content and the structure of the glycerin fatty acid ester.
含量については、 機能を得られる範囲であることが必要であり、 好ま しくは前記範囲であって、 かつ、 人体への悪影響の可能性が低いほど好 ましく、 さらには商業上または工業上、 できるだけ低含量であることが 好ましい。  It is necessary that the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
さらには、 構造によって吸収経路の違い等により、 その効果の強さ、 時間的な特徴 (即効性、 持続性）、 他の要因の発生等が異なる。 この構 造の違いを利用して、 機能の強さ、 時間的特徴等の設計や、 安全性の設 計を行うことができる。 例えば、 グリセリンに少なくとも 1以上の中鎖 脂肪酸が結合している脂肪酸エステル （以下、 「M L C T」 という） や、 特に中鎖脂肪酸の結合する位置や他の脂肪酸の種類を特定して設計され たグリセリン脂肪酸エステル （以下、 「構造体」 「構造油脂」 という） を 例示することができる。 M L C Tや構造体 （油脂） を含有する製剤等に おける中鎖脂肪酸、 該 M L C Tや構造油脂の含量は上記を参考とするこ とができる。 In addition, the strength of the effect, temporal characteristics (immediate effect, sustainability), occurrence of other factors, etc. differ depending on the structure of the absorption pathway depending on the structure. This structure By utilizing the differences in structure, it is possible to design the strength of functions, temporal characteristics, etc., and to design safety. For example, fatty acid esters in which at least one or more medium-chain fatty acids are bonded to glycerin (hereinafter referred to as “MLCT”), or glycerin specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids Fatty acid esters (hereinafter, referred to as “structures” and “structured fats and oils”) can be exemplified. The content of the medium-chain fatty acid, the MLCT, and the content of the structural fats and oils in the preparations containing the MLCT and the structure (oils and fats) can be referred to the above.
ここで、 上述したが、 中鎖脂肪酸の含量は機能を得られる範囲である ことが必要であり、 好ましくは前記範囲であって、 かつ、 人体への悪影 響の可能性が低いほど好ましく、 さらには商業上または工業上、 できる だけ低含量であることが好ましい。  Here, as described above, the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
上記視点から検討すると、 例えば、 長期摂取や体質改善を目的とする 場合には、 全脂肪酸に占める中鎖脂肪酸の割合が 3〜2 3質量％、 好ま しくは 4〜2 0質量 °/0、 さらに好ましくは 5〜 1 7質量％、 特に好まし くは 6〜 1 5質量％、 最も好ましくは 7〜 1 4質量％、 最も特に好まし くは 8〜 1 3質量％である。 Considering the above viewpoints, for example, in the case of long-term intake or improvement of constitution, the ratio of medium-chain fatty acids to total fatty acids is 3 to 23 mass%, preferably 4 to 20 mass ° / 0 , It is more preferably from 5 to 17% by weight, particularly preferably from 6 to 15% by weight, most preferably from 7 to 14% by weight, most preferably from 8 to 13% by weight.
さらに、 該体脂肪分解促進効果を得るための、 中鎖脂肪酸としての所 要量は、 上述の通り特に限定されないが、 例えば、 0 . 4 g Z日以上、 好ましくは l gノ日以上、 より好ましくは 2 g Z日以上、 さらに好まし くは 5 g Z日以上、 特に好ましくは 8 g /日以上、 最も特に好ましくは Further, the amount required as a medium-chain fatty acid for obtaining the body fat degradation promoting effect is not particularly limited as described above, but is, for example, 0.4 g Z days or more, preferably 1 g days or more, more preferably Is more than 2 g Z days, more preferably more than 5 g Z days, particularly preferably more than 8 g / day, most particularly preferably
1 0 g Z日以上を例示することができる。 More than 10 g Z days can be exemplified.
本発明の好ましい形態として、 中鎖脂肪酸トリグリセリン脂肪酸エス テルを有効成分とする体脂肪分解促進剤に関する。 中鎖脂肪酸トリグリ セリン脂肪酸エステルについては上述の通りである。 この場合の含量も 上述の通り特に限定されないが、 例えば、 0 . 5質量％以上、 好ましく は 1質量％以上、 より好ましくは 5質量％以上、 さらに好ましくは 5〜 9 9. 9質量％、 特に好ましくは 1 0〜 9 9. 9質量％、 最も特に好ま しくは 1 3〜9 9. 9質量0 /0である。 A preferred embodiment of the present invention relates to a body fat degradation promoter containing a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient. The medium-chain triglycerin fatty acid ester is as described above. The content in this case is not particularly limited as described above, but is, for example, 0.5% by mass or more, preferably Is 1% by mass or more, more preferably 5% by mass or more, further preferably 5 to 99.9% by mass, particularly preferably 10 to 99.9% by mass, and most preferably 13 to 99.9% by mass. 9 mass is 0/0.
また、 上記と同様に、 中鎖脂肪酸トリグリセリン脂肪酸エステルを主 要成分とする場合が好ましく、 含量も上記を例示できる。  Similarly to the above, it is preferable to use a medium-chain fatty acid triglycerin fatty acid ester as a main component, and the content can be exemplified as described above.
上述の通り、 本発明の体脂肪血中放出促進剤全体に対する中鎖脂肪酸 および/ ^または中鎖脂肪酸を含むグリセリン脂肪酸エステルの含量は体 脂肪血中放出促進剤作用を有する程度含有すれば特に制限されない。 こ こで、 有効成分として含有するとは、 その体脂肪血中放出促進剤を発揮 する程度に含有するということであるが、 その含量は特に制限されず、 摂取の頻^、 摂取量、 使用の目的によって適宜調整すれば良い。 該効果 を得るための所要量は、 摂取の形態、 対象者の性別、 体重、 体調等によ り異なり、 特に制限されないが、 例えば、 0. 5 §ノ日以上、 好ましく は l g 日以上、 より好ましくは 2 g/ 3以上、 さらに好ましくは 5 g Z日以上、 特に好ましくは 8 gZ日以上、 最も特に好ましくは 1 0 g/ 日以上を例示することができる。 含量としては、 特に限定されないが、 例えば、 0. 5質量％以上、 好ましくは 1質量％以上、 より好ましくは 5質量％以上、 さらに好ましくは 5〜9 9. 9質量％、 特に好ましくは 1 0〜9 9. 9質量％、 最も特に好ましくは 1 3〜9 9. 9質量％であ る。 また、 短期間かつ少量で該体脂肪血中放出促進の効果を期待する場 合の中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エス テル含量は、 上述の通り特に制限されないが、 例えば、 50〜9 9. 9 質量％、 好ましくは 70〜 99. 9質量％、 さらに好ましくは 9 0〜 9 9. 9質量％を例示することができる。 As described above, the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid relative to the whole body fat blood release-promoting agent of the present invention is particularly limited as long as it contains the body fat blood release-promoting agent. Not done. Here, containing as an active ingredient means containing the substance to the extent that it exerts its body fat blood release promoter, but the content is not particularly limited, and the frequency of ingestion, the amount of ingestion, and the use of What is necessary is just to adjust suitably according to the objective. Requirements for obtaining the effect, ingestion of forms, subject's sex, weight, varies based on the physical condition and the like are not particularly limited, for example, 0. 5 § Bruno day or more, preferably lg day or more, more It is preferably 2 g / 3 or more, more preferably 5 gZ days or more, particularly preferably 8 gZ days or more, and most preferably 10 g / day or more. The content is not particularly limited, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, further preferably 5 to 99.9% by mass, and particularly preferably 10% by mass. To 99.9% by weight, most preferably 13 to 99.9% by weight. When the effect of promoting the release of body fat into blood is expected in a short time and in a small amount, the content of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids is not particularly limited as described above. 50 to 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass.
中鎖脂肪酸おょぴ Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エステ ルは、 つまり中鎖脂肪酸の存在により、 各機能が発生する。 ここで、 そ の含量やグリセリン脂肪酸エステルの構造により、 その効果の特徴も異 なる。 Medium-chain fatty acids Z or glycerin fatty acid esters containing medium-chain fatty acids, that is, each function is generated by the presence of medium-chain fatty acids. Where The effect differs depending on the content of glycerin and the structure of the glycerin fatty acid ester.
含量については、 機能を得られる範囲であることが必要であり、 好ま しくは前記範囲であって、 かつ、 人体への悪影響の可能性が低いほど好 ましく、 さらには商業上または工業上、 できるだけ低含量であることが 好ましい。  It is necessary that the content is within the range in which the function can be obtained, and it is preferable that the content is within the above range, and that the possibility of adversely affecting the human body is low. It is preferred that the content is as low as possible.
さらには、 構造によって吸収経路の違い等により、 その効果の強さ、 時間的な特徴 （即効性、 持続性）、 他の要因の発生等が異なる。 この構 造の違いを利用して、 機能の強さ、 時間的特徴等の設計や、 安全性の設 計を行うことができる。 例えば、 グリセリンに少なくとも 1以上の中鎖 脂肪酸が結合している脂肪酸エステル （以下、 「M L C T」 という） や、 特に中鎖脂肪酸の結合する位置や他の脂肪酸の種類を特定して設計され たグリセリン脂肪酸エステル （以下、 「構造体」 「構造油脂」 という） を 例示することができる。 M L C Tや構造体 （油脂） を含有する製剤等に おける中鎖脂肪酸、 該 M L C Tや構造油脂の含量は上記を参考とするこ とができる。  Furthermore, the strength of the effect, temporal characteristics (immediate effect, sustainability), occurrence of other factors, etc., differ depending on the structure of the absorption pathway depending on the structure. By utilizing this difference in structure, it is possible to design the strength of functions, temporal characteristics, etc., and to design safety. For example, fatty acid esters in which at least one or more medium-chain fatty acids are bonded to glycerin (hereinafter referred to as “MLCT”), or glycerin specifically designed to identify the position at which the medium-chain fatty acids are bonded and the type of other fatty acids Fatty acid esters (hereinafter, referred to as “structures” and “structured fats and oils”) can be exemplified. The content of the medium-chain fatty acid and the content of the MLCT and the structured fat / oil in the preparation or the like containing the MLCT or the structure (oil / fat) can be referred to the above.
ここで、 上述したが、 中鎖脂肪酸の含量は機能を得られる範囲である ことが必要であり、 好ましくは前記範囲であって、 かつ、 人体への悪影 響の可能性が低いほど好ましく、 さらには商業上または工業上、 できる だけ低含量であることが好ましい。  Here, as described above, the content of the medium-chain fatty acid needs to be in a range in which a function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, it is preferable that the content is as low as possible commercially or industrially.
上記視点から検討すると、 例えば、 長期摂取や体質改善を目的とする 場合には、 全脂肪酸に占める中鎖脂肪酸の割合が 3〜2 3質量％、 好ま しくは 4〜 2 0質量0 /0、 さらに好ましくは 5〜 1 7質量％、 特に好まし くは 6〜 1 5質量％、 最も好ましくは 7〜1 4質量％、 最も特に好まし くは 8〜 1 3質量0 /0である。 Considering the above viewpoint, for example, for the purpose of long-term intake and body modification, the proportion is 3 to 2 3% by weight of medium chain fatty acids to the total fatty acids, the preferred properly 4-2 0 weight 0/0, more preferably 5-1 7 mass%, particularly preferably rather from 6 1 to 5 wt%, and most preferably 7 to 4% by weight, most particularly rather preferably is 8-1 3 mass 0/0.
さらに、 該体脂肪血中放出促進効果を得るための、 中鎖脂肪酸として の所要量は、 上述の通り特に限定されないが、 例えば、 0 . 4 g /曰以 上、 好ましくは 1 g /日以上、 より好ましくは 2 g /日以上、 さらに好 ましくは 5 g /日以上、 特に好ましくは 8 g /日以上、 最も特に好まし くは 1 0 g Z日以上を例示することができる。 Further, as a medium-chain fatty acid for obtaining the body fat blood release promoting effect. Although the required amount is not particularly limited as described above, for example, 0.4 g / or more, preferably 1 g / day or more, more preferably 2 g / day or more, and still more preferably 5 g / day Above, particularly preferably 8 g / day or more, most preferably 10 g Z day or more.
本発明の好ましい形態として、 中鎖脂肪酸トリグリセリン脂肪酸エス テルを有効成分とする体脂肪血中放出促進剤に関する。 中鎖脂肪酸トリ グリセリン脂肪酸エステルについては上述の通りである。 この場合の含 量も上述の通り特に限定されないが、 例えば、 0 . 5質量％以上、 好ま しくは 1質量％以上、 より好ましくは 5質量％以上、 さらに好ましくは 5〜9 9 . 9質量％、 特に好ましくは 1 0〜9 9 . 9質量％、 最も特に 好ましくは 1 3〜9 9 . 9質量％である。  A preferred embodiment of the present invention relates to a body fat blood release promoter containing a medium-chain fatty acid triglycerin fatty acid ester as an active ingredient. The medium-chain triglycerin fatty acid ester is as described above. The content in this case is not particularly limited as described above, but is, for example, 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, and still more preferably 5 to 99.9% by mass. Particularly preferably, it is 10 to 99.9% by mass, most preferably 13 to 99.9% by mass.
また、 上記と同様に、 中鎖脂肪酸トリグリセリン脂肪酸エステルを主 要成分とする場合が好ましく、 含量も上記を例示できる。  Similarly to the above, it is preferable to use a medium-chain fatty acid triglycerin fatty acid ester as a main component, and the content can be exemplified as described above.
ここで、 本発明のホルモン感受性リパーゼ発現亢進剤、 J3 3—ァドレ ナリン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤等 は、 ヒ ト及ぴ動物に対し、 医薬品、 医薬部外品等として経口的及ぴ非経 口的に安全に投与できる。 非経口的投与としては、 例えば静脈注射、 動 脈注射、 筋肉注射、 皮下注射、 皮内注射、 腹腔内注射、 脊髄内注射、 硬 膜外注射、 経皮投与、 経肺投与、 経鼻投与、 経腸投与、 口腔内投与、 経 粘膜投与等が挙げられ、 その剤形としては、 例えば注射剤、 坐剤 （肛門 座剤、 尿道座剤、 膣座剤等） などが挙げられる。 また、 経口投与製剤と しては、 例えば、 内服用錠剤 （素錠、 糖衣錠、 コーティング錠、 腸溶錠、 チユアブル錠など）、 口腔内錠剤 （パッカル錠、 舌下錠、 トローチ錠、 付着錠など）、 散剤、 カプセル剤 （硬カプセル剤、 軟カプセル剤など）、 顆粒剤 （コーティングした物、 丸剤、 トローチ剤、 液剤、 またはこれら の製剤学的に許容され得る徐放化製剤など） などが挙げられる。 経口投 , Here, the hormone-sensitizing lipase expression enhancer, J33-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, etc. of the present invention are used in humans and animals, as pharmaceuticals, It can be safely administered orally or parenterally as a quasi drug. Parenteral administration includes, for example, intravenous injection, arterial injection, intramuscular injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intraspinal injection, epidural injection, transdermal administration, pulmonary administration, nasal administration, Enteral administration, buccal administration, transmucosal administration and the like are mentioned, and examples of the dosage form include injections, suppositories (such as rectal suppositories, urethral suppositories, and vaginal suppositories). Oral preparations include, for example, tablets for internal use (uncoated tablets, sugar-coated tablets, coated tablets, enteric-coated tablets, chewable tablets, etc.) and oral tablets (pacal tablets, sublingual tablets, troche tablets, adhesive tablets, etc.) ), Powders, capsules (hard capsules, soft capsules, etc.), granules (coated, pills, troches, liquids, or pharmaceutically acceptable sustained-release preparations thereof) No. Oral throw ,
26 与用液剤としては、 例えば、 内用水剤、 振とう合剤、 懸濁剤、 乳剤、 シ ロップ剤、 ドライシロップ剤、 エリキシル剤、 浸剤、 煎剤、 リモナーデ 剤などが挙げられるが、 これらの形態に特に限定されない。 油脂組成物 の態様も好適な態様の一つである。  26 Examples of liquid preparations include water solutions for internal use, shaking mixtures, suspensions, emulsions, syrups, dry syrups, elixirs, dips, decoctions, limonades, and the like. There is no particular limitation. The embodiment of the oil and fat composition is also one of the preferred embodiments.
これらの製剤は公知の製剤学的製法に準じ、 製剤として薬理学的に許 容され得る基剤、 担体、 賦形剤、 結合剤、 崩壊剤、 滑沢剤、 着色剤等と 共に製剤化され投与される。  These preparations are formulated together with pharmacologically acceptable bases, carriers, excipients, binders, disintegrants, lubricants, coloring agents, etc. according to known pharmaceutical manufacturing methods. Is administered.
これらの製剤に用いる担体ゃ賦形剤としては、 例えば糖類 （乳糖、 白 糖、 プドウ糖等）、 デンプン （トウモロコシ、 馬鈴薯、 コムギ）、 マンニ トール、 炭酸カルシウム、 リン酸カルシウム、 硫酸カルシウム、 結晶セ ルロース、 微結晶セルロース、 カンゾゥ粉末、 ゲンチアナ粉末などが挙 げられる。  Carriers and excipients used in these preparations include, for example, saccharides (lactose, sucrose, pudose, etc.), starch (corn, potato, wheat), mannitol, calcium carbonate, calcium phosphate, calcium sulfate, crystalline cellulose, Examples include microcrystalline cellulose, powdered Canzo powder and gentian powder.
これらの製剤に用いる結合剤としては、 例えばデンプン、 トラガント ゴム、 ゼラチン、 シロップ、 ポリ ビュルアルコール、 ポリ ビュルエーテ ノレ、 ポリ ビニルピロ リ ドン、 ヒ ドロキシプロピノレセノレロース、 メチノレセ ルロース、 ェチノレセル'ロース、 カルボキシメチルセルロースなどが挙げ られる。  Binders used in these preparations include, for example, starch, tragacanth gum, gelatin, syrup, polyvinyl alcohol, polyvinyl butyral, polyvinylpyrrolidone, hydroxypropinoresenorelose, methinoreserulose, ethinorescellulose, carboxymethylcellulose. And so on.
これらの製剤に用いる崩壊剤としては例えばデンプン、 寒天、 ゼラチ ン粉末、 カルボキシメチルセルロースナトリ ウム、 カスレボキシメチルセ ルロースカルシウム、 結晶セルロース、 炭酸カルシウム、 炭酸水素ナト リウム、 アルギン酸ナトリウムなどが挙げられる。  Disintegrants used in these preparations include, for example, starch, agar, gelatin powder, sodium carboxymethylcellulose, calcium carboxymethylcellulose, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, sodium alginate and the like.
これらの製剤に用いる滑沢剤としては例えばステアリン酸マグネシゥ ム、 タルク、 水素添加植物油、 マクロゴールなどが挙げられる。  Lubricants used in these preparations include, for example, magnesium stearate, talc, hydrogenated vegetable oil, macrogol and the like.
これらの製剤に用いる着色剤としては医薬品に添加することが許容さ れているものを、 それぞれ用いることができる。  As the coloring agents used in these preparations, those permitted to be added to pharmaceuticals can be used.
また、 注射剤を調製する場合は、 必要に応じて、 ρ Η調節剤、 緩衝剤、 安定化剤、 可溶化剤などを添加して、 常法により各注射剤とする。 When preparing injections, if necessary, ρ regulators, buffers, Stabilizers, solubilizers, etc. are added and each injection is made in the usual manner.
錠剤、 顆粒剤を調製する場合は、 必要に応じて、 白糖、 ゼラチン、 ヒ ドロキシプロピノレセノレロース、 精製セラック、 ゼラチン、 グリセリン、 ソルビトーノレ、 ェチノレセノレロース、 ヒ ドロキシプロピノレセノレロース、 ヒ ドロキシプロピノレメチノレセノレロース、 ポリ ビニノレピロリ ドン、 フタ/レ蹄 セル'口一スァセテート、 ヒ ドロキシプ口ピルメチノレセノレロースフタレー ト、 メチルメタタリレート、 メタアクリル酸重合体などで被膜しても良 いし、 2つ以上の層で被膜しても良い。 さらにェチルセルロースゃゼラ チンのような物質のカプセノレでも良い。  When preparing tablets and granules, as needed, sucrose, gelatin, hydroxypropinoresenololose, purified shellac, gelatin, glycerin, sorbitole, etinoresenorelose, hydroxypropinoresenorelose, Coated with hydroxypropynolemethinoresenolylose, polyvinylinolepyrrolidone, lid / hoof, cell mouth, acetate, hydroxymethine pilmethinoresenololose phthalate, methyl methacrylate, methacrylic acid polymer, etc. Or two or more layers. Further, capsenolle of a substance such as ethyl cellulose-gelatin may be used.
また、 本発明の各機能剤に含まれる中鎖脂肪酸おょぴノまたは中鎖脂 肪酸を含むグリセリン脂肪酸エステルは油性成分であることから、 これ らへの溶解性が良好である栄養生理機能成分のビタミン 、 ビタミン0、 ビタミン E、 ァスコルビン酸脂肪酸エステル、 リグナン、 コェンザィム Further, since the medium-chain fatty acid or glycerin fatty acid ester containing a medium-chain fatty acid contained in each functional agent of the present invention is an oily component, nutritional and physiological functions that have good solubility in these are included. Ingredients Vitamin, Vitamin 0, Vitamin E, Ascorbic acid fatty acid ester, Lignan, Kenzaim
Q、 リン脂質、 トリテルペン類、 オリザノール等を配合することができ る。 Q, phospholipids, triterpenes, oryzanol, etc. can be added.
本発明のホルモン感受性リパーゼ発現亢進剤は、 中鎖脂肪酸および z または中鎖脂肪酸を含むグリセリン脂肪酸エステル、 好ましくは中鎖脂 肪酸トリグリセリン脂肪酸エステルを含有することを特徴とする。 ここ で、 ホルモン感受性リパーゼとは、 脂肪組織に存在するリパーゼ （ァシ ルグリセロールのエステル結合を水解する酵素の総称） で、 脂肪組織中 に溜め込まれたトリグリセリン脂肪酸エステルをグリセロールと遊離脂 肪酸にまで分解する酵素のことをいい、 ホルモン感受性リパーゼ発現亢 進剤とは、 該酵素の m R N A発現量を亢進させるものをいう。 一般に、 酵素の m R N A発現量の亢進は、 該酵素活性の上昇を表しているため酵 素活性の強弱の判断基準となる。 本発明では、 該酵素の m R N A発現量 を、 特異的プライマーを用いたリアルタイム定量 P C Rにて測定するこ とで、 該酵素 niRN A発現量を定量的に算出しその増減を確認している。 ここで、 mRNA発現量の定量法は、 通常の固形飼料を摂取させた同週 齢のラット脂肪組織由来の全 RNAを逆転写酵素で DNAに変換したも のを標準品として検量線を作成し、 ハウスキーピング遺伝子である /3— ァクチンの mRNA発現量に対する該酵素 mRNA発現量の相対値を％ で算出し、 長鎖脂肪酸トリグリセリン脂肪酸エステルを摂取させたラッ トのそれと比較することで評価している。 本発明品を長期的に摂取する ことで、 この値が 1 25〜 1 70 %であるため、 本発明により、 好適な ホルモン感受性リパーゼ発現亢進剤を供与できる。 The hormone-sensitized lipase expression enhancer of the present invention is characterized by containing a medium-chain fatty acid and a glycerin fatty acid ester containing z or a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester. Here, hormone-sensitive lipase is a lipase (an enzyme that hydrolyzes the ester bond of acylglycerol) present in adipose tissue, and converts triglycerin fatty acid esters accumulated in adipose tissue into glycerol and free fatty acids. The term "hormone-sensitive lipase expression enhancer" refers to an agent that enhances the mRNA expression level of the enzyme. In general, an increase in the mRNA expression level of an enzyme indicates an increase in the enzyme activity, and thus serves as a criterion for determining the strength of the enzyme activity. In the present invention, the mRNA expression level of the enzyme is measured by real-time quantitative PCR using specific primers. Thus, the expression amount of the enzyme niRNA was quantitatively calculated and the increase or decrease was confirmed. Here, the method for quantifying mRNA expression was as follows: a standard curve was prepared using as a standard a sample of total RNA derived from adipose tissue of the same age in rats fed normal chow and converted to DNA using reverse transcriptase. The relative value of the mRNA expression level of the enzyme relative to the mRNA level of the housekeeping gene / 3 / 3-actin was calculated in% and evaluated by comparing it with that of rats fed the long-chain fatty acid triglycerin fatty acid ester. ing. By taking the product of the present invention for a long time, this value is 125 to 170%. Therefore, a suitable hormone-sensitive lipase expression enhancer can be provided by the present invention.
上記ホルモン感受性リパーゼは、 中鎖脂肪酸おょぴ Zまたは中鎖脂肪 酸を含むグリセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセ リン脂肪酸エステルを摂取することにより交感神経等の刺激が生じ、 そ の刺激が脂肪細胞上の受容体を介して細胞内に伝達され、 該酵素 mRN A遺伝子発現量が亢進した結果活性化しているものと考えられる。 事実、 本発明品の摂取により、 脂肪細胞上に交感神経活性物質であるァドレナ リンに対する受容体の一つ、 /3 3—アドレナリン受容体の mRNA発現 量の亢進が認められていることから、 本発明は、 中鎖脂肪酸およびノま たは中鎖脂肪酸を含むグリセリン脂肪酸エステル、 好ましくは中鎖脂肪 酸トリグリセリン脂肪酸エステルを含有することを特徴とする J3 3—ァ ドレナリン受容体発現亢進剤として使用することができ、 非常に好まし レ、。  The above hormone-sensitive lipase is stimulated by sympathetic nerves or the like by ingesting medium-chain fatty acid Z or glycerin fatty acid ester containing medium-chain fatty acid, preferably medium-chain fatty acid triglycerin fatty acid ester. It is thought that it is transmitted into cells via receptors on adipocytes and activated as a result of increased expression of the enzyme mRNA gene. In fact, the ingestion of the product of the present invention has been found to increase the mRNA expression level of / 33-adrenoceptor, one of the receptors for adrenergic, a sympathetic nerve active substance, on adipocytes. The invention provides a J33-adrenergic receptor expression enhancer comprising a medium chain fatty acid and a glycerin fatty acid ester containing a medium chain fatty acid, preferably a medium chain fatty acid triglycerin fatty acid ester. Can, very favored Les ,.
また、 該 3—アドレナリン受容体の mRNA発現亢進は、 前記ホル モン感受性リパーゼの mRN A発現亢進の指標とすることができる。 つ まり、 該 3—アドレナリン受容体の発現が亢進されている場合、 前記 ホルモン感受性リパーゼの発現が亢進されていると考えられる。  In addition, the increase in mRNA expression of the 3-adrenergic receptor can be used as an index of the increase in mRNA expression of the hormone-sensitive lipase. In other words, when the expression of the 3-adrenergic receptor is enhanced, it is considered that the expression of the hormone-sensitive lipase is enhanced.
体脂肪分解促進作用は、 上述したホルモン感受性リパーゼ mRN A発 現量亢進と、 後に詳述する血中遊離脂肪酸量により容易に認められる。 すなわち、 脂肪細胞中に蓄積された体脂肪がホルモン感受性リパーゼに より分解され、 血中へ遊離脂肪酸として放出されたり、 再び脂肪細胞内 で 酸化を受けエネルギー源となる結果、 体脂肪が分解されていること がわかる。 これらの指標を元に検討したところ、 中鎖脂肪酸おょぴ Zま たは中鎖脂肪酸を含むグリセリン脂肪酸エステル、 好ましくは中鎖脂肪 酸トリグリセリン脂肪酸エステルを摂取することにより、 ホルモン感受 性リパーゼ！！！ 発現量が大豆油摂取に比べ約 1 . 3〜 2倍亢進した c さらに、 血中遊離脂肪酸濃度も有意に上昇したことにより、 本発明によ り体脂肪分解が進んでいることがわかる。 The body lipolysis-promoting action is based on the hormone-sensitive lipase mRNA described above. It is easily recognized by the increase in the present amount and the amount of free fatty acids in blood described in detail below. In other words, body fat accumulated in fat cells is broken down by hormone-sensitive lipase and released into the blood as free fatty acids, or oxidized again in fat cells to become an energy source, resulting in the breakdown of body fat You can see that Investigations based on these indices revealed that the ingestion of medium-chain fatty acids Z or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain fatty acid triglycerin fatty acid esters, resulted in hormone-sensitive lipase! ! ! The expression level was increased about 1.3 to 2 times as compared to the intake of soybean oil. C Furthermore, the blood free fatty acid concentration was also significantly increased, indicating that the body fat degradation is progressing according to the present invention.
体脂肪として脂肪細胞内に蓄積されているトリグリセリン脂肪酸エス テルが、 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸 エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステルを摂取 することで遊離脂肪酸に分解された結果、 該遊離脂肪酸が血中に放出さ れる。 本発明を長期的に摂取することで、 対象である大豆油摂取群に比 ベ有意に血中遊離脂肪酸濃度が上昇していることがわかる。 このことは、 脂肪細胞内で上述した j3 .3—ァドレナリン受容体を介したシグナル伝達 によりホルモン感受性リパーゼが活性化され、 蓄積されていた脂肪が上 記作用により分解され、 遊離脂肪酸として血中へ放出されたためと、 説 明される。  Triglycerin fatty acid esters accumulated in fat cells as body fat are converted into free fatty acids by ingesting medium chain fatty acids and / or glycerin fatty acid esters containing medium chain fatty acids, preferably medium chain fatty acid triglycerin fatty acid esters. As a result of the decomposition, the free fatty acids are released into the blood. It can be seen that the long-term intake of the present invention significantly increased the free fatty acid concentration in blood as compared to the target soybean oil intake group. This indicates that hormone-sensitive lipase is activated in adipocytes by the signal transduction via j3.3-adrenergic receptor described above, and the accumulated fat is degraded by the above-mentioned action and released into the blood as free fatty acids. It is explained that it was released.
本発明品の摂取により、 交感神経等から何らかのシグナルが発生され ていること、 M C T自体の存在が刺激剤として働いていること、 また、 M C Tが肝臓で燃焼されてできたケトン体類が刺激となっていること等 が考えられ、 また、 これらの組合せにより生じているとも考えられる。 さらに、 M C T摂取数時間後には、 M C Tは完全に燃焼され摂取由来の エネルギー源が枯渴してしまっているため、 末梢のエネルギー蓄積臓器 である脂肪組織から前述と同様の作用機序で遊離脂肪酸が放出され、 リ ポ蛋白がエネルギー源として各組織に供給されているものとも考えられ る。 何らかのシグナルが発生していることに関しては、 MCT摂取によ り脂肪細胞内のホルモン感受性リパーゼゃ、 交感神経活性化物質の受容 体のひとつである β 3—ァドレナリン受容体の mRNA発現量が L CT 摂取よりも増加していることから、 説明される。 Ingestion of the product of the present invention causes some signals to be generated from the sympathetic nerves, etc., that the presence of MCT itself acts as a stimulant, and that ketone bodies formed by burning MCT in the liver cause irritation. It is considered that they are caused by the combination of these. In addition, several hours after ingestion of MCTs, MCTs are completely burned and the energy sources derived from ingestion have died, so peripheral energy storage organs It is considered that free fatty acids are released from the adipose tissue by the same mechanism of action as described above, and lipoprotein is supplied to each tissue as an energy source. Regarding the occurrence of some signal, the level of mRNA expression of hormone-sensitive lipase II in adipocytes and β3-adrenergic receptor, one of the receptors for sympathetic activators, was increased by MCT intake. It is explained because it is higher than intake.
さらに、 L CT 1 0 0%と、 MCTを含有するもの （例えば MCTを 2 0%含有するもの） を比較した場合、 これらの総エネルギー量はほぼ 同等であるが、 ホルモン感受性リパーゼ発現亢進効果は大きく異なり、 その結果、 長期摂取後の体脂肪量は大きく異なる。 逆に、 当該 MCT 2 0%と、 MCT 1 0 0%のものとを比較しても、 そのホルモン感受性リ パーゼ発現亢進効果に大きな差異はなく、 長期摂取後の体脂肪量にも大 きな差異はなく、 MCT含量に比例していない。  Furthermore, when LCT 100% and those containing MCT (for example, those containing 20% MCT) are compared, their total energy amounts are almost the same, but the effect of enhancing hormone-sensitive lipase expression is They vary widely and, as a result, the body fat mass after long-term intake varies greatly. Conversely, when comparing the MCT 20% and the MCT 100%, there is no significant difference in the effect of enhancing the expression of hormone-sensitive lipase, and the body fat after long-term ingestion has a large effect. No difference and not proportional to MCT content.
これらのことから、 ホルモン感受性リパーゼ発現亢進効果等を得るた めには、 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリ ン脂肪酸 エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステルを一定 量摂取することが重要であると解される。 つまり、 その量は前記シグナ ル等が発せられる、 機能が発揮されるための一定量であればよい。 言い 換えると、 あたかもスィツチを押すために必要な一定量を摂取すればよ い、 とレヽうことである。  From these facts, in order to obtain the effect of enhancing the expression of hormone-sensitive lipase, it is necessary to ingest a certain amount of medium-chain fatty acid and / or glycerin fatty acid ester containing medium-chain fatty acid, preferably medium-chain fatty acid triglycerin fatty acid ester. Is understood to be important. That is, the amount may be a certain amount for the signal and the like to be emitted and for the function to be exhibited. In other words, it is as if you only need to take a certain amount necessary to press the switch.
高濃度品を摂取することや、 多量に摂取することでも目的を達成する ことができるが、 比較的低濃度品の摂取や、 少量の摂取でも目的を達成 することができる。 この点を踏まえ、 上述の通り使用態様や摂取期間に 応じて調整することができる。 特に、 中鎖脂肪酸およびノまたは中鎖脂 肪酸を含むグリセリン脂肪酸エステルはエネルギー源であることから、 過度の摂取を押さえる様に商品設計されたものが好ましく、 適量を摂取 することが好ましい。 The purpose can be achieved by ingesting a high-concentration product or a large amount, but the purpose can also be achieved by ingesting a relatively low-concentration product or a small amount. Based on this point, it can be adjusted according to the usage mode and the intake period as described above. In particular, since glycerin fatty acid esters containing medium-chain fatty acids and glycerol or medium-chain fatty acids are energy sources, products designed to suppress excessive intake are preferred. Is preferred.
また、 本発明がもたらす効果によって更なる効果が導かれる。 その一 つとして、 体脂肪低減効果は、 動物の総体重に占める体脂肪の量で測定 することができる。 すなわち、 試験動物に本発明品あるいは長鎖脂肪酸 トリグリセリ ドを長期連続摂取させた後、 腎周囲脂肪組織および副睾丸 周囲脂肪組織およぴ腸間膜脂肪組織等の内臓脂肪と皮下脂肪とを合わせ た体脂肪量を、 体重あたりの割合で比較することで求められる。 本発明 品は、 内臓脂肪のみでも皮下脂肪のみでも、 また、 これらを組み合わせ た体脂肪でも、 L C T摂取に比べ有意な減少が見られる。 本発明品の摂 取により、 L C T摂取に比べておおよそ内臓脂肪重量では 8〜 1 5 %減 少し、 皮下脂肪重量では 1 0〜 2 0 %減少し、 これらを組み合わせた体 脂肪重量では 1 0〜 1 8 %程度の減少が認められ、 有意な減少が認めら れる。  Further, further effects are derived from the effects provided by the present invention. For example, the effect of reducing body fat can be measured by the amount of body fat in the total body weight of an animal. That is, after a test animal ingests the product of the present invention or the long-chain fatty acid triglyceride for a long time, the visceral fat and percutaneous fat such as perirenal adipose tissue, epididymal adipose tissue, and mesenteric adipose tissue are combined. It is determined by comparing the amount of body fat in the body per body weight. In the product of the present invention, a significant decrease is observed in the visceral fat only, the subcutaneous fat only, and the body fat in which these are combined as compared with the LCT intake. By taking the product of the present invention, the visceral fat weight is reduced by approximately 8 to 15%, the subcutaneous fat weight is reduced by 10 to 20%, and the combined body fat weight is reduced by 10 to A decrease of about 18% was observed, and a significant decrease was observed.
さらに、 前記動物による長期摂食試験結果で、 該試験動物の体内エネ ルギ一の消費に伴い、 U C Pが内蔵脂肪よりも皮下脂肪に高く発現する ことがわかっている。 このことと、 上記試験結果より、 本発明による体 脂肪の分解は、 皮下脂肪から優先的に行われることがわかる。 すなわち、 本発明は体に負荷のかからないスムースな体脂肪の分解を提供する。 本発明の体脂肪低減効果は、 従来知られている体脂肪低蓄積性とはそ の効果の内容において異なる。 体脂肪低蓄積性とは、 単に、 摂取した中 鎖脂肪酸トリグリセリ ド等が体に蓄積されることなくすぐに燃やされる ことでエネルギーになりやすいことを理由として脂肪が蓄積しにいとい う効果であり、 本発明において見出されている体脂肪低減効果とは、 摂 取により、 また、 継続性な摂取により、 低蓄積性に加えこれまで蓄積し ていた体脂肪が分解等することにより低減することを示す。  Furthermore, the results of the long-term feeding test using the animal show that UCP is expressed in subcutaneous fat higher than visceral fat with the consumption of energy in the test animal. This and the above test results show that the decomposition of body fat according to the present invention is preferentially performed from subcutaneous fat. That is, the present invention provides a smooth body fat decomposition that does not burden the body. The body fat reducing effect of the present invention differs from the conventionally known low body fat accumulating property in the content of the effect. Low body fat accumulation simply means that the ingested medium-chain fatty acid triglyceride, etc. is not easily accumulated in the body, but is easily burned without energy, so that it is easy to generate fat because it easily becomes energy. The body fat reduction effect found in the present invention means that the body fat is reduced by ingestion and continuous intake, in addition to low accumulation, by decomposing body fat accumulated so far. Is shown.
摂取した中鎖脂肪酸およぴ Zまたは中鎖脂肪酸を含むグリセリン脂肪 酸エステルなどが好適に燃焼すること、 具体的には、 本発明品を長期間 ラットに摂取させた後の肝臓および副睾丸周囲脂肪組織中の脱共役蛋白 質 m R N A発現レベルを検討すると、 当該品摂取群の方が対象である大 豆油摂取群に比べ、 肝臓で 1 . 4〜2倍、 副睾丸周囲脂肪組織で 2 . 2 〜3倍の脱共役蛋白質亢進機能を有することから、 摂取した中鎖脂肪酸 トリグリセリ ド等がすぐに燃やされエネルギーとなっていることがわか る。 かかる作用により、 体脂肪低蓄積性を有し、 本願発明により、 元々 蓄積されている体脂肪が分解等されることで低減することを併せると、 人体全身の効果としては優れた痩身効果を有することがわかる。 Ingested medium-chain fatty acids and glycerin fat containing Z or medium-chain fatty acids Considering that the acid ester and the like burn properly, specifically, the expression level of uncoupling protein mRNA in liver and epididymal adipose tissue after long-term ingestion of the product of the present invention to rats shows that Compared to the soybean oil intake group, the product intake group had 1.4 to 2 times the liver and 2.2 to 3 times the uncoupled protein enhancing function in the epididymal adipose tissue. It can be seen that medium-chain fatty acids, triglycerides, etc. are immediately burned and become energy. By this action, it has a low body fat accumulating property, and according to the present invention, when combined with the fact that body fat originally accumulated is decomposed and reduced, it has an excellent slimming effect as a whole body effect. You can see that.
具体的な効果としては、 本発明を長期連続摂取した場合、 L C T摂取 時に比べ摂餌量は殆ど変わらないにもかかわらず、 体重の減少が認めら れ、 体蛋白や水分含量にも差異が認められないことから、 明らかに体脂 肪重量が減少していることがわかる。 すなわち、 L C T摂取時に比べ体 重変化量は 7〜 1 5 %減少し、 体脂肪重量では 1 0〜 1 8 %程度の減少 が認められる。 このため、 優れた痩身効果が認められる。  As a specific effect, when the present invention is taken continuously for a long period of time, the body weight is reduced, and the body protein and water content are different even though the food intake is almost the same as when LCT was taken. This indicates that the body fat weight is clearly reduced. That is, the change in body weight is reduced by 7 to 15% and the weight of body fat is reduced by about 10 to 18% as compared with the intake of LCT. Therefore, an excellent slimming effect is recognized.
本発明は中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリ ン脂肪 酸エステルを有効成分とするホルモン感受性リパーゼ発現亢進、 β 3— ア ドレナリン受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用 の油脂組成物に関する。 また、 好ましくは、 中鎖脂肪酸トリグリセリン 脂肪酸エステルを有効成分とするホルモン感受性リパーゼ発現亢進、 β The present invention relates to an increase in the expression of hormone-sensitive lipase containing medium-chain fatty acid and glycerin fatty acid ester containing Z or medium-chain fatty acid as an active ingredient, an increase in expression of β3-adrenoceptor, promotion of body lipolysis, and release of body fat into blood. The present invention relates to a fat and oil composition for promotion. Preferably, the expression of hormone-sensitive lipase containing medium-chain fatty acid triglycerin fatty acid ester as an active ingredient is enhanced,
3—アドレナリ ン受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出促 進用の油脂組成物に関する。 The present invention relates to an oil / fat composition for enhancing expression of adrenergic receptors, promoting body fat degradation, and promoting body fat blood release.
中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸ェステ ルは油脂類から得ることができ、 また、 油脂類への溶解性が良好である ことから、 本発明のホルモン感受性リパーゼ発現亢進剤、 3—ァドレ ナリン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤の 一形態でもあり、 また、 下記に示すホルモン感受性リパーゼ発現亢進、 /3 3—アドレナリン受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出 促進用の飲食物の好適な一形態として、 中鎖脂肪酸および/または中鎖 脂肪酸を含むグリセリン脂肪酸エステルを含有する油脂組成物があげら れる。 また、 中鎖脂肪酸を含むグリセリン脂肪酸エステルを製造する場 合において、 その過程において該油脂組成物が製造されているため好適 である。 該油脂組成物の形態としては、 液状、 固体状、 半固体状のいず れでも良く、 特に制限されない。 The medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid can be obtained from fats and oils, and has good solubility in fats and oils. —Adrenaline receptor expression enhancer, body fat degradation promoter, body fat blood release promoter One of the preferred forms of food and drink for enhancing the expression of hormone-sensitive lipase, enhancing the expression of / 33-adrenergic receptor, promoting body fat degradation, and promoting the release of body fat into blood, as shown below, is a medium chain. An oil / fat composition containing a glycerin fatty acid ester containing a fatty acid and / or a medium-chain fatty acid is exemplified. In addition, when producing a glycerin fatty acid ester containing a medium-chain fatty acid, the oil / fat composition is preferably produced in the process. The form of the oil / fat composition may be any of a liquid, a solid, and a semi-solid, and is not particularly limited.
本発明の油脂組成物は、 上記ホルモン感受性リパーゼ発現亢進剤、 3 —アドレナリン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放 出促進剤の一形態でもあり、 また、 下記ホルモン感受性リパーゼ発現亢 進、 3 3—アドレナリン受容体発現亢進、 体脂肪分解促進、 体脂肪血中 放出促進用の飲食物の一形態であり、 また、 これらに配合する原料とし ての形態でもある。 また、 調理用としても使用でき、 このように使用し た結果、 飲食物に含有されるため、 間接的に飲食物へも影響を与える。 該油脂組成物における中鎖脂肪酸および zまたは中鎖脂肪酸を含むグ リセリン脂肪酸エステル、 中鎖脂肪酸トリグリセリン脂肪酸エステルの 含量は剤としての利用である場合は剤の含量であり、 飲食物としての使 用である場合は飲食の含量である。 ここで、 調理用油脂として使用する 場合においては、 飲食物への使用量によってその含量は異なるが、 例え ば 5〜 9 0質量％、 好ましくは 7〜 9 0質量0 /0、 より好ましくは 1 0〜 9 0質量％、 さらに好ましくは 1 5〜7 0質量％以上、 特に好ましくは 2 0〜2 5質量％以上を例示することができる。 調理用として使用する 場合、 油はね、 油煙等の調理適性の面から、 あまり高濃度にすることは 好ましくないため、 使用量等との調整が必要である。 その他、 用途によ つてその含量を調整することができる。 本発明の油脂組成物は、 上述の通り中鎖脂肪酸トリグリセリン脂肪酸 エステルを含有する油脂を原料として これをエステル交換処理するこ とで得ることができ、 また、 遺伝子組換の技術を用いて、 本発明の油脂 組成物を生産するように品種改良した植物、 例えば大豆、 菜種、 コーン、 ヤシ、 パーム、 オリープ、 亜麻仁、 ひまわり、 紅花、 つばき、 綿実、 ク ヘア等から抽出によって得ることも可能である。 The oil / fat composition of the present invention is also a form of the above-mentioned hormone-sensitive lipase expression enhancer, 3-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, and It is a form of food and drink for enhancing the expression of lipase, enhancing the expression of 33-adrenoceptor, promoting the decomposition of body fat, and promoting the release of fat into the body, and also as a raw material to be added to these. It can also be used for cooking, and as a result of its use in foods and drinks, indirectly affects foods and drinks. The content of medium-chain fatty acid and glycerin fatty acid ester containing z or medium-chain fatty acid and medium-chain fatty acid triglycerin fatty acid ester in the oil / fat composition is the content of the agent when it is used as an agent, and is used as a food or drink. If it is used, it is the content of food and drink. Here, in the case of using as a cooking oil, the content is different by the use of the food, For example 5-9 0% by weight, preferably 7-9 0 weight 0/0, more preferably 1 0 to 90% by mass, more preferably 15 to 70% by mass or more, and particularly preferably 20 to 25% by mass or more. When used for cooking, it is not preferable to make the concentration too high from the viewpoint of cooking suitability such as oil splashes and oil smoke, so it is necessary to adjust the amount used. In addition, the content can be adjusted according to the application. The oil / fat composition of the present invention can be obtained by subjecting an oil / fat containing a medium-chain fatty acid triglycerin fatty acid ester to a transesterification treatment as described above, and using a gene recombination technique as described above. It can also be obtained by extraction from plants bred to produce the oil and fat composition of the present invention, for example, soybeans, rapeseed, corn, palm, palm, olive, linseed, sunflower, safflower, tsubaki, cottonseed, khair, etc. It is.
上記のようにして得られる本発明の油脂組成物は、 そのままで、 もし くは調理用油脂組成物に通常用いられる添加剤を配合して、 調理用油脂 組成物として使用することができる。  The fat and oil composition of the present invention obtained as described above can be used as it is or as a cooking fat and oil composition by blending additives usually used in cooking fat and oil compositions.
かかる添加剤としては、 保存安定性向上、 酸化安定性向上、 熱安定性 向上、 低温化での結晶抑制等を目的としたポリグリセリン脂肪酸エステ ル、 ショ糖脂肪酸エステル、 ソルビタン脂肪酸エステル等が挙げられる。 また、 当然に、 上記ホルモン感受性リパーゼ発現亢進剤、 3 3—ァドレ ナリン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤に おいて添加することができる添加剤等も配合することができる。  Examples of such additives include polyglycerin fatty acid esters, sucrose fatty acid esters, and sorbitan fatty acid esters for the purpose of improving storage stability, improving oxidative stability, improving thermal stability, suppressing crystallization at low temperatures, and the like. . Naturally, additives that can be added in the above-mentioned hormone-sensitive lipase expression enhancer, 33-adrenergic receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, etc. are also blended. can do.
本発明の油脂組成物は、 菜種油、 コーン油、 紅花油、 大豆油といった 一般に市販されている通常の食用油と同等あるいはそれ以上の風味を持 ち、 炒め物、 揚げ物、 マリネなどの調理に使用できることはもちろんの こと、 油脂を含有する食品であるドレッシング、 マヨネーズ、 マーガリ ン、 菓子類、 ケーキ、 飲料等にも使用可能である。 調理品の種類によつ て風味の特性は異なるが、 素材の味を生かしたさっぱりとした料理を作 ることが可能である。 また、 フライ調理時における油のハネ度合いは、 通常の食用油と同等あるいはそれ以下である。  The oil / fat composition of the present invention has a flavor equal to or higher than ordinary edible oils such as rapeseed oil, corn oil, safflower oil, and soybean oil, and is used for cooking stir-fry, fried food, marinade, etc. Not only can it be used, but it can also be used for foods containing fats and oils such as dressings, mayonnaise, margarine, confectioneries, cakes and beverages. The flavor characteristics differ depending on the type of food, but it is possible to make a refreshing dish that takes advantage of the taste of the ingredients. In addition, the degree of splash of oil during frying is equal to or lower than that of ordinary cooking oil.
本発明は、 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂 肪酸エステルを含有するホルモン感受性リパーゼ発現亢進、 3—アド レナリン受容体発現亢進剤、 体脂肪分解促進、 体脂肪血中放出促進用飲 食物等に関し、 好ましくは中鎖脂肪酸トリグリセリ ン脂肪酸エステルを 含有するホルモン感受性リパーゼ発現亢進、 /3 3—アドレナリン受容体 発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用飲食物等に関する。 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エステ ル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステルを含有する飲 食物は、 飲食によって好適に経口摂取され、 ホルモン感受性リパーゼ発 現亢進、 3 3—アドレナリン受容体発現亢進、 体脂肪分解促進、 体脂肪 血中放出促進作用を奏するため好ましい形態である。 The present invention relates to a hormone-sensitive lipase-containing expression-enhancing agent containing medium-chain fatty acids and glycerol fatty acid esters containing Z or medium-chain fatty acids, a 3-adrenergic receptor expression-enhancing agent, body fat decomposition promotion, body fat blood release promotion Drinking The present invention relates to foods and the like, preferably foods for enhancing the expression of hormone-sensitive lipase containing a medium-chain fatty acid triglycerin fatty acid ester, enhancing the expression of / 33-adrenoceptor, promoting body fat degradation, and promoting body fat blood release. Foods and drinks containing medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain fatty acid triglycerin fatty acid esters, are preferably orally ingested by eating and drinking to enhance the expression of hormone-sensitive lipase. It is a preferred form because it has an effect of enhancing adrenergic receptor expression, promoting body fat decomposition, and promoting body fat release into blood.
中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸ェステ ル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステルにホルモン感 受性リパーゼ棻現亢進、 3 3—アドレナリン受容体発現亢進、 体脂肪分 解促進、 体脂肪血中放出促進効果を発現させる好ましい形態として経口 摂取があげられ、 特に日常継続的に摂取するためには飲食物の形態が好 ましい。 摂取量は特に制限されないが、 前述の各種剤における摂取量を 参考にすることができる。 また、 過剰な摂取は当然に本発明における効 果を得ることができない。 該飲食物として、 含量は摂取の回数、 量等に よって調整することができ特に制限されないが、 中鎖脂肪酸およびノま たは中鎖脂肪酸を含むグリセリン脂肪酸エステルの場合、 例えば、 0 . 1〜 5 0質量％、 好ましくは 0 . 2〜5 0質量％、 より好ましくは 0 . 5〜 4 0質量％、 さらに好ましくは 1〜 2 0質量％、 特に好ましくは 2 〜1 0質量％、 また、 中鎖脂肪酸トリグリセリ ドの場合、 例えば 0 . 0 5〜 3 0質量0 /0、 好ましくは 0 . 1〜3 0質量％、 より好ましくは 0 . 2〜2 0質量％、 さらに好ましくは 0 . 5〜1 0質量％、 特に好ましく は 1〜 5質量％を例示することができる。 Medium chain fatty acids and / or glycerin fatty acid esters containing medium chain fatty acids, preferably medium chain fatty acid triglycerin fatty acid esters, increase hormone-sensitive lipase expression, promote 33-adrenergic receptor expression, promote body fat decomposition, Oral ingestion is a preferred form for exhibiting the effect of promoting the release of body fat into blood, and especially for continuous intake, food and drink are preferred. The amount of intake is not particularly limited, but the amount of intake for the various agents described above can be referred to. In addition, excessive intake naturally cannot obtain the effects of the present invention. The content of the food or drink can be adjusted according to the number of times of ingestion, the amount, etc., and is not particularly limited. In the case of a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid, for example, 0.1 to 0.1 50% by mass, preferably 0.2 to 50% by mass, more preferably 0.5 to 40% by mass, further preferably 1 to 20% by mass, particularly preferably 2 to 10% by mass, when medium chain fatty acid triglyceride, for example, 0.0 5-3 0 weight 0/0, preferably from 0.1 to 3 0 wt%, more preferably from 0.2 to 2 0% by weight, more preferably 0.5 To 10% by mass, particularly preferably 1 to 5% by mass.
ここで、 上述したが、 中鎖脂肪酸の含量は機能を得られる範囲である ことが必要であり、 好ましくは前記範囲であって、 かつ、 人体への悪影 響の可能性が低いほど好ましく、 さらには商業上または工業上、 できる だけ低含量であることが好ましい。 Here, as described above, the content of the medium-chain fatty acid needs to be in a range in which the function can be obtained, and is preferably in the above range, and has a bad effect on the human body. The lower the possibility of sound is, the more preferable it is, and furthermore, it is preferable that the content is as low as possible commercially or industrially.
ここで、 前記ホルモン感受性リパーゼ発現亢進剤、 3—アドレナリ ン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤や、 ホ ルモン感受性リパーゼ発現亢進、 3—アドレナリン受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用飲食物において、 中鎖脂肪酸、 または、 中鎖脂肪酸と中鎖脂肪酸残基の総量によつても規定することが き、 その好適な含量としては、 前記中鎖脂肪酸トリグリセリ ドの含量か ら換算することができる。  Here, the above-mentioned hormone-sensitive lipase expression enhancer, 3-adrenergic receptor expression enhancer, body lipolysis promoter, body fat blood release promoter, hormone-sensitive lipase expression enhancer, 3-adrenergic receptor expression enhancer In foods and drinks for promoting body fat degradation and promoting release of body fat into the blood, the content can be defined by medium-chain fatty acids or the total amount of medium-chain fatty acids and medium-chain fatty acid residues. It can be calculated from the content of the medium-chain fatty acid triglyceride.
ここで、 本発明のホルモン感受性リパーゼ発現亢進、 /3 3—アドレナ リン受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用飲食物の 形態としては、 特に制限はないが、 例えば、 飲食物が、 飲料、 栄養ドリ ンク、 菓子、 加工食品、 油脂類、 乳製品、 レトルト食品、 レンジ食品、 冷凍食品、 調味料、 健康補助食品等の形態が挙げられ、 形状 ·性状も特 に制限されず、 固体状、 半固体状、 ゲル状、 液体状、 粉末状等いずれで もよく、 また、 錠剤、 カプセル剤、 液剤、 顆粒剤等いずれでも良い。 本発明のホルモン感受性リパーゼ発現亢進、 13 3—アドレナリン受容 体発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用飲食物について、 下記に具体例を列記するが、 本発明はこれらに制限されるものではない。 本発明のホルモン感受性リパーゼ発現亢進、 3—アドレナリン受容体 発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用飲食物としては、 そ の形態等について特に制限はないが、 例えば、 おかき、 煎餅、 おこし、 饅頭、 飴等の和菓子、 クッキー、 ビスケット、 クラッカー、 パイ、 カス テラ、 ドーナッツ、 プリン、 スポンジケーキ、 Vッフル、 パタータリー ム、 カスタードクリーム、 シュークリーム、 チョコレート、 チョコレー ト菓子、 キャラメル、 キャンデー、 チューインガム、 ゼリー、 ホットケ ーキ、 パン、 菓子パン等の各種洋菓子、 ポテトチップ等のスナック菓子、 アイスクリーム、 アイスキャンデー、 シャーベット等の氷菓、 乳酸飲料、 乳酸菌飲料、 濃厚乳性飲料、 果汁飲料、 果肉飲料、 機能性飲料、 炭酸飲 料等の清涼飲料水、 緑茶、 紅茶、 コーヒー、 ココア等の嗜好品およびこ れらの飲料、 発酵乳、 加工乳、 チーズ等の乳製品、 豆乳、 豆腐等の大豆 加工食品、 ジャム、 果実のシロップ漬、 フラワ^ ^一スト、 ピーナツぺ ースト、 フノレーッペースト等のペースト類、 漬物類、 うどんの'麵、 パス タ等の穀物製品類、 ハム、 ソーセージ、 ベーコン、 ドライソーセージ、 ビーフジャーキー、 ハンバーグ等の畜肉製品類、 魚肉ハム、 魚肉ソーセ ージ、 かまぼこ、 ちくわ、 はんぺん等の魚貝類製品、 魚、 貝等の干物、 鰹、 鯖、 鰺等の各種節、 ゥニ、 イカ等の塩辛、 スルメ、 魚等のみりん干、 鮭等の燻製品、 のり、 小魚、 貝、 山菜、 椎茸、 昆布等の佃煮、 カレー、 シチュー等のレトルト食品、 みそ、 醤油、 ソース、 ケチャップ、 プィョ ン、 焼肉のタレ、 カレールー、 シチューの素、 スープの素、 だしの素等 の各種調味料、 米飯類、 油脂やマーガリン、 ショートニング、 マヨネ一 ズ、 ドレッシング等の油脂加工品や、 '油脂を含有する各種レンジおょぴ 冷凍食品等が挙げられる。 特に、 継続的な摂取という面からは、 米飯や 各種調味料や、 油脂やマーガリン、 ショートニング、 マヨネーズ、 ドレ ッシング等の油脂加工品が好ましいといえる。 また、 形状 ·性状も特に 制限されず、 固体状、 半固体状、 ゲル状、 液体状、 粉末状等いずれでも よく、 また、 健康補助飲食料等として使用される場合等の錠剤、 ソフト 力プセルゃハードカプセルに充填 ·加ェした力プセル剤、 液剤、 顆粒剤 等いずれでも良い。 Here, the form of the food or drink for enhancing the expression of the hormone-sensitive lipase of the present invention, enhancing the expression of / 33-adrenoceptor, promoting body fat degradation, and promoting body fat blood release is not particularly limited. Food and beverages include beverages, nutritional drinks, confectionery, processed foods, fats and oils, dairy products, retort foods, range foods, frozen foods, seasonings, health supplements, etc., and the shape and properties are particularly limited. Instead, they may be solid, semi-solid, gel, liquid, powder, etc., and may be tablets, capsules, liquids, granules, etc. Specific examples of the foods and drinks for enhancing the expression of hormone-sensitive lipase, enhancing the expression of 133-adrenoceptor, promoting body fat degradation, and promoting body fat blood release according to the present invention are listed below, but the present invention is not limited thereto. Not something. The food and drink for enhancing the expression of hormone-sensitive lipase, enhancing the expression of 3-adrenoceptor, promoting body fat degradation, and promoting the release of body fat into blood according to the present invention are not particularly limited with regard to the form and the like. , Okoshi, buns, candy and other Japanese sweets, cookies, biscuits, crackers, pies, castellas, donuts, puddings, sponge cakes, vuffels, patters, custard cream, cream puffs, chocolate, chocolate, sweets, caramel, candy, Chewing gum, jelly, hot cake Sake, bread, confectionery bread, etc., snacks such as potato chips, ice cream, ice candy, sherbet, etc., lactic acid drinks, lactic acid bacteria drinks, thick milk drinks, fruit juice drinks, pulp drinks, functional drinks, carbonated drinks Soft drinks such as beverages, luxury items such as green tea, black tea, coffee, and cocoa, as well as these beverages, dairy products such as fermented milk, processed milk and cheese, processed soybeans such as soy milk and tofu, jams and fruits Pastes such as pickled syrup, flour ^^, peanut paste, fenolae paste, pickles, udon noodles, pasta and other cereal products, ham, sausage, bacon, dry sausage, beef jerky Hamburger and other meat products, fish ham, fish sausage, fish and shellfish products such as kamaboko, chikuwa, and ham Dried fish such as dried bonito, mackerel, aji, etc., salted fish such as sea urchin, squid, dried squid, fish and other dried fish, salmon and other smoked products, glue, small fish, shellfish, wild vegetables, shiitake mushroom, kelp, etc. Retort foods such as tsukudani, curry, stew, etc., miso, soy sauce, sauce, ketchup, pyon, grilled meat sauce, curry roux, stew ingredients, soup ingredients, soup ingredients, various seasonings such as rice, oil and fat, margarine Fats and oils processed products such as oils, shortenings, mayonnaises and dressings, and various types of frozen foods containing oils and fats. In particular, from the viewpoint of continuous consumption, cooked rice and various seasonings, and oils and fats and processed products such as margarine, shortening, mayonnaise, and dressing are preferable. Also, the shape and properties are not particularly limited, and may be any of solid, semi-solid, gel, liquid, powder, etc., tablets and soft capsules for use as a health supplement food and drink, etc.充填 Filled into hard capsules · Any added forceps, liquids, granules, etc. may be used.
特に好ましい形態としては油脂組成物の形態の飲食物であり、 また、 該油脂組成物を用いて調理された飲食物であり、 配合された飲食物であ る。 上述の通り、 中鎖脂肪酸トリグリセリ ド等が油脂類であることや、 中鎖脂肪酸トリグリセリ ドの製造の過程において得ることができるため- 使用性、 安定性、 製造性等に優れている。 Particularly preferred forms are foods and drinks in the form of fats and oils compositions, and foods and drinks cooked using the fats and oils composition, and foods and drinks mixed therewith. As described above, medium-chain fatty acid triglycerides and the like are fats and oils, Since it can be obtained in the process of producing medium-chain triglycerides, it is excellent in usability, stability, manufacturability and the like.
また、 上述の通り、 前記脱共役蛋白質発現亢進剤や油脂組成物を配合 することもできる。 また、 該油脂組成物を用いて調理することで得るこ ともできる。 該ホルモン感受性リパーゼ発現亢進、 3—アドレナリン 受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出促進用飲食物は、 こ れらの効果を介した糖尿病 ·動脈硬化 ·高脂血症 ·高血圧等の生活習慣 病に対する予防および Zまたは改善効果も期待されるため、 好ましい。 本発明おいて、 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリ ン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸エステ ルをホルモン感受性リパーゼ発現亢進剤として使用することができる。 また、 本発明おいて、 中鎖脂肪酸および/または中鎖脂肪酸を含むグ リセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸 エステルを β 3—アドレナリン受容体発現亢進剤として使用することが できる。  In addition, as described above, the uncoupling protein expression enhancer and the oil / fat composition can be blended. Moreover, it can also be obtained by cooking using the fat or oil composition. Foods and drinks for enhancing the expression of hormone-sensitive lipase, enhancing the expression of 3-adrenoceptor, promoting body fat degradation, and promoting release of body fat into the blood are used for diabetes, arteriosclerosis, hyperlipidemia, and hypertension. It is preferable because it is expected to have a preventive and / or Z- or ameliorating effect on lifestyle-related diseases such as. In the present invention, medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain triglycerin fatty acid esters, can be used as a hormone-sensitive lipase expression enhancer. In the present invention, a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester, can be used as a β3-adrenergic receptor expression enhancer.
また、 本発明おいて、 中鎖脂肪酸おょぴノまたは中鎖脂肪酸を含むグ リセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸 エステルを体脂肪分解促進剤として使用することができる。  In the present invention, a medium-chain fatty acid or a glycerin fatty acid ester containing a medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester, can be used as a body fat degradation promoter.
また、 本発明おいて、 中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグ リセリン脂肪酸エステル、 好ましくは中鎖脂肪酸トリグリセリン脂肪酸 エステルを体脂肪血中放出促進剤として使用することができる。  In the present invention, a medium-chain fatty acid and a glycerin fatty acid ester containing a medium- or medium-chain fatty acid, preferably a medium-chain fatty acid triglycerin fatty acid ester, can be used as a body fat blood release accelerator.
本発明は中鎖脂肪酸および Ζまたは中鎖脂肪酸を含むグリセリン脂肪 酸エステルを含有することを特徴とするホルモン感受性リパーゼ発現亢 進剤、 /3 3—アドレナリン受容体発現宂進剤、 体脂肪分解促進剤、 体脂 肪血中放出促進剤の原料に関し、 特に中鎖脂肪酸トリグリセリ ドを含有 することを特徴とするホルモン感受性リパーゼ発現亢進剤、 3 3—アド レナリン受容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤 の原料に関する。 The present invention provides a hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and a glycerol fatty acid ester containing a medium-chain fatty acid, a / 33-adrenergic receptor expression-increasing agent, and a body fat degradation promoting agent. , A hormone-sensitive lipase expression enhancer characterized by containing medium-chain fatty acid triglyceride, 33-ad The present invention relates to raw materials for a renaline receptor expression enhancer, a body fat degradation promoter, and a body fat blood release promoter.
本発明のホルモン感受性リパーゼ発現亢進剤、 β 3—アドレナリン受 容体発現亢進剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤等は中鎖脂 肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エステルを含有 することを特徴とし、 特に中鎖脂肪酸トリグリセリ ドを含有することを 特徴とし、 これによりホルモン感受性リパーゼ発現亢進、 3—ァドレ ナリン受容体発現亢進、 体脂肪分解促進、 体脂肪血中放出促進作用を有 する。 よって、 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン 脂肪酸エステルを、 特に中鎖脂肪酸トリグリセリ ドを含有するものはホ ルモン感受性リパーゼ発現亢進剤、 β 3—アドレナリン受容体発現亢進 剤、 体脂肪分解促進剤、 体脂肪血中放出促進剤の原料として好適であり、 特に高濃度に含有するものは原料として好適である。 含量は特に制限さ れないが、 例えば、 5〜9 9 . 9質量％、 好ましくは 1 0〜9 9 . 9質 量％、 より好ましくは 2 0〜9 9 . 9質量％、 さらに好ましくは 5 0〜 9 9 . 9質量。 /0、 特に好ましくは 7 0〜 9 9 . 9質量％、 最も好ましく は 9 0〜9 9 . 9質量％を例示することができる。 The hormone-sensitized lipase expression enhancer, β3-adrenoceptor expression enhancer, body fat degradation accelerator, body fat blood release enhancer, etc. of the present invention are medium-chain fatty acids and / or glycerin fatty acids containing medium-chain fatty acids. It is characterized by containing an ester, especially a medium-chain fatty acid triglyceride, which enhances the expression of hormone-sensitive lipase, increases the expression of 3-adrenergic receptor, promotes body fat degradation, and releases body fat into the blood. It has a promoting effect. Therefore, medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, particularly those containing medium-chain fatty acid triglycerides, are those that enhance the expression of hormone-sensitive lipase, those that increase the expression of β3-adrenoceptor, and those that degrade body fat. It is suitable as a raw material for an accelerator and a body fat blood release accelerator, and those containing a high concentration are particularly suitable as raw materials. The content is not particularly limited, but is, for example, 5 to 99.9% by mass, preferably 10 to 99.9% by mass, more preferably 20 to 99.9% by mass, and further preferably 5 to 99.9% by mass. 0-99.9 mass. / 0 , particularly preferably 70 to 99.9% by mass, and most preferably 90 to 99.9% by mass.
[実施例 1 ホルモン感受性リパーゼ、 /3 3—アドレナリン受容体 m R N A発現量の測定]  [Example 1 Measurement of hormone-sensitive lipase, / 33-adrenergic receptor mRNA expression level]
6週齢の W i s t a r雄性ラットを 1週間予備飼育した後、 大豆油添 加群、 中鎖脂肪酸トリグリセリ ドを 1 0 0 %含有する油脂組成物添加群 の計 2群 （各群 2 0匹） に分け、 A I N 9 3標準食のシユークロースを 全てコーンスターチに置換した実験食と水を自由に与えた。 経時的に体 重、 摂餌量を測定し、 6週間飼育後、 1 8時間絶食後、 各群のラットを 屠殺し、 副睾丸周囲脂肪をホルモン感受性リパーゼ、 ]3 3—アドレナリ ン受容体 m R N A発現量の測定に供した。 ホルモン感受性リパーゼ等の mRNA発現量測定は以下のように実施 した。 すなわち、 摘出した副睾丸周囲脂肪中の全 RNAを I s o g e n (二ツボンジーン製) にてホモジナイズ後、 クロ口ホルムおよびィソプ 口ピルアルコールにて抽出し、 全； RNAを得た。 分光光度計 （G e n e Qu a n t ： フアルマシア製） にて濃度を測定後、 M— MLV (プロメ ガ製） の逆転写酵素を添加し、 付属の反応緩衝液、 0. 5mM dNT P (インビトロジェン製） および 25 g/m 1オリゴ （dT) 1 5プ ライマー （プロメガ製） 存在下で 3 7°C、 1時間反応させ、 対応する c DNAを調製した。 調製した c DNAを铸型として、 ラッ トのホルモン 感受性リパーゼに対するプライマーを設定し、 固形飼料 （ラボ MR—ス トツク ： 日本農産製） を食べさせたラット副睾丸周囲脂肪由来 c DNA 铸型を基準品として、 各群の同臓器由来 c DN A铸型中のホルモン感受 性リパーゼ瓜 発現量を定量 P C R装置 （L i g h t C y c l e r ： ロシュ ·ダイァグノスティック製) にて測定した。 発現量 （％) は、 数式 1に示したように、 βーァクチンの mRNA発現量に対する相対値 で比較した。 また、 同様な方法により 3—アドレナリン受容体 mRN A発現量を比較した。 Six-week-old male male Wistar rats were preliminarily reared for one week, and then a group added with soybean oil and a group added with an oil / fat composition containing 100% of medium-chain fatty acid triglyceride (20 rats in each group) The test food and water, in which all sucrose of the AIN 93 standard diet was replaced with corn starch, were given freely. The body weight and food consumption were measured over time. After breeding for 6 weeks and after an 18-hour fast, the rats in each group were sacrificed and the epididymal fat was reduced to hormone-sensitive lipase,] 33-adrenergic receptor m It was used for measurement of RNA expression level. The measurement of mRNA expression levels of hormone-sensitive lipase and the like was performed as follows. That is, the total RNA in the extracted epididymal fat was homogenized with Isogen (manufactured by Nitsubon Gene), and then extracted with black mouth form and isopu pill alcohol to obtain total RNA. After measuring the concentration with a spectrophotometer (GeneQuant: manufactured by Pharmacia), reverse transcriptase of M—MLV (manufactured by Promega) was added, and the attached reaction buffer, 0.5 mM dNTP (manufactured by Invitrogen) And 25 g / m1 oligo (dT) 15 primer (Promega) at 37 ° C for 1 hour to prepare the corresponding cDNA. Using the prepared cDNA as type II, a primer for rat hormone-sensitive lipase was set, and cDNA type II from rat epididymal fat fed solid feed (Lab MR—Stock: manufactured by Nippon Agricultural Products) was used as a reference. As a product, the expression level of hormone-sensitive lipase melon in cDNA type I derived from the same organ in each group was measured using a quantitative PCR device (Light Cycler: manufactured by Roche Diagnostics). The expression level (%) was compared with the β-actin mRNA expression level, as shown in Equation 1. The expression of 3-adrenergic receptor mRNA was compared by the same method.
<数式 1 > <Formula 1>
ホルモン感受性リパーゼ等の; mRNA発現量 （％) = (ラットのホ ルモン感受性リパーゼ等の mRN A発現量） Z (ラットの j3—ァクチン mRN A発現量） X 1 00 上記方法によってホルモン感受性リパーゼ、 ）3 3—アドレナリン受容 体 mRNA発現亢進効果を評価した。 その結果を mRNA発現量 （％) として表 1に示す。 く表 1 > MRNA expression level (%) of hormone-sensitive lipase, etc. = (mRNA expression level of rat hormone-sensitive lipase, etc.) Z (rat 3-actin mRNA expression level of rat) X100 Hormone-sensitive lipase by the above method) The effect of enhancing the expression of 33-adrenoceptor mRNA was evaluated. The results are shown in Table 1 as mRNA expression levels (%). Table 1>
Figure imgf000043_0001
Figure imgf000043_0001
Mann-Whitney U-test (両側検定） による検定  Mann-Whitney U-test (two-sided test)
* ： p<0.05 上記方法によってホルモン感受性リパーゼ等の mRN A発現量を大豆 油添加群と比較した結果、 表 1に示されるように、 ホルモン感受性リパ 一ゼで約 1. 4倍、 /3 3—アドレナリン受容体で約 1. 8倍の mRNA 発現亢進効果が認められた。 このことより、 中鎖脂肪酸トリグリセリ ド を有効成分とする油脂組成物がホルモン感受性リパーゼ発現亢進効果や 体脂肪分解促進作用を有していることが明らかとなった。  *: P <0.05 As a result of comparing the mRNA expression levels of hormone-sensitive lipase and so on with the soybean oil-added group by the above method, as shown in Table 1, it was found that hormone-sensitive lipase was approximately 1.4-fold, / 33 —Adrenergic receptor showed about 1.8-fold increase in mRNA expression. From these results, it was revealed that the oil and fat composition containing a medium-chain fatty acid triglyceride as an active ingredient has an effect of enhancing the expression of hormone-sensitive lipase and an effect of promoting body fat degradation.
つまり、 脂肪組織中に溜め込まれたトリグリセリン脂肪酸エステルが グリセロールと遊離脂肪酸とに好適に分解されていると考えられる。  That is, it is considered that the triglycerin fatty acid ester stored in the adipose tissue is suitably decomposed into glycerol and free fatty acids.
[実施例 2 血清中の遊離脂肪酸濃度の測定]  [Example 2 Measurement of Free Fatty Acid Concentration in Serum]
6週齢の W i s t a r雄性ラットを 1週間予備飼育した後、 大豆油添 加群、 中鎖脂肪酸トリグリセリ ドを 1 00%含有する油脂組成物添加群 の計 2群 （各群 20匹） に分け、 A I N 9 3標準食のシユークロースを 全てコーンスターチに置換した実験食と水を自由に与えた。 経時的に体 重変化、 摂餌量を測定し、 6週間飼育後、 1 8時間絶食させた各群のラ ットを屠殺し血液を採取、 血清として分取した後、 得られた血清中の遊 離脂肪酸濃度を測定キット （NEFA E— t e s t Wa k o) にて 測定した。  Six-week-old male male Wistar rats were preliminarily reared for one week, and then divided into two groups: a group added with soybean oil and a group added with a fat and oil composition containing 100% of medium-chain fatty acid triglycerides (20 rats in each group). The experimental food and water in which all of the AIN 93 standard diet sucrose was replaced with corn starch were given ad libitum. Changes in body weight and food consumption were measured over time, and after breeding for 6 weeks, rats in each group that had been fasted for 18 hours were sacrificed, blood was collected, collected as serum, and collected in serum. The concentration of free fatty acids was measured using a measurement kit (NEFA E-test Wako).
上記方法によって血中遊離脂肪酸濃度を評価した。 その結果を表 2に 示す。 <表 2〉
Figure imgf000044_0001
Blood free fatty acid concentration was evaluated by the above method. The results are shown in Table 2. <Table 2>
Figure imgf000044_0001
平均値士標準誤差 Standard error
Mann— Whitney U test (両側検定） による検定 Mann—Whitney U test (two-sided test)
* ： pく 0. 05 上記方法によって試験油脂長期摂取後の血中遊離脂肪酸濃度を測定し た。 その結果、 大豆油投与群に比べ油脂組成物投与群で明らかな遊離脂 肪酸濃度の上昇が認められた。  *: P <0.05 The blood free fatty acid concentration after long-term ingestion of the test fat was measured by the above method. As a result, a clear increase in the free fatty acid concentration was observed in the oil / fat composition administration group as compared with the soybean oil administration group.
前記ホルモン感受性リパーゼ m R N A発現量の評価結果において、 本 発明の油脂組成物は大豆油に比べて脂肪組織に蓄積されていた体脂肪を 分解し、 血中に放出していること、 特に長期的な摂取により優れた効果 が得られることがわかる。  In the evaluation results of the hormone-sensitive lipase mRNA expression amount, the fat composition of the present invention decomposed body fat accumulated in adipose tissue compared to soybean oil and released it into the blood, It can be seen that an excellent effect can be obtained by ingestion.
[実施例 3 ]  [Example 3]
[体内各部位の脂肪量比較]  [Comparison of fat content in various parts of the body]
6週齢の W i s t a r雄性ラットを 1週間予備飼育した後、 大豆油添 加群、 中鎖脂肪酸トリグリセリ ドを 1 0 0 %含有する油脂組成物添加群 の計 2群 （各群 2 0匹） に分け、 A I N 9 3標準食のシユークロースを 全てコーンスターチに置換した実験食と水を自由に与えた。 経時的に-体 重変化、 摂餌量を測定し、 6週間飼育後、 1 8時間絶食させた各群のラ ットを屠殺し、 肝臓および内臓脂肪 （副睾丸周囲脂肪、 腸間膜脂肪、 腎 周囲脂肪） を摘出、 重量を測定した。 さらに屠体の内臓を摘出後、 凍結 乾燥にかけ、 ソックスレー法により求めた総脂肪量と屠体重とから皮下 脂肪量を算出し、内臓脂肪量とあわせて体脂肪量を求め、体脂肪重量を算 出した。 P T/JP2003/007736 Six-week-old male male Wistar rats were preliminarily reared for one week, and then a group added with soybean oil and a group added with an oil / fat composition containing 100% of medium-chain fatty acid triglyceride (20 rats in each group) The test food and water, in which all sucrose of the AIN 93 standard diet was replaced with corn starch, were given freely. Over time-body weight changes, food consumption were measured, rats were kept for 6 weeks, fasted for 18 hours, and rats in each group were sacrificed, and liver and visceral fat (peri-testicular fat, mesenteric fat) , And perinephric fat) were excised and weighed. Furthermore, the internal organs of the carcass were removed, freeze-dried, and the subcutaneous fat mass was calculated from the total fat mass and carcass weight determined by the Soxhlet method. Issued. PT / JP2003 / 007736
43 上記方法によって体脂肪蓄積抑制効果を評価した。 その結果を生育評 価とあわせて表 3に示す。 く表 3 >  43 The body fat accumulation inhibitory effect was evaluated by the above method. Table 3 shows the results together with the growth evaluation. Table 3>
Figure imgf000045_0001
Figure imgf000045_0001
Mann-Whitney U-test (両側検定） による検定  Mann-Whitney U-test (two-sided test)
* ： p < 0. 05 ネ氺 ： p < 0. 01 その結果、 表 3に示されるように、 体重増加量は群間に有意な差はな かったが、 油脂組成物添加群において大豆油添加群よりも体脂肪量は減 少した。 さらに、 内臓脂肪量および皮下脂肪量共に大豆油群よりも減少 した。 なお、 飼育期間中には両群とも軟便、 下痢などの症状は見られず、 便の量にも差は見られなかった。  *: P <0.05 Neighborhood: p <0.01 As a result, as shown in Table 3, there was no significant difference in body weight gain between the groups, but the soybean oil in the fat and oil composition-added group Body fat content was lower than in the supplemented group. In addition, both visceral fat and subcutaneous fat decreased compared to the soybean oil group. During the breeding period, there were no symptoms such as loose stool or diarrhea in both groups, and there was no difference in stool volume.
これにより、 中鎖脂肪酸トリグリセリ ドを有効成分とする油脂組成物 力 s、 体脂肪低蓄積効果を有することが明らかとなった。 また、 油脂組成 物添加群は、 大豆油添加群のラットと比較して皮下脂肪重量の減少が特 に大きい。 すなわち、 内臓の脂肪量の減少が比較的少ないので、 内臓の 機能を維持したまま体脂肪を減少させていることがわかる。 また、 実施 例 1との比較よりホルモン感受性リパーゼ、 J3 3—アドレナリン受容体 の発現量の増加が、 脂肪の燃焼に大きく影響していることがわかる。 As a result, it was clarified that the fat and oil composition containing a medium-chain fatty acid triglyceride as an active ingredient has a power s and a low body fat accumulation effect. In addition, the fat composition-added group showed a particularly large decrease in subcutaneous fat weight compared to the rats in the soybean oil-added group. In other words, there is relatively little loss of visceral fat, It can be seen that the body fat is reduced while maintaining the function. In addition, comparison with Example 1 shows that an increase in the expression level of hormone-sensitive lipase and J33-adrenoceptor greatly affects fat burning.
[実施例 4 体內脂肪酸燃焼に伴う U C P— 2、 ホルモン感受性リパ ーゼ、 3—アドレナリ ン受容体の発現量の変化]  [Example 4 Changes in Expression of UCP-2, Hormone-Sensitive Lipase, and 3-Adrenergic Receptor Following Body Fatty Acid Burning]
本実施例は中鎖脂肪酸トリグリセリ ドを投与した場合の体内各部位の 脂肪の燃焼態様を、 投与しない場合のそれと調査検討したものである。 調査は、 各部位の U C Pの発現量の経時変化を比較することにより行つ た。 また、 ホルモン感受性リパーゼ、 3 3—アドレナリン受容体の発現 量の経時変化についても合わせ行った。  In this example, the manner of burning fat in various parts of the body when the medium-chain fatty acid triglyceride was administered was investigated and examined in comparison with the case where the medium was not administered. The investigation was performed by comparing the time-dependent changes in the expression level of UCP at each site. In addition, changes over time in the expression levels of hormone-sensitive lipase and 33-adrenoceptor were also performed.
[調査方法]  [Survey method]
6週齢の W i s t a r雄性ラットを 1週間予備飼育した後、 大豆油添 加群、 中鎖脂肪酸トリグリセリ ドを 1 0 0 %含有する油脂組成物添加群 の計 2群 （各 2 0匹） に分け、 A I N 9 3標準食のシユークロースを全 てコーンスターチに置換した実験食と水を自由に与えた。 経時的に体重、 摂餌量を測定し、 6週間飼育した。 その後、 試験に供したラットを 6時 間絶食させた。 その後、 各群のラットを屠殺し、 副睾丸周囲脂肪おょぴ 皮下脂肪の U C P— 2の発現量等の測定に供した。 結果を表 4に示す。  Six-week-old male male Wistar rats were preliminarily reared for one week, and then divided into two groups: a soybean oil-added group and an oil-and-fat composition containing 100% medium-chain fatty acid triglyceride (total of 20 rats). The AIN93 standard diet sucrose was replaced with corn starch, and an experimental diet and water were freely provided. Body weight and food consumption were measured over time, and the animals were reared for 6 weeks. Thereafter, the test rats were fasted for 6 hours. Thereafter, the rats in each group were sacrificed and subjected to measurement of the expression level of UCP-2 in the epididymal fat and subcutaneous fat. Table 4 shows the results.
<表 4 > <Table 4>
Figure imgf000046_0001
上記表は、 大豆油添加群のラットと、 中鎖脂肪酸トリグリセリ ド添加 群のラットの U C P— 2の発現量を比較したもので以下の数式 2により 得られたものである。 <数式 2 >
Figure imgf000046_0001
The above table compares the expression levels of UCP-2 between rats in the soybean oil-added group and rats in the medium-chain fatty acid triglyceride-added group. It is obtained. <Formula 2>
表 4の値 =UC P― 2/UC P― 2 ' X 1 00  Value in Table 4 = UC P-2 / UC P-2 'X 100
UC P - 2 ：油脂組成物添加群のラットの UC P— 2 UC P-2: UC P-2 of rats in the oil composition group
UC P- 2' ：大豆油添加群のラットの UC P— 2 また、 上記表の実測値を表 5 に示す。 く表 5 > UCP-2 ': UCP-2 of rats in the soybean oil-supplemented group. Table 5 shows the measured values in the above table. Table 5>
Figure imgf000047_0001
Figure imgf000047_0001
LCT ：大豆投与群 MC Τ ：油脂組成物添加群 また、 ホルモン感受性リパーゼ、 β 3—アドレナリン受容体の各部位 の発現量を表 6に示す。  LCT: soybean administration group MC ：: fat composition addition group Table 6 shows the expression levels of hormone-sensitive lipase and β3-adrenoceptor at each site.
<表 6 > <Table 6>
Figure imgf000047_0002
Figure imgf000047_0002
LCT ：大豆投与群 MC Τ ：油脂組成物添加群 上記表より以下のことがいえる。 すなわち、 油脂組成物添加群のラッ トは大豆油添加群のラットと比較して、 内蔵脂肪よりも、 皮下脂肪の方 が燃焼しやすい。 すなわち、 油脂組成物添加を添加した場合、 体内エネ ルギ一はより理想的な燃焼をすることがわかる。 LCT: soybean administration group MC ：: fat and oil composition added group The following can be said from the above table. That is, the rats in the group added with the oil and fat composition burn more easily in subcutaneous fat than in visceral fat compared to rats in the group added with soybean oil. That is, it can be seen that when the fat and oil composition is added, the energy in the body performs more ideal combustion.
以下に処方例を示す。  The following is a prescription example.
[処方例 1 錠組成物]  [Prescription example 1 tablet composition]
表 7に示す配合比率にて、 各物質をよく混合し、 この混合物を打錠し て一錠 3 0 O m g錠組成物を得た。  At a compounding ratio shown in Table 7, each substance was mixed well, and the mixture was tableted to obtain a 30 Omg tablet composition per tablet.
<表 7 ><Table 7>
Figure imgf000048_0001
Figure imgf000048_0001
[処方例 2 カプセル組成物] [Formulation Example 2 Capsule composition]
表 8に示す配合比率にて、 各物質をよく混合したものを、 カプセル 充填して力プセル組成物を得た。  At a mixing ratio shown in Table 8, a well-mixed material was filled into capsules to obtain a force capsule composition.
<表 8 > <Table 8>
中鎖脂肪酸トリグリセリ ド 1 5 0 . 0 m g 乳糖 7 0 . 0 m g トウモロコシデンプン 3 8 . 0 m g ステアリン酸マグネシウム 2 . 0 m g [処方例 3 散剤] Medium-chain fatty acid triglycerides 15.0 mg Lactose 70.0 mg Maize starch 38.0 mg Magnesium stearate 2.0 mg [Prescription Example 3 Powder]
表 9に示す配合比率にて、 まず、 中鎖脂肪酸トリグリセリ ドと乳糖を よく混合した後、 ヒ ドロキシプロピルセルロースを加えて造粒する。 こ れを乾燥後に製粒し、 軟質無水ケィ酸を加えてさらによく混合して、 散 剤を得た。  At the mixing ratio shown in Table 9, first, medium-chain fatty acid triglyceride and lactose are mixed well, and then hydroxypropyl cellulose is added and granulated. This was granulated after drying, and soft kaic anhydride was added and further mixed well to obtain a powder.
<表 9 > <Table 9>
Figure imgf000049_0001
Figure imgf000049_0001
[処方例 4 注射剤] [Prescription Example 4 Injection]
表 1 0に示す配合比率にて、 まず （1 ) を （2 ) によく混合した後、 ( 3 ) を適量加えて全量 1 m 1 とし、 注射剤を得た。 なお、 この溶液は、 適当量の生理食塩水で希釈することにより投与することができる。  At the mixing ratio shown in Table 10, (1) was first mixed well with (2), and then (3) was added in an appropriate amount to make the total amount 1 ml, whereby an injection was obtained. This solution can be administered by diluting it with an appropriate amount of physiological saline.
<表 1 0 > <Table 10>
Figure imgf000049_0002
Figure imgf000049_0002
[処方例 5 清涼飲料] [Prescription example 5 soft drink]
表 1 1の原料を均一に混合し、 健康用飲料を得た, <表 1 1 >
Figure imgf000050_0001
The ingredients in Table 11 were evenly mixed to obtain a health drink, <Table 11>
Figure imgf000050_0001
[処方例 6 シリアル食品] [Prescription example 6 cereal food]
表 1 2の配合比率にて混合したものを、 加水、 成型し、 オーブンで加 熱乾燥して、 球形状のシリアル食品を得た。  The mixture obtained in the mixing ratio shown in Table 12 was added to water, molded, and heated and dried in an oven to obtain a spherical cereal food.
<表 1 2 ><Table 1 2>
Figure imgf000050_0002
Figure imgf000050_0002
[処方例 7 食用調合油脂] [Prescription example 7 Edible oils and fats]
表 1 3の配合比率にて、 攪拌機を用いて溶解を行い、 食用調合油脂を 製造した。 <表 1 3 > At the mixing ratio shown in Table 13, dissolution was carried out using a stirrer to produce edible oils and fats. <Table 13>
中鎖脂肪酸トリグリセリ ド 10.0 g 大豆油 90.0 g  Medium-chain triglycerides 10.0 g Soybean oil 90.0 g
[処方例 8 マーガリン] [Prescription example 8 margarine]
表 14の原料を常法により混合し、 コンビネ -ターを用い急冷混捏 理してマーガリンを得た。  The raw materials shown in Table 14 were mixed by a conventional method, and quenched and kneaded using a combination to obtain margarine.
<表 14 > <Table 14>
菜種油 37.0 g 中鎖脂肪酸トリグリセリ ド 2.0 g 菜種硬化油 42.0 g 水 1 7.0 g  Rapeseed oil 37.0 g Medium-chain fatty acid triglyceride 2.0 g Hardened rapeseed oil 42.0 g Water 1 7.0 g
0.5 g レシチン 0.5 g モノグリセリ ド 0.4 g 香料  0.5 g lecithin 0.5 g monoglyceride 0.4 g fragrance
力ロチン 微量  Power rotin trace
[処方例 9 ドレッシング] [Prescription example 9 dressing]
表 1 5の配合比率にて、 まず大豆サラダ油、 中鎖脂肪酸トリグリセリ ドを除く原材料を、 攪拌機付きの加温可能な容器に投入し、 プロペラ攪 拌機を用いて 100 r pmで攪拌しながら品温が 90°Cになるまで加熱 し、 品温を 90°Cに保持しながら 25分間攪拌を行った。 その後、 品温 が 20°Cになるまで冷却して大豆サラダ油、 中鎖脂肪酸トリグリセリ ド と合わせてドレッシングを得た。 At the compounding ratio in Table 15, first put the raw materials excluding soybean salad oil and medium-chain fatty acid triglyceride into a warmable container equipped with a stirrer, and stir at 100 rpm using a propeller stirrer. The mixture was heated until the temperature reached 90 ° C, and stirring was performed for 25 minutes while maintaining the product temperature at 90 ° C. Then, cool until the product temperature reaches 20 ° C, soybean salad oil, medium-chain fatty acid triglyceride To obtain a dressing.
<表 1 5 > <Table 15>
Figure imgf000052_0001
Figure imgf000052_0001
[処方例 10 マヨネーズ] [Prescription example 10 mayonnaise]
表 16の配合比率にて、 まず大豆サラダ油、 中鎖脂肪酸トリグリセリ ド、 加塩卵黄を除く原材料を、 混合攪拌しながら 90°Cまで加熱し、 9 0°Cに保持しながら 25分間攪拌を行った。 20°Cまで冷却した後、 大 豆サラダ油、 中鎖脂肪酸トリグリセリ ド、 加塩卵黄を合わせて減圧下で 撹拌し、 マヨネーズを得た。 At the mixing ratio shown in Table 16, the raw materials excluding soybean salad oil, medium-chain fatty acid triglyceride, and salted egg yolk were heated to 90 ° C with mixing and stirring, and stirred for 25 minutes while maintaining at 90 ° C. . After cooling to 20 ° C, soybean salad oil, medium-chain fatty acid triglyceride, and salted egg yolk were combined and stirred under reduced pressure to obtain mayonnaise.
<表 16 > <Table 16>
大豆サラダ油 45.0 g 中鎖脂肪酸トリグリセリ ド 30.0 g 水 8.4 g 砂糖 1.0 g グルタミン酸ナトリウム 0.3 g 粉末マスタード 0.3 g 食塩 1.0 g 米酢 4.0 g 加塩卵黄 10.0 g  Soybean salad oil 45.0 g Medium-chain fatty acid triglyceride 30.0 g Water 8.4 g Sugar 1.0 g Sodium glutamate 0.3 g Powder mustard 0.3 g Salt 1.0 g Rice vinegar 4.0 g Salted egg yolk 10.0 g
[処方例 1 1 マーガリン] [Prescription example 1 1 Margarine]
表 1 7の原料を常法により混合し、 コンビネ -ターを用い急冷混捏 理してマーガリンを得た。  The raw materials shown in Table 17 were mixed by a conventional method, and quenched and kneaded using a combination to obtain margarine.
<表 1 7 > <Table 17>
油脂組成物 A 39.0 g 菜種硬化油 42.0 g 水 1 7.0 g  Oil composition A 39.0 g Hardened rapeseed oil 42.0 g Water 1 7.0 g
0.5 g レシチン 0.5 g 香料 適量 カロチン 微量  0.5 g lecithin 0.5 g flavoring appropriate amount carotene trace amount
[処方例 1 2 ドレッシング] 表 1 8の配合比率にて、 まず油脂組成物 Aを除く原材料を、 攪拌機付 きの加温可能な容器に投入し、 プロペラ攪拌機を用いて 1 0 0 r p mで 攪拌しながら品温が 9 0 °Cになるまで加熱し、 品温を 9 0 °Cに保持しな がら 2 5分間撩拌を行った。 その後、 品温が 2 0 °Cになるまで冷却して 油脂組成物 Aと合わせてドレッシングを得た。 く表 1 8 > [Formulation example 1 2 dressing] At the compounding ratio shown in Table 18, the raw materials except for the oil and fat composition A were first charged into a warmable container equipped with a stirrer, and the product temperature was increased to 90% while stirring at 100 rpm using a propeller stirrer. ° C, and stirred for 25 minutes while maintaining the product temperature at 90 ° C. Thereafter, the product was cooled until the product temperature reached 20 ° C, and a dressing was obtained in combination with the oil and fat composition A. Table 1 8>
Figure imgf000054_0001
Figure imgf000054_0001
[処方例 1 3 マヨネーズ] [Prescription example 13 mayonnaise]
表 1 9の配合比率にて、 まず油脂組成物 A、 加塩卵黄を除く原材料を、 混合攪拌しながら 9 0 °Cまで加熱し、 9 0 °Cに保持しながら 2 5分間攪 拌を行った。 2 0 °Cまで冷却した後、 油脂組成物 A、 加塩卵黄を合わせ て減圧下で撹拌し、 マヨネーズを得た。 <表 1 9 > At the mixing ratio in Table 19, first, the raw materials except for the oil composition A and the salted egg yolk were heated to 90 ° C while mixing and stirring, and stirred for 25 minutes while maintaining the temperature at 90 ° C. . After cooling to 20 ° C, the oil composition A and the salted egg yolk were combined and stirred under reduced pressure to obtain mayonnaise. <Table 19>
Figure imgf000055_0001
Figure imgf000055_0001
[製造例 1 ] [Production Example 1]
菜種白絞油 （日清製油 （株） 製） 8 0質量部と構成脂肪酸が質量比で 力プリル酸 Zカプリン酸 = 3 Z 1である M C T 2 0質量部とを混合後、 減圧下 1 2 0 °Cで攪拌し、 脱気および脱水処理を行った。 これに触媒と してナトリウムメチラート 0 . 1質量部を加え、 1 2 0 °Cで 3 0分間、 ランダムエステル交換反応を行った。 反応生成物を常法により水洗、 乾 燥後、 脱色、 脱臭して油脂組成物 Aを得た。  Rapeseed white squeezed oil (manufactured by Nisshin Oil Co., Ltd.) After mixing 80 parts by mass and 20 parts by mass of MCT in which the constituent fatty acids have a weight ratio of caprylic acid Z capric acid = 3 Z 1, the mixture is then reduced in pressure 12 The mixture was stirred at 0 ° C., and degassed and dehydrated. To this was added 0.1 part by mass of sodium methylate as a catalyst, and a random transesterification reaction was performed at 120 ° C. for 30 minutes. The reaction product was washed with water, dried, decolorized and deodorized by a conventional method to obtain a fat composition A.
本発明の体脂肪分解促進剤等を摂取することで蓄積された体脂肪が低 減する等により、 非常に優れた痩身効果を享受することができる。 また、 中鎖脂肪酸トリグリセリン脂肪酸エステル等は人体に安全であり、 食事 等において自然に摂取することで本発明の効果を得ることができる。 さ らに、 痩身効果等を得るためには通常カロリー制限が課されるが、 本発 明の体脂肪分解促進剤等によれば、 このような体に対する無理をするこ となく、 健康を維持しながら好適に当該効果を得ることができる。  By taking the body fat degradation promoter of the present invention and the like, the accumulated body fat is reduced and the like, so that a very excellent slimming effect can be enjoyed. Also, medium-chain fatty acid triglycerin fatty acid esters and the like are safe for the human body, and the effects of the present invention can be obtained by ingesting them naturally at meals and the like. In addition, calorie restriction is usually imposed in order to obtain a slimming effect, etc., but according to the body lipolysis accelerator of the present invention, health is maintained without overdosing such a body. This effect can be suitably obtained while doing so.

Claims

請 求 の 範 囲  The scope of the claims
I . 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とするホルモン感受性リパーゼ発現亢進剤。 I. A hormone-sensitive lipase expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
2 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とする皮下脂肪細胞ホルモン感受性リパーゼ発現亢進剤 c 2. Subcutaneous adipocyte hormone-sensitive lipase expression enhancer c containing medium chain fatty acid and glycerin fatty acid ester containing Z or medium chain fatty acid as active ingredients c
3 . 中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグリセリ ン脂肪酸エス テルを有効成分とする /3 3—アドレナリン受容体発現亢進剤。 3. A 3-adrenergic receptor expression enhancer containing a medium chain fatty acid and a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
4 . 中鎖脂肪酸おょぴノまたは中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とする体脂肪分解促進剤。  4. A body fat degradation promoter containing medium chain fatty acids or glycerin fatty acid esters containing medium chain fatty acids as active ingredients.
5 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリ ン脂肪酸エス テルを有効成分とする皮下脂肪分解促進剤。  5. A subcutaneous lipolysis promoter containing a medium-chain fatty acid and glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients.
6 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とする体脂肪血中放出促進剤。  6. An agent for promoting the release of body fat into blood containing medium chain fatty acids and glycerin fatty acid esters containing Z or medium chain fatty acids as active ingredients.
7 . 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とする皮下脂肪血中放出促進剤。 7. A subcutaneous fat blood release promoter comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
8 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とする体脂肪が分解しやすい体質への体質改質剤。  8. An agent for improving body constitution, which is composed of medium-chain fatty acids and Z or glycerin fatty acid esters containing medium-chain fatty acids as active ingredients, for the purpose of easily decomposing body fat.
9 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸エス テルを有効成分とする皮下脂肪が分解しゃすい体質への体質改質剤。 9. An agent for improving the constitution of subcutaneous fat, which is composed of medium-chain fatty acids and glycerol fatty acid esters containing Z or medium-chain fatty acids as active ingredients.
1 0 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とするホルモン感受性リパーゼ発現亢進用油脂組成物 c 10. A fat / oil composition c for enhancing the expression of hormone-sensitive lipase comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients
I I . 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする 3 3—アドレナリン受容体発現亢進用油脂組成 物。 I I. A 33-adrenergic receptor expression-enhancing oil / fat composition comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
1 2 . 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする体脂肪分解促進用油脂組成物。 1 2. Medium chain fatty acids and / or glycerin fatty acids containing medium chain fatty acids An oil / fat composition for promoting body fat decomposition, comprising stell as an active ingredient.
1 3 . 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする体脂肪血中放出促進用油脂組成物。  13. An oil / fat composition for promoting body fat blood release, comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
1 4 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とするホルモン感受性リパーゼ発現亢進用飲食物。 14. Foods and drinks for enhancing the expression of hormone-sensitive lipase, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients.
1 5 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする皮下脂肪細胞ホルモン感受性リパーゼ発現亢進 用飲食物。 15. A food or drink for enhancing expression of subcutaneous adipocyte hormone-sensitive lipase, which comprises a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients.
1 6 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする 3 3—アドレナリン受容体発現亢進用飲食物。 16. A food or drink for enhancing the expression of 33-adrenergic receptors, comprising a medium chain fatty acid and a glycerin fatty acid ester containing Z or a medium chain fatty acid as active ingredients.
1 7 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする体脂肪分解促進用飲食物。 17. Foods and drinks for promoting body lipolysis, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or medium-chain fatty acid as active ingredients.
1 8 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする皮下脂肪分解促進用飲食物。  18. Food and drink for promoting subcutaneous lipolysis, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients.
1 9 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする体脂肪血中放出促進用飲食物。  1 9. A food and drink for promoting the release of body fat into blood, comprising a medium chain fatty acid and a glycerin fatty acid ester containing Z or medium chain fatty acid as an active ingredient.
2 0 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする皮下脂肪血中放出促進用飲食物。  20. A food or beverage for promoting release of subcutaneous fat into blood, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients.
2 1 . 中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする体脂肪が分解しゃすい体質への体質改質用飲食 物。  21. A food or beverage for modifying the body fat into a degradable body, comprising a medium-chain fatty acid and a glycerol fatty acid ester containing a medium-chain fatty acid as an active ingredient.
2 2 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを有効成分とする皮下脂肪が分解しやすい体質への体質改質用飲 食物。  2 2. A food or beverage for modifying the body into a body in which subcutaneous fat is easily decomposed, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as an active ingredient.
2 3 . 中鎖脂肪酸および Zまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを含有するホルモン感受性リパーゼ発現亢進剤原料。 23. A raw material for a hormone-sensitive lipase expression enhancer containing medium-chain fatty acids and glycerol fatty acid esters containing Z or medium-chain fatty acids.
2 4 . 中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを含有する ^ 3—アドレナリン受容体発現亢進剤原料。 24. A raw material for a ^ 3-adrenoceptor expression enhancer containing a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid.
2 5 . 中鎖脂肪酸および/または中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを含有する体脂肪分解促進剤原料。  25. Raw material for body fat degradation promoter containing medium chain fatty acid and / or glycerin fatty acid ester containing medium chain fatty acid.
2 6 . 中鎖脂肪酸およびノまたは中鎖脂肪酸を含むグリセリン脂肪酸ェ ステルを含有する体脂肪血中放出促進剤原料。  26. A body fat blood release promoter material containing medium-chain fatty acids and glycerin fatty acid esters containing medium- or medium-chain fatty acids.
PCT/JP2003/007736 2002-06-19 2003-06-18 Body fat degradation promoters and foods and drinks WO2004000299A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003242466A AU2003242466A1 (en) 2002-06-19 2003-06-18 Body fat degradation promoters and foods and drinks

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002-179104 2002-06-19
JP2002179104 2002-06-19
JP2002-260670 2002-09-05
JP2002260670A JP2004075653A (en) 2002-06-19 2002-09-05 Adipose decomposition accelerator and food or beverage

Publications (1)

Publication Number Publication Date
WO2004000299A1 true WO2004000299A1 (en) 2003-12-31

Family

ID=30002240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/007736 WO2004000299A1 (en) 2002-06-19 2003-06-18 Body fat degradation promoters and foods and drinks

Country Status (3)

Country Link
JP (1) JP2004075653A (en)
AU (1) AU2003242466A1 (en)
WO (1) WO2004000299A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006117557A (en) * 2004-10-20 2006-05-11 Nisshin Oillio Group Ltd Blood adiponectin level increasing agent
ATE535158T1 (en) * 2007-10-16 2011-12-15 Exichol Sa COMPOSITION FOR THE REGULATION OF LIPID METABOLISM
EP2316445A4 (en) * 2008-06-11 2011-12-21 Ricom Corp HUMAN beta3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME
JP5702292B2 (en) * 2009-09-30 2015-04-15 日清オイリオグループ株式会社 Visceral fat loss inhibitor in Parkinson's disease patients
CN105722399B (en) 2013-11-15 2020-12-15 日清奥利友集团株式会社 Improved soybean milk and its preparation method
JPWO2015129107A1 (en) * 2014-02-27 2017-03-30 日清オイリオグループ株式会社 Food using soybean powder and method for producing the same
US20170202239A1 (en) * 2014-07-17 2017-07-20 The Nisshin Oillio Group, Ltd. Baked confectionery that substantially includes no flour
JP6225278B2 (en) * 2015-06-15 2017-11-01 日清オイリオグループ株式会社 Plastic oil composition
CN110582276A (en) * 2017-05-12 2019-12-17 日清奥利友集团株式会社 Agent for increasing total ketone body concentration, oil and fat composition, pharmaceutical composition, and food composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407821A (en) * 1980-09-24 1983-10-04 Roussel Uclaf Lipidic compositions for use in dietetics, reanimation and therapeutics
JPS62255422A (en) * 1986-04-25 1987-11-07 Snow Brand Milk Prod Co Ltd Nutrition improver containing triglyceride of middle-chain fatty acid as active ingredients
JPH08269478A (en) * 1995-03-29 1996-10-15 Kao Corp Oil or fat composition and food containing the same
WO2001037827A1 (en) * 1999-10-13 2001-05-31 Chacon Marco A Therapeutic intervention to mimic the effect of caloric restriction
EP1110548A1 (en) * 1998-09-01 2001-06-27 Janiftec, Inc. Substances having antiobese and visceral fat-reducing functions and utilization thereof
JP2002188096A (en) * 2000-10-12 2002-07-05 Kanegafuchi Chem Ind Co Ltd New glyceride, method for producing the same and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3098560B2 (en) * 1991-03-28 2000-10-16 花王株式会社 Weight gain inhibitor
JP3482253B2 (en) * 1994-08-25 2003-12-22 花王株式会社 Cooking fats and oils
JP3569116B2 (en) * 1996-10-18 2004-09-22 花王株式会社 Liquid general-purpose fat composition
JP4733246B2 (en) * 1998-11-13 2011-07-27 日清オイリオグループ株式会社 Oil composition
JP2001161265A (en) * 1999-12-13 2001-06-19 Nisshin Oil Mills Ltd:The Oil and fat composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407821A (en) * 1980-09-24 1983-10-04 Roussel Uclaf Lipidic compositions for use in dietetics, reanimation and therapeutics
JPS62255422A (en) * 1986-04-25 1987-11-07 Snow Brand Milk Prod Co Ltd Nutrition improver containing triglyceride of middle-chain fatty acid as active ingredients
JPH08269478A (en) * 1995-03-29 1996-10-15 Kao Corp Oil or fat composition and food containing the same
EP1110548A1 (en) * 1998-09-01 2001-06-27 Janiftec, Inc. Substances having antiobese and visceral fat-reducing functions and utilization thereof
WO2001037827A1 (en) * 1999-10-13 2001-05-31 Chacon Marco A Therapeutic intervention to mimic the effect of caloric restriction
JP2002188096A (en) * 2000-10-12 2002-07-05 Kanegafuchi Chem Ind Co Ltd New glyceride, method for producing the same and its use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIROYUKI TAKEUCHI: "Chu-Chosa triacylglycerol ni kansuru kenkyu", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE SOKA KOEN YISHISHU, vol. 53, 1999, pages 41, XP002973802 *
ROTHWELL N.J.: "Stimulation of thermogenesis and brown fat activity in rats fed medium chain triglyceride", METABOLISM: CLINICAL AND EXPERIMENTAL, vol. 36, no. 2, February 1987 (1987-02-01), pages 128 - 130, XP002973520 *

Also Published As

Publication number Publication date
AU2003242466A1 (en) 2004-01-06
JP2004075653A (en) 2004-03-11

Similar Documents

Publication Publication Date Title
CA2418348C (en) Oil/fat composition
CN100421565C (en) Oil/fat composition
CA2418350C (en) Oil/fat composition
RU2376782C2 (en) Oil composition and food products that contain it, pharmaceutical composition and food additive
US6762203B2 (en) Oil composition
JPWO2003074043A1 (en) Body temperature raising agent
KR20110049868A (en) Diacylglycerol rich fats, oils and functional foods
WO2001010989A1 (en) Fat compositions
WO2004000299A1 (en) Body fat degradation promoters and foods and drinks
JPWO2004022049A1 (en) Slimming agent and its food and drink
WO2012105130A1 (en) Fat and oil composition for promoting insulin secretion
WO2007129439A1 (en) Inhibitor of increase in postprandial blood insulin level
JPWO2004022051A1 (en) Peroxisome proliferator activated receptor modulator
JPWO2004022050A1 (en) Lipid metabolism regulator and food and drink
JP6153241B2 (en) Liver dysfunction prevention and improvement agent
KR100684641B1 (en) Oil composition, food and health food containing the same
JPWO2003074042A1 (en) Uncoupling protein expression enhancer
JP5479696B2 (en) In vivo plasmalogen increasing agent
WO2004080209A1 (en) Serum remnant-like lipoprotein concentration regulator
JP6470879B1 (en) Anti-inflammatory agent, anti-inflammatory pharmaceutical composition, anti-inflammatory food composition
JP2007045789A (en) Improving agent of hyperinsulinism after meal
JP2023055836A (en) Composition for improving vascular endothelial function
JP2023055877A (en) Composition for reducing tmao in serum
JPWO2003092396A1 (en) Oil composition for lowering body fat, and food containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase